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Every day we are facing a complex variety of microbial agents and components in indoor 
environments of whom a major part derives from fungal and bacterial origin. Exposure to 
residential mould has repeatedly been found to be an environmental hazard and a risk factor 
for human health: Living in a damp and mouldy environment was consistently associated 
with respiratory disorders including asthma, wheeze and allergic rhinitis. On the other hand, 
recent studies in children have been shown that early life exposure to increased levels of 
fungal and bacterial agents was inversely related to the development of allergy.  
 
However, little is known about the causal agents provoking or arresting the development of 
allergic, respiratory disorders in children. To draw a causal relationship is hindered by the 
variability of microbial components in indoor air and a reliable and valid exposure 
assessment as well as analyses methods. Moreover, a considerable part of existing studies 
are cross-sectional and based on a single time point of health assessment only. Therefore, it 
is first important to specify mould exposure as detailed as possible. Secondly, prospective, 
population based birth cohort studies should be given more weight as they can better assign 
the temporal sequence of causality and ideally assess multiple follow-ups. Moreover, the 
collaboration of birth cohort studies with a similar design has substantial impact on the power 
and the relevance of the findings. 
 
In the first publication of this thesis I performed a comprehensive, systematic review on 
residential mould exposure and allergic health outcomes in children, followed by a meta-
analysis. I observed that exposure to visible mould at home was consistently associated with 
an increased risk for asthma, wheeze and allergic rhinitis. In contrast, there was a tendency 
of a decreased risk of allergic health outcomes in relation to elevated levels of mould derived 
components. However, the evidence is mainly based on cross-sectional studies. In the 
second publication I performed meta-analyses in European birth cohorts to investigate 
whether a damp and/or mouldy environment early in life is associated with the development 
of asthma and allergic disorders later in life. I was able to look at different time points of 
health outcome assessment between birth and 10 years of age in a large, prospective 
dataset of 8 European birth cohort studies. Our main findings indicated that early life 
exposure to visible mould and/or dampness significantly increased the risk of allergic rhinitis 
symptoms up to 10 years of age. We also found a modest and significantly increased risk of 
early asthma (<3 years) and a non-significantly increased risk for later asthma outcomes (6-8 
and 3-10 years). No association was observed for sensitisation against aero-allergens or 
mould allergens at school age. In a third publication, I addressed the microbial pollution in 
mattress dust in school age children from three European birth cohorts in Germany and the 
Netherlands. I aimed to investigate whether the protective effects of microbial pollution on 
asthma and allergic diseases observed in studies among farm children could be also 
confirmed in children from urban areas. Within the German sample, exposure to higher levels 
of mould derived components including (1,3)-ß-D-glucan and Extracellular Polysaccharides 
(EPS) as well as bacterial endotoxin were inversely related to the risk of respiratory 
diseases, whereas there was no association among the Dutch children. It was suggested 
that different life-style factors such as day care attendance or other microbial sources, apart 
from the measured ones, might be related to the different observations in allergic health 
outcomes. Nevertheless, this study in children from an urban area could partly confirm the 
findings from the so-called ‘farm studies’, suggesting protective effects on asthma and allergy 
in relation to elevated microbial exposure.  
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In conclusion, this thesis confirms and extends the existing literature on health effects of 
fungal and microbial exposure at home during childhood. It is among the first to examine the 
exposure to residential visible mould in prospective, population-based birth cohorts. Further, I 
was able to confirm that exposure to elevated levels of microbial agents had also protective 
effects on asthma among school children from urban areas and that this effect is not 
restricted to farm children. However, the various environmental hazards indoor and the 
complex interplay between environmental and genetic factors hampers to identify a causal 
relationship between exposure to mould, microbial agents and allergic disorders. It is 
suggested recently, that the diversity of microbial pollution at home might play a more 
decisive role than just the quantity of microbial agents. Elaborated analyses techniques 
including molecular methods might help to identify at least patterns of causal agents in 
relation to harmful or protective health effects.  
 
Future research should address interventions in homes of children with asthma, with pre- 
and post-evaluation measures of mould at genus and species levels. Politics, civil 
engineering and health care professionals should cooperate in a greater extent in order to 
ensure healthy indoor air quality and to not only get rid of visible mould but also preventing it 
in the first place, especially in susceptible populations. Lastly, the impact of exposure to 
mould and microbial agents on the development of diseases beyond respiratory health is 




Mikroorganismen, vor allem Schimmelpilze und Bakterien sind ein allgegenwärtiger und 
natürlicher Bestandteil unserer Atemluft im Innenraum. Zahlreiche epidemiologische Studien 
postulieren einen Zusammenhang zwischen Schimmelpilzexposition im Wohnraum und dem 
Auftreten diverser gesundheitlicher Beschwerden, darunter Atemwegserkrankungen wie 
Asthma, Asthma-Symptome (keuchende Ausatmung) oder allergische Rhinitis. Im 
Gegensatz dazu stehen Studien, die Hinweise darauf geben, dass eine höhere mikrobielle 
Belastung in der Wohnumgebung des Kindes, vor allem in den ersten Lebensjahren, vor der 
Entwicklung einer allergischen Erkrankung schützen kann. Jedoch sind die ursächlichen 
Faktoren einer schädlichen wie auch protektiven Wirkung noch unklar.  
 
Zahlreiche Faktoren limitieren einen Kausalitätsnachweis: Zum einen repräsentieren 
Schimmelpilze die mikrobielle Vielfalt im Innenraum nur partiell, zum anderen haben auch 
die vorhandenen Methoden der Expositionsbestimmung einen limitierenden Einfluss. 
Darüber hinaus basieren die Ergebnisse der meisten Studien auf 
Querschnittsuntersuchungen und nur auf einem Zeitpunkt der Expositionserfassung, was 
einen Kausalitätsnachweis erschwert. Um zumindest den formalen Anforderungen einer 
Kausalitätsaussage zu entsprechen, sollten epidemiologische Studien den Risikofaktor 
„Schimmelexposition“ so spezifisch wie möglich definieren. Prospektive Geburtskohorten 
eignen sich besonders die Entstehung eines Asthmas oder allergischen Erkrankung zu 
erfassen, da im Falle mehrerer Untersuchungszeitpunkte eine zeitlich vorausgegangene 
Exposition klar definiert werden kann. Darüber hinaus kann eine gemeinsame Auswertung 
von Daten zu vergleichbaren Geburtskohorten die Aussagekraft und Relevanz der 
Forschungsergebnisse erhöhen.  
 
Ziel der ersten Publikation dieser Dissertation war es, auf Basis der Ergebnisse eines 
systematischen Reviews und nachfolgender Meta-Analyse, die Auswirkungen einer 
Schimmelpilzexposition im Wohnraum auf die Atemwegsgesundheit von Kindern zu 
untersuchen. Ein sichtbarer Schimmelschaden war mit einem signifikant erhöhten Risiko für 
Asthma, Asthma-Symptome und allergische Rhinitis verbunden. Jedoch zeigte sich auch, 
dass Kinder mit einer höheren Belastung an Schimmelpilzbestandteilen im Hausstaub wie 
zum Beispiel (1,3)-ß-D-Glucan weniger gefährdet waren, eine allergische Erkrankung zu 
entwickeln. In einer zweiten Veröffentlichung konnte ich das Ergebnis des Reviews in einer 
Meta-Analyse von 8 europäischen Geburtskohorten bestätigen. Aufgrund des prospektiven 
Studiendesigns war es möglich, die Auswirkungen einer frühen Schimmelexposition im 
Wohnraum auf das spätere Auftreten von Asthma und allergischer Rhinitis zu verschiedenen 
Zeitpunkten zwischen Geburt und 10 Jahren zu untersuchen. Kinder, die in den ersten zwei 
Lebensjahren in einer Wohnung mit Schimmelproblemen aufwuchsen, zeigten ein signifikant 
erhöhtes Risiko für eine allergische Rhinitis in der späteren Kindheit zwischen 3 und 10 
Jahren und auch im frühen Schulalter zwischen 6 und 8 Jahren. Des Weiteren könnten wir 
auch für Asthma in der Kindheit ein (nicht signifikant) erhöhtes Risiko feststellen. Eine frühe 
Exposition gegenüber Schimmel und/oder Feuchtigkeit im Innenraum war jedoch nicht mit 
einem erhöhten Risiko für eine allergische Sensibilisierung gegenüber Inhalationsallergenen 
im frühen Schulalter zwischen 6 und 8 Jahren assoziiert. In einer dritten Studie mit Kindern 
von zwei deutschen und einer niederländischen Geburtskohorte konnte ich den protektiven 
Effekt einer erhöhten mikrobiellen Belastung auf Asthma und allergische Rhinitis bei Kindern 
bestätigen. Das Besondere an diesem Studienergebnis liegt darin begründet, dass die 
Kinder in einer urbanen Umgebung aufgewachsen sind, denn für Kinder von Bauernhöfen 
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oder aus einer ländlichen Umgebung ist dieser Zusammenhang bereits gut belegt. Eine 
höhere Belastung an Schimmelpilzkomponenten (1,3)-ß-D-glucan, Extrazellulären 
Polysacchariden (EPS) sowie Endotoxin von gram-negativen Bakterien zeigte einen inversen 
Effekt in Bezug auf Asthma und allergische Rhinitis, allerdings nur innerhalb der deutschen 
Kohorten. Andere Lebenstilfaktoren wie eine erhöhte Inanspruchnahme von Kinderkrippen in 
den Niederlanden oder andere, nicht gemessene mikrobielle Kontaminanten im Innenraum 
könnten einen Einfluss auf die länderspezifischen Unterschiede haben.  
 
Diese drei Publikationen bestätigen und bereichern bereits veröffentliche Untersuchungen zu 
Gesundheitswirkungen von Schimmelpilzexposition im Wohnraum bei Kindern. Darüber 
hinaus ist sie eine der ersten Studien, die die möglichen Gesundheitsauswirkungen einer 
Schimmelpilzexposition prospektiv in europäischen Geburtskohorten untersucht. Ich konnte 
weiterhin feststellen, dass die protektiven Effekte einer erhöhten mikrobiellen Belastung im 
Hausstaub auf Asthma und Allergien sich nicht nur auf Schulkinder aus dem ländlichen 
Raum beschränken. Die Komplexität der Bioaerosole im Innenraum sowie die Exposition 
gegenüber weiteren Umweltfaktoren und dem Einfluss der genetischen Disposition 
erschweren jedoch einen Kausalitätsnachweis im Hinblick auf das Entstehen von Asthma 
und allergischen Erkrankungen im Kindesalter. Neuere Untersuchungen geben Hinweise 
darauf, dass möglicherweise die Diversität der mikrobiellen Belastung im Innenraum eine 
entscheidende Rolle spielt. In dem Zusammenhang könnten Analysemethoden wie zum 
Beispiel die quantitative Polymerase-Kettenreaktion (qPCR) helfen, die Zusammensetzung 
der mikrobiellen Spezies in der Raumluft oder im Hausstaub besser zu charakterisieren.  
 
Zukünftige Studien sollten sich auch mit den Auswirkungen von Sanierungsmaßnahmen im 
Wohnraum von Kindern mit einer Asthmaerkrankung beschäftigen. Vor und nach der 
Entfernung beziehungsweise Sanierung von Schimmel oder Feuchtigkeitsschäden sollten 
Konzentrationen und auch die Artenzusammensetzung von Schimmelspezies bestimmt 
werden, vor allem im Zusammenhang mit Gesundheitsauswirkungen. Um eine gesunde 
Raumluft in Wohnräumen zu garantieren, sollten Vertreter aus Politik, Gesundheitswesen 
sowie dem Bauingenieurswesen verstärkt zusammenarbeiten um Schimmel oder 
Feuchtigkeitsschäden schon im Vorfeld zu verhindern. Abschließend sollten neben 
Atemwegserkrankungen auch andere Krankheitsbilder bei Kindern diskutiert werden, die 




1. Domestic mould and microbial agents: state of the art 
 
Asthma and allergy are still a global burden and one of most frequent chronic diseases 
diagnosed during childhood [1-6]. These diseases have a substantial impact on the quality of 
life in children and adults [7] and are also associated with considerable health care 
expenditures. It is suggested that heredity is linked to the development of allergic diseases, 
however, not exclusively but rather implicating an environmental exposure component [8]. 
 
1.1 Allergy and respiratory diseases: definitions and nomenclature 
 
Atopy and allergic sensitisation 
‘Allergy is a hypersensitivity reaction initiated by immunologic mechanisms’ [9], according to 
the nomenclature proposal established by the European Academy of Allergology and Clinical 
Immunology (EAACI). ‘Atopic’ subjects have the natural tendency to become sensitized 
against common environmental exposure and to respond with an enhanced Immunoglobulin 
E antibody production compared to their healthy peers [10, 11]. In most cases, an allergic 
reaction is mediated by antibodies from the Immunoglobulin E isotype (IgE) to allergens from 
the indoor or outdoor environment. Although not yet fully understand, there are also cases of 
non-IgE-mediated respiratory outcomes, imitating allergic reactions [9].  
 
The process of sensitisation against aero-allergens including pollen, pet and mite allergens 
or mould proteins is a major risk factor for later developing symptoms in the mucosal 
membranes of the airways [9]. However, the reasons for the ‘switch’ towards an allergic 
immune response, dominated by a T-Helper cell type 2 immune response with the respective 
cytokine milieu is still not yet fully understand. Some studies have been shown that allergens 
might have the potential to injure airway epithelium in such way, that the epithelial barrier is 
damaged leading to allergic sensitisation. It is suggested that healthy subjects obtain a 
tolerance to allergic sensitisation due to increased cell regulation within the mucosal surface 
in the airways [12]. 
 
Asthma 
Asthma is a complex, chronic disease and the WHO characterized asthma as having 
symptoms of recurrent attacks of breathlessness, bronchial obstruction and wheezing [9]. 
According to the WHO, over 235 million people worldwide are currently suffering from 
asthma [9]. In a recent international investigation, the mean prevalence of an asthma 
diagnose was reported with 10.8% for 6 to 7 year old children with similar patterns for the 
asthma symptom wheeze [2]. The underlying causes of asthma are still not revealed 
whereas genetic predispositions and exposure to environmental pollutants and irritants are 
suggested to play an important role [10, 11].  
 
In about 80 percent of childhood asthma and about 40%-50% adult asthma cases, the 
development of asthma is mediated by IgE antibodies against aero-allergens [7], also called 
‘extrinsic’ asthma. However, allergic sensitisation is not an essential precondition for asthma 
or asthma-like symptoms. It is suggested that 10%-30% asthma cases in childhood are 
attributed to the non-allergic, ‘intrinsic’ form. However, in both variants, bronchial obstruction 
and systemic inflammation are the predominant features [12]. In contrast to allergic asthma, 
the non-allergic form was observed to induce increased neutrophilic inflammation responses 
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[13]. The intrinsic form was found to be strongly associated with occupational exposure in 
animal farming environments with increased exposure to microbial agents in adults [14-16]. 
The aetiology of non-allergic asthma in children is not well defined, but it is suggested that 
viral infections might be an important trigger [6, 17, 18].  
 
Allergic rhinitis 
Allergic rhinitis or hay fever are often used interchangeably and are characterised by 
inflammation of the mucous membrane of nose, often in combination with the eyes and 
induced after exposure to allergens [19, 20]. Reported symptoms are runny, blocked or itchy 
nose, mostly in combination with itchy watery eyes [21]. It is one of the most common allergic 
disorders and the current prevalence worldwide ranged from 8.5% to 14.6% among children 
and adolescents as reported from the latest ISAAC survey [22]. Allergic sensitisation to aero-
allergens is an important risk factor next to family history and more pronounced for allergic 
rhinitis than for asthma [23]. In general, allergic rhinitis symptoms can occur seasonal, 
induced by exposure to outdoor allergens such as pollen or perennial triggered by mostly 
indoor derived allergens including house dust mites, pet or mould allergens [19]. Although it 
is not well evaluated in children populations, there are also forms of non-allergic rhinitis 
which are not mediated by the IgE-isotype but mimic the clinical phenotype. It is suggested 
that infections, physical or chemical agents might play a role in the development of non-
allergic rhinitis symptoms [19]. Moreover, there is a large body of evidence that allergic 
rhinitis is an important risk factor for asthma and they are often co-morbidities [20]. The 
connection between both should therefore be carefully considered in future studies.  
 
1.2 Exposure to mould and microbial agents 
 
Every day we are facing a complex variety of microbial agents in indoor environments with a 
major part deriving from fungal or bacterial origin. ‘The enormous diversity of the Fungal 
Kingdom is well recognized’ [24] and fungal species are ubiquitous in indoor and outdoor 
surroundings: In ‘healthy’ indoor environments, the predominant part of fungi is presented by 
the outdoor air genera Cladosporium, Penicillium and Aspergillus [25, 26]. However, once 
there is dampness or visible mould, the composition of the fungal profile is shifting mainly to 
‘indicator mechanisms’: Species such as Penicillium chrysogenum, Penicillium expansum, 
Aspergillus versicolor, Aspergillus penicillioides and also Stachybotrys chartarum were 
reported to be detected typically in moisture damaged environments [27, 28].  
 
Several studies assessed mould derived components such as (1,3)-β-D-glucan and 
Extracellular Polysaccharides (EPS) in house dust samples as surrogates for mould 
exposure [29-31]. (1,3)-β-D-glucan may account for up to 60% of the dry weight of the cell 
wall of fungi. However, (1,3)-β-D-glucan can be also part of the structure of plant materials, 
including pollen and cellulose, as well as soil bacteria [29, 32, 33] and a fungal exposure 
might therefore be overestimated by measurement of (1,3)-ß-D-glucan. Fungal Extracellular 
Polysaccharides (EPS) are heat stable and water-soluble non-branched carbohydrates. 
During fungal growth, EPS are secreted in the environment. These polysaccharides have 
antigenic specificity at the genus level [34] except for EPS from Aspergillus and Penicilium 
spp. which are cross reactive [35]. Compared to (1,3)-β-D-glucan there are only a few 
studies on exposure to extra cellular polysaccharides. As there is no evidence for EPS 
inducing inflammatory reactions at present [36] the exposure amount might serve as a good 
marker for fungal biomass contamination in indoor environment [35].  
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Endotoxin is often used as a surrogate for bacterial exposure in a number of studies [37-40]. 
Endotoxins are part of the outer membrane of gram-negative bacteria and are composed of 
proteins, lipids and lipopolysaccharides (LPS) [13, 40]. The term endotoxin refers to 
biological active LPS from cell walls or cell wall fragments [31, 41]. Endotoxin has been 
found to be very heat resistant and stable within the environment which emphasizes its 
persistent biological activity over prolonged periods [40]. Increased endotoxin levels within 
the dwelling have shown to be associated with the presence of moisture damage and fungal 
spores [42]. This applies especially to agricultural settings with animal stables which have 
been observed to transport the microbial components into the home environment [43]. 
Increased levels of endotoxin were also found in non-farming and urban settings with varying 
levels [31]. The presence of pets, carpets, dampness, mould or air-conditioning has a 
considerable influence on the endotoxin levels indoors [13, 44].  
 
In general, total exposure to microbial agents during childhood and later on depends on the 
different microenvironments such as workplace, school, kindergarten and residential area. 
Further, personal factors such as air-conditioning, ventilation, frequency of airing, fungal 
exposure from outside, building materials, characteristics of the substrate and type of 
moisture or water damage have also a substantial impact on the individualized exposure 
amount [45]. Several strategies have been developed in the past in order to determine the 
relevant, inhaled exposure of residential mould or microbial pollution. 
 
1.3 Exposure assessment of mould and microbial agents 
 
 
Figure 1: Different strategies for assessing mould and microbial exposure according to 




There are several strategies for assessing visible mould and microbial exposure in indoor 
environments (Figure 1). The choice for a specific exposure assessment method and the 
analysis method can have a considerable impact on the interpretation of the findings later on. 
A common, simpler method attended with low costs and feasible within a large group of 
participants is to assess domestic visible mould or dampness by means of questionnaires. 
This common approach might lead to misclassification if moulds were not reported in spite of 
being present (e.g. hidden behind furniture) or not aerosolized and therefore not relevant for 
inhaled exposure. In order to reflect the potential inhaled amount, some studies measured 
mould exposure via settled house dust or air sampling [30, 46-48]. Settled house dust is 
usually assessed by vacuuming a predefined area from mattresses or the floor, following a 
standardized protocol. This procedure can be performed either by trained fieldworkers or by 
the study participants themselves [49-51]. However, a limitation of this method is that some 
particles in settled house dust are too heavy to become airborne and therefore might not be 
inhalable. As a consequence, some epidemiological studies considered air sampling 
methods in order to mirror the actual exposure to inhalable components [52-54]. These 
methods are very costly and work intensive and the concentrations of fungal and microbial 
agents within the air are very unstable and showed considerable variation [26]. Recently 
introduced assessment methods try to overcome the disadvantages from previous sampling 
methods. In a recent publication on determining indoor air dust concentration, passive 
sampler consisting of an electrostatic cloth showed good results in handling, costs and 
reproducibility [50]. However, the universal application on a wider range of allergens and in 
large epidemiological studies has to be evaluated in further studies.  
 
The analyses methods of mould or microbial agents from settled house dust or airborne dust 
have limiting factors themselves (Figure 2). Cultivation methods are common but these are 
time consuming, expensive and the validity was critically discussed because of ‘overgrowing’ 
of some species and the strong seasonality effect. Further, this method applies only to living 
fungal and bacterial species [55-57]. Recent studies suggested that non-viable fungal 
fragments have also allergenic potential and are of biological relevance. The smaller 
fragments might deposit much deeper in the lung than fungal spores and therefore may also 
contribute to mould-related health disorders [24, 57-59]. Countable methods by microscope 
have the advantage to include also the non-viable components of microbial agents, however, 
could give no information at the genus level. Therefore, elaborated and cost intensive 
analysis techniques including assayable or molecular methods are performed in order to 
identify specific agents of fungal and microbial exposure at the genus level [26, 57]. These 
methods have also the potential to evaluate the diversity level of microbial pollution in indoor 




Figure 2: Different methods of analysing mould and microbial exposure according to usage 
and specificity 
In conclusion, the assessment of settled or airborne dust is considered to be an objective 
method, but on the other hand costly, work intense and often not feasible in larger cohorts. 
Moreover, fungal species may only partly represent the true pollutant mixture in the home 
and to draw a causal relationship is hindered by the variability of microbial components in 
indoor air and the limitations of assessment strategies and analyses methods. Therefore, 
apart from being a subjective method and the limitations mentioned above, the 
questionnaire-based assessment of visible mould might still serve as a fair indicator that the 
indoor environment is out of balance [25].  
 
1.4 Health effects of mould and microbial agents 
 
Available data are indicating that at least 20% of the homes worldwide have dampness 
problems or visible mould [60]. There is a large body of literature which found consistent 
associations of living in a damp and mouldy environment in relation to adverse respiratory 
and allergic health disorders in children from different regions worldwide [31, 42, 60-62]. 
Occupational exposure to high levels of bacteria or mould derived allergens was linked to 
allergic diseases including asthma and allergic rhinitis among adults [63]. On the other hand, 
being exposed to increased levels of microbial agents early in life was observed to protect 
children from allergic diseases [39, 46, 47, 51, 64-66]. However the knowledge of relevant 
exposure or causal agents in relation to health disorders – harmful and protective – is still 
limited.  
 
We know that there are several biological pathways suggested between exposure to 
microbial agents in relation to allergic health outcomes. Allergic respiratory diseases are 
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characterized by inflammatory reactions of the mucosal membrane of the upper and lower 
airways and eyes against environmental agents, dominated by a T-Helper cell type 2 
immune response [6]. Fungal species are able to induce inflammatory reactions [42, 67, 68] 
and several fungi and isolated mycotoxins were linked to inflammatory responses in vitro [69-
71]. Further, sensitisation to mould allergens was linked to severe asthma [72] and 
associations between exposure to spores of Penicillium indoors and an increased risk of 
respiratory disorders in children were described in epidemiological studies [73, 74]. Other 
biological active components such as (1,3)-ß-D-glucan or endotoxin were also suggested to 
have pro-inflammatory properties and to be associated with allergic and non-allergic 
respiratory symptoms [29, 30, 46, 47, 64, 75]. Further, these properties are not limited on 
viability and the amount of (1,3)-β-D-glucan from non-viable sources are suggested to be 
equally important [13, 40, 76]. By contrast, exposure to Extracellular polysaccharides (EPS) 
was not linked to health effects in existing literature, but is often used as indicator for fungal 
biomass [35, 48].  
 
Interestingly, epidemiological studies on exposure to mould and bacterial derived 
components revealed conflicting results. Studies in occupational settings with high levels of 
exposure to endotoxin or mould allergens reported an increased risk for non-atopic asthma in 
adult subjects [63]. As opposed to this, some studies among farm children observed that 
elevated levels of endotoxin early in life protected from allergic disorders including asthma 
and allergic rhinitis [13, 65, 77]. Similar was found for elevated levels of mould components 
including (1,3)-ß-D-glucan and EPS, also among children without a farming background [39, 
46, 47, 51, 64-66]. These inverse effects on allergic diseases were explained by the so-
called ‘hygiene hypothesis’ [78] stating that early expo sure to a rich microbial environment 
including viruses may decrease the risk for allergic diseases later in life by stimulating the 
immune system towards an non-allergic immune response. Although a plausible explanation, 
this hypothesis could not be confirmed in all studies [66] and exposure to mould or bacterial 
derived components could not be confined to specific agents. It was recently suggested that 
the composition and the diversity might play a more important role than the quantity of 
microbial exposure levels, and assuming different health effects from different fungal or 
microbial profiles [39]. Therefore, further research on the specific exposure types is needed. 
Molecular techniques including qPCR analyses or DNA finger printing might help in order to 
better characterise the indoor environment and to give evidence about the diversity of the 
microbial pollution. Moreover, more weight should be given to longitudinal birth cohort 
studies because of the prospective study design and the use of evaluation and validation 
criteria also in epidemiological studies could emphasize, but also mitigate the study results.  
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2. Specific aims and results 
 
Aims 
This thesis is based on the hypothesis that exposure to mould at home is associated with 
allergic, respiratory disorders in children. The main objectives of this thesis are as follows: 
 
 To review systematically the existing literature on specific types of residential mould 
exposure assessment in relation to allergic disorders in children, separated by 
epidemiological study design. In addition, meta-analyses to quantify the associations 
were performed. 
 
 To study whether early exposure to visible mould and dampness at home is 
associated with the development of asthma and allergic rhinitis as main health 
outcomes in children later in life in a collaboration of 8 European birth cohorts. 
 
 To analyse the effect of exposure to mould and bacteria derived components 
measured in settled house dust in relation to asthma and allergic rhinitis in school age 
children from three European birth cohorts.  
 
This thesis contains three manuscripts, accepted and published within the European 
Respiratory Journal and the Allergy Journal. For all three publications I developed the 
research question, study design, performed the statistical analyses, and interpreted the 
results. After the preparation of the first draft, the manuscripts were sent to the co-authors 
and finalized based on their comments and suggestions. Once I got response from the 
journals with the permission to resubmit the drafts, the manuscripts were again edited based 
on the discussions with my supervisor as well as the reviewers’ comments and resubmitted 
to the respective journal, together with the responses to the reviewers.  
 
Study population and Methods 
The three manuscripts are based on three different study populations. For the systematic 
review, the literature research in pubmed identified 1398 peer reviewed scientific publications 
of the past 30 years worldwide on exposure to mould and allergic, respiratory health 
outcomes in children. In total, 61 studies with comparable health outcome and exposure 
information were included. We restricted the study population to children only (between birth 
and 17 years) and the findings were analysed separated by epidemiological study design. 
The findings were additionally quantified with the help of meta-analyses. For this purpose, we 
focused on studies which used logistic regression models with similar adjustment for risk 
factors. To summarize the effect estimates among appropriate studies and to account for the 
heterogeneity between the different studies, random effect models were applied. 
 
The meta-analysis on the association between early exposure to visible mould at home (birth 
to 2 years) in relation to the development of allergic diseases was performed in 31,742 
children from 8 ongoing European birth cohorts. The birth cohorts were selected based on 
their comparability regarding exposure and health outcome assessment. Exposure to mould 
and allergic health outcomes were assessed by parental questionnaires at different time 
points from birth up to 10 years of age. Exposure was defined as parent-reported mould 
and/or dampness in any room of the home during the first two years of life. We determined 
seven health end points: “Early childhood asthma” (0-3 years), “school age asthma” (6-8 
years), and “ever asthma” at any time between 3 and 10 years of life. School age and 
childhood “symptoms of allergic rhinitis” was defined as sneezing attacks, runny, blocked and 
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itchy nose without having a cold. Sensitisation against aero-allergens and mould allergens 
was available for five of the eight cohorts and defined as having specific IgE (Immunoglobulin 
E) of at least 0.35 kU/L to at least one of the measured aero-allergens (cat dander, dog 
dander, mite, mould allergens, grass or tree pollen) between 6 and 8 years. Meta-analyses 
with fixed and random effect models were applied to account for the heterogeneity between 
different cohorts. The number of the studies included in each analysis varied, based on the 
outcome data available for each cohort.  
 
For the third manuscript I investigated the association of exposure to mould derived (1,3)-ß-
D-glucan and EPS as well as bacterial endotoxin in relation to asthma and allergic rhinitis at 
early school age. This investigation was the follow-up of an originally nested case-control 
study among three European birth cohorts (AirAllerg). A more detailed description of the 
study design and the study population is provided elsewhere [51, 79]. Children from two 
ongoing birth cohort studies performed in Germany (GINIplus and LISAplus, n=358) and one 
in The Netherlands (PIAMA, n=338) were selected. Levels of (1,3)-ß-D-glucan, EPS and 
endotoxin were measured in settled house dust sampled from children’s mattress and living-
room floor, when the children were on average 5 years old. Information on respiratory and 
allergic disorders, as well as visible mould in the child’s home was collected at age 6, using 
self-administered questionnaires. At the age of 6, health outcome information was available 
for 678 children. Earlier AirAllerg investigations were based on health outcomes measured 
before exposure assessment. However, in the present analysis, we were able to look at the 
health outcomes after exposure assessment. 
 
Results 
In the first publication of this thesis I performed a comprehensive, systematic review on 
residential mould exposure and allergic health outcomes in children. Compared to previous 
investigations, mould exposure was specified into visible mould, measured fungal spores and 
mould derived components including (1,3)-ß-D-glucan and Extracellular polysaccharides 
(EPS). We found that exposure to visible mould at home was consistently associated with an 
increased risk for asthma, wheeze and allergic rhinitis, regardless of the study design. These 
findings were also confirmed by the results of the meta-analyses later on. Exposure to fungal 
spores measured from airborne or settled house dust was found to increase the risk for 
asthma and wheeze in children up to one year, but there are inconclusive results at later 
ages. In contrast, there was a tendency of a decreased risk of allergic health outcomes in 
relation to elevated levels of mould derived components. We additionally evaluated the 
results of the systematic review according to the “Bradford Hill criteria” for assessing 
evidence of causation. The evaluation supports the findings of our review, especially with 
regard to aspects such as strength of an association, temporal relationship, biological 
gradient, plausibility and coherence, however, the evidence is mainly based on cross-
sectional studies. Nevertheless, this study revealed that further research is needed in order 
to disentangle and specify the effects of mould exposure in indoor environments to a greater 
extent.  
 
In the second publication I performed meta-analyses to investigate whether a damp and 
mouldy environment early in life is associated with the development of asthma, allergic 
rhinitis and sensitization to aero-allergens later in life in a large, prospective dataset of 8 
European birth cohort studies. We were able to look at different time points of health 
outcome assessment between birth and 10 years of age. Our main findings indicated that 
early life exposure to visible mould and/or dampness during the first two years of life 
significantly increased the risk of allergic rhinitis symptoms up to 10 years of age. We also 
found a modest and significantly increased risk of early asthma (<3 years) and a non-
  14
significantly increased risk for later asthma outcomes (6-8 and 3-10 years). No association 
was observed for sensitisation against aero-allergens or mould allergens at school age (6-8 
years). However, a damp and mouldy environment might be also associated with non-allergic 
forms of asthma as observed among adults [14-16]. After stratifying children by their atopic 
status, there was a positive, however not statistically significant association for non-IgE-
mediated asthma at early school age compared to the children with increased IgE levels to 
aero-allergens in five birth cohorts. The mechanisms of non-allergic form of asthma in 
children is not well understood to date, but it is suggested to result from similar inflammatory 
changes, mainly by the production of antibodies of the IgG, IgA, and IgM isotype after 
inhalation of large amounts of mould protein [7, 17]. We further observed an increased risk of 
visible mould exposure in relation to asthma and symptoms of allergic rhinitis in children with 
allergic parents, but not in children without this hereditary component. This underscores the 
recommendation to ensure healthy indoor air quality and to both remove visible mould or 
signs of moisture and actively prevent its formation in the first place, especially in susceptible 
populations.  
 
In a third publication, I aimed to investigate whether the protective effects of an increased 
microbial pollution on allergic diseases observed in studies among farm children could be 
also confirmed in school children from urban areas in Germany and the Netherlands. The 
results revealed a mixed picture of the relationship between exposure to biocontaminant 
levels at home and the risk of respiratory diseases and symptoms. Within the German 
sample, exposure to higher levels of mould derived components including (1,3)-ß-D-glucan 
and Extracellular Polysaccharides (EPS) as well as bacterial endotoxin from children’s 
mattresses was inversely related to the risk of respiratory diseases including asthma and 
allergic rhinitis. In contrast, there was no association observed among the Dutch children. 
The reasons for the differences are not quite clear and require further study, however, we 
observed that endotoxin and (1,3)-ß-D-glucan loads as well as (1,3)-ß-D-glucan 
concentrations from children’s mattresses in Germany were significantly higher compared to 
the Dutch sample. Further, the percentage of children exposed to visible mould was higher 
among the Dutch sample which could indicate the presence of an increased exposure to a 
wider range of microbial agents. In addition, different life-style factors such as a higher day 
care attendance in the Netherlands might be also related to the different observations in 
allergic health outcomes. Furthermore, compared to the two previous manuscripts, current 
visible mould exposure at school age was not associated with the allergic health outcomes in 
children from both countries. In conclusion, these findings underscore that the true fungal 
and microbial pollution at home is considered to be very heterogeneous and specific. The 
complex interplay of different microbial sources associated with personal behaviour might 
end up in individual microbial profiles with specific exposure, not only at home, and health 
responses later on [39]. Nevertheless, this study in children from an urban area could partly 
confirm the findings from the so-called ‘farm studies’, suggesting protective effects on allergy 
in relation to elevated microbial exposure.  
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3. Conclusion and outlook 
 
This thesis confirms and extends the existing literature on health effects of mould and 
microbial exposure at home during childhood. The systematic review on the literature in the 
past 30 years revealed that a mouldy home environment was consistently associated with 
allergic health outcomes including asthma, wheeze and allergic rhinitis among children and 
adolescents, regardless of epidemiological study design. Additionally, the results were 
evaluated according to the “Bradford Hill criteria which supports the findings, especially with 
regard to aspects such as strength of an association, temporal relationship, biological 
gradient, plausibility and coherence. However, the evidence is mainly based on cross-
sectional studies. For the first time, I could reinforce these findings in a collaborative study 
among 8 European prospective birth cohorts: Early exposure to visible mould at home during 
the first two years of life increased the risk for symptoms of allergic rhinitis at different time 
points between birth and 10 years of age and was also associated with asthma prevalence 
during childhood. In contrast, we could also partly confirm that exposure to elevated levels of 
mould and bacteria derived components might protect from asthma and allergic rhinitis in 
childhood, not only among children with farming or rural background.  
 
Although we could confirm harmful as well as protective effects of residential exposure to 
mould and mould related agents in relation to allergic disorders, there are a number of 
factors which have to be considered carefully. This thesis revealed that ‘mould’ exposure is 
just an umbrella term for a broader spectrum of specific exposure types, viable and non-
viable, which are in turn often associated with different health outcomes. Dampness and 
moisture damage is not only an important precondition for mould growth, but favours the 
spread of microbial agents in general. The release activity of mould spores and the impact on 
health is further depending on personal behaviour and synergistic or repressive effects of the 
overall microbial pollution indoors [26, 41]. A recent cross-sectional study in farm children 
concluded that not single agents, but rather the diversity of microbial pollution might play a 
decisive role [39]. Up to now, this could not be confirmed for children living in urban or rural 
areas. In order to identify at least patterns of agents, evoking harmful or protective effects on 
the development of allergic diseases, more attention should be given to elaborated analyses 
techniques, including molecular methods (e.g. quantitative polymerase chain reactions 
(qPCR)).  
 
Apart from the specification of exposure type, the development of allergic diseases is based 
on a complex interplay between environmental and genetic factors. There are a number of 
genes identified to be associated with the development of asthma and allergies in genome 
wide association studies [80, 81]. Mutations in the toll-like receptor (TLR) pathway genes, 
especially TLR 4 which is the major signalling receptor for Lipopolysacchardies (LPS), were 
observed to alter the response to environmental, microbial exposure [82]. Moreover, recent 
publications are suggesting that genetic variants in genes related to the cell protection 
controlling the inflammatory and antioxidative systems (e.g., GSTP1 gene) may modify the 
risk for allergic respiratory diseases including asthma and rhinitis as it was observed for 
ambient air pollution [83-85]. There might be also a joint effect of residential mould or 
microbial exposure and genetic variants in the pathogenesis of allergic diseases.  
 
The various environmental hazards indoors and the complex interplay between 
environmental and genetic factors hampers to identify a causal relationship between 
exposure to mould, microbial agents and allergic disorders. Only few epidemiological studies 
have evaluated their findings according to validation criteria and one can speculate about the 
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proportion of studies which found no association and in turn, have never been published. 
However, the significance of future studies on environmental exposure in relation to allergic 
disorders can be strengthened by regarding factors such as strength of an association, 
plausibility, consistency and specificity, but should also include the genetic evidence as a 
new criterion. In relation to that, there is limited knowledge about interventional trials on 
mould remediation in relation to allergic disorders. A recent review on housing intervention 
concluded that there is sufficient evidence for reducing respiratory symptoms after 
remediation activities, but the validity of the included studies is impaired by differences in 
local regions [86]. Moreover, exposure to mould and microbial agents in indoor environments 
is not only considered to affect respiratory health. A damp and mouldy environment during 
childhood might be also embedded in a broader spectrum of children’s health. In two recent 
publications from a German birth cohort (LISAplus) it could be shown that maternal smoking 
during pregnancy was associated with hyperactivity and inattention problems at 10 years [87] 
and exposure to environmental tobacco smoke was also suggested to influence insulin 
resistance later in childhood [88]. The impact of exposure to mould and microbial agents on 




In conclusion, this thesis confirmed that growing up in a damp and mouldy environment at 
home increases the risk for later asthma and allergic health disorders among children. An 
increased risk was especially seen for children with allergic parents. Further, the effect of 
mould remediation on respiratory health in children is still under-investigated. Future 
research should assess interventions in homes of children with asthma, with pre- and post-
evaluation measures of mould at genus and species levels. Politics, civil engineering and 
health care professionals should cooperate in a greater extent in order to ensure healthy 
indoor air quality and to not only get rid of visible mould but also preventing it in the first 
place, especially in susceptible populations. This is highly recommended, especially against 
the backdrop that the impact of exposure to mould and indoor contaminants during childhood 
might not only affect respiratory health but also the health development in children in general 
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ABSTRACT: Critical reviews over the past 10 yrs have found increased respiratory and allergic
health outcomes for children living in damp and mouldy environments. However, recent studies
have suggested that early childhood exposure to specific mould components may actually protect
children from developing allergy.
We conducted a systematic review of observational studies published in English from January
1980 to July 2010. This review was conducted according to systematic guidelines for Meta-
analyses of Observational Studies in Epidemiology (MOOSE). The literature was searched using a
computerised bibliographic database, PubMed. In order to increase the quality of the reviewed
studies, meta-analyses of the effects of visible mould exposure on allergic health outcomes were
performed and we evaluated the findings according to the Bradford Hill criteria for evidence of
causation.
The literature search identified 1,398 peer-reviewed scientific publications, and 61 studies that
fulfilled the inclusion criteria were included in this review. We observed increased risks of allergic
respiratory health outcomes in children exposed to visible mould and mould spores. These findings
were confirmed by the results of the meta-analysis and in line with the evaluation criteria according
to Bradford Hill. Visible mould was positively associated with asthma (OR 1.49 (95% CI 1.28–1.72)),
wheeze (OR 1.68 (95% CI 1.48–1.90)) and allergic rhinitis (OR 1.39 (95% CI 1.28–1.51)). However,
there was a tendency of lower risk for allergic health outcomes in children exposed to mould-
derived components such as (1,3)-b-D-glucan and extracellular polysaccharides.
These findings suggest that home environments with visible mould and mould spore exposure
increase the risk of allergic respiratory health outcomes in children. However, further
investigations are needed to examine the effects of exposure to mould-derived components as
the current literature is inconclusive. In order to disentangle the different effects of overall
microbial exposure on children’s health, research should focus on specific microbial markers in
the home, in combination with new assessment techniques including molecular methods.
KEYWORDS: Allergy, asthma, biomarkers, moulds, systematic review, wheeze
N
umerous studies have analysed the rela-
tionship between living in a damp and
mouldy environment and effects on re-
spiratory health. Reviews conducted in the past
10 yrs have found an increased risk of respiratory
and allergic health outcomes in children with a
parent-reported damp and mouldy home environ-
ment. A review of the European studies (NORD
DAMP) published prior to 1998 concluded that
there was strong evidence for an association
between dampness at home and increased risk of
respiratory and allergic symptoms in children and
young adults [1], which was also confirmed in a
subsequent review (EUROEXPO) of studies pub-
lished from 1998–2000 [2]. In 2004, the Institute of
Medicine (IOM) of the US National Academy of
Sciences reviewed studies published up to late 2003
and concluded that there is sufficient evidence for
an association between exposure to dampness and
mould and wheezing symptoms in children.
Similar associations were also observed for
physician-diagnosed asthma and asthma symp-
toms [3]. Subsequent epidemiological studies have
strengthened the evidence for a positive association
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between home dampness and new-onset asthma in children aged
up to 7 yrs [4]. The only meta-analysis to date [5] found a positive
association between exposure to dampness or visible mould in
the home and wheezing symptoms in children (OR combined
estimate 1.53 (95% CI 1.39–1.68)). Recently, the World Health
Organization (WHO) presented guidelines for the protection of
public health from dampness- and mould-derived risks and
concluded that there was sufficient epidemiological evidence that
dampness and mould were associated with an increased risk of
respiratory symptoms and exacerbation of asthma in children
and adults [6]. However, this review was neither systematic nor
were combined quantitative effect estimates given.
While the previous reviews and publications focused mainly on
self- or parent-reported indoor exposure to dampness, visible
mould and mould spores, there are also some recent studies
which used measured mould components, such as (1,3)-b-D-
glucan and extracellular polysaccharides (EPS) in house dust
samples as surrogates for mould exposure [6, 7]. (1,3)-b-D-
glucans are nonallergenic water-insoluble structural cell wall
components of most fungi. The biological active polyglucose
molecule may account for up to 60% of the weight of the fungal
cell wall [7]. However, (1,3)-b-D-glucans are also part of the
structure of plant materials, including pollen and cellulose, as
well as of soil bacteria. Therefore, the level of mould exposure
may be overestimated by using (1,3)-b-D-glucan as a surrogate.
Fungal EPS are stable carbohydrates secreted or shed during
fungal growth and have antigenic specificity at the genus level.
In contrast to the findings on visible mould, longitudinal studies
have shown that exposure to (1,3)-b-D-glucan and EPS was
inversely associated with the development of wheezing symp-
toms and reported physician-diagnosed asthma in children
[8–12]. In addition, one case–control study reported that elevated
levels of (1,3)-b-D-glucan and EPS exposure from mattress dust
were associated with a lower prevalence of allergic sensitisation
in 2–4-yr-old children [13]. The mechanism of these negative
associations is not yet understood. It has been hypothesised that
exposure to (1,3)-b-D-glucan and EPS may have a similar impact
on regulating the development of the infant immune system as
does endotoxin exposure during the perinatal period.
Previous investigations (NORDDAMP, EUROEXPO, IOM and
WHO) [1–3, 6] have summarised the main findings of the
studies reviewed here. However, only the work of FISK et al. [5]
also provided quantitative summaries. Furthermore, almost all
of the previous reviews failed to distinguish between exposure
to visible mould at home, measured mould spores and mould-
derived components. Finally, several publications have been
published since the inclusion deadline for the most recent
meta-analysis by FISK et al. [5] in 2007.
There is a strong need for a comprehensive and specific review
that distinguishes mould and dampness exposure into visible
mould, mould spores and measured mould components.
Although some investigations have also included endotoxin
exposure, we concentrated on mould exposure specifically.
Additionally, meta-analyses were used to quantitatively assess
the exposure–response relationships. While previous reviews
investigated a broad range of health outcomes in adults and
children, we have restricted our analysis to children and the
development of allergic diseases and symptoms. Lastly, birth
cohort and cohort studies with a prospective design were given
more weight than cross-sectional investigations as they can
better assign the temporal sequence. To account for the different
value of each epidemiological design we have presented the
results according to their epidemiological study design.
METHODS
This review was conducted following the Meta-analysis of
Observational Studies in Epidemiology (MOOSE) guidelines
for meta-analyses of observational studies [14]. The literature
was searched using a computerised bibliographic database,
PubMed, with the free text search terms listed in table 1.
Inclusion criteria were: observational study, human study
population, English, publication date between January 1, 1980
and July 1, 2010, and study population recruited from commu-
nity. The review included publications that specifically assessed
exposure to mould and mould-derived components for children
at home. This included inspector- or subject-reported visible
mould, measured airborne or dust-borne fungal genera, and
measured specific biomarkers of mould species such as (1,3)-b-D-
glucan and EPS within the domestic area. Exposure to dampness,
and exposure to dampness or mould as well as endotoxin, were
excluded from the current review to ensure a specific exposure
definition. Studies that did not evaluate asthma or allergic health
outcomes were also excluded. Further hand searches were
conducted using citations from the previous systematic reviews
[3–6] and personal files, published until July 1, 2010.
Longitudinal studies, cross-sectional studies and case–control
studies were included. We restricted the health outcomes to
physician-diagnosed allergic diseases including asthma, allergic
rhinitis or hay fever and eczema, as well as allergic symptoms
TABLE 1 Terms used to search PubMed
1) b-glucan

















19) Itchy, runny, blocked nose
20) Respiratory
21) Eczema
22) Itchy skin rash
23) 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
24) 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
25) 23 and 24
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such as wheezing, itchy, blocked or running nose without
having a cold, itchy skin rash and allergic sensitisation to
inhalant allergens. Each relevant article underwent standar-
dised data extraction.
Statistical analysis
In order to increase the quality of the reviewed studies, we have
reported the results of a quantitative meta-analysis for the
exposure–response relationships between exposure to visible
mould and asthma, wheeze and allergic rhinitis. The specific risk
factor and outcome definitions of each investigation included in
the meta-analysis are listed in tables 2–4. To summarise the effect
estimates among appropriate studies, we used random effect
models to account for the heterogeneity between different
studies. The results are presented as forest plots with central
point estimates and confidence intervals of odds ratios, and
summarise the intensity of increased risk of asthma, wheeze and
allergic rhinitis with exposure to visible mould. In order to assess
possible publication bias, which may lead to an overestimation
of the health effects, funnel plots were performed.
Statistical analyses were performed using the statistical soft-
ware R, version R 2.9.1 (The R Foundation for Statistical Com-
puting, Vienna, Austria).
RESULTS
The literature search identified 1,398 peer-reviewed scientific
publications, out of which 36 reported relevant exposures and
health outcomes in suitable study populations (fig. 1). Hand
searching of previously published reviews and personal files
identified 25 additional publications. In total, 61 investiga-
tions are included in this review. The funnel plots for the
quantitative assessment of the exposure–response relationship
between visible mould and asthma showed a symmetric shape.
However, there was a higher publication rate for studies that
found positive associations between exposure to visible mould
and wheeze or allergic rhinitis (see online supplement 1).
Of the 1,398 peer-reviewed scientific publications identified
through PubMed, 1,366 were excluded. A large number were
background papers such as comments and reviews, laboratory
experimental and animal studies or genetic studies (n5727).
Studies that lacked essential information about the exposure–
response relationship, had objectives other than to investigate
the relationship between exposure to mould and allergic health
outcomes, or that examined only adult study populations were
also excluded (n5622). Finally, studies that focused solely on
exposure to endotoxin were not considered in this systematic
review (n517).
Results from the systematic review: birth cohort studies
The birth cohort findings are summarised in online supple-
ment 2. Exposure to domestic visible mould increased the risk
for wheezing in children. No effects were observed for allergic
rhinitis and allergic sensitisation. The findings also suggested
that exposure to higher levels of mould components may
decrease the risk of allergic disorders.
Visible mould exposure
Wheeze
Of the nine publications evaluating the longitudinal effect of
early exposure to visible mould at home and wheezing in the
first 3 yrs of life, seven studies observed a significant positive
association [8, 12, 36, 41, 42, 48, 49]. In one US birth cohort
study (the Cincinnati Childhood Allergy and Air Pollution
Study) from IOSSIFOVA et al. [8], the reported increase in risk
was persistent from 1–3 yrs of age. BAKER et al. [50] observed
no effect of current exposure to visible mould and wheezing at
6 months of age, and TISCHER et al. [30] also found no effect in
children followed until 6 yrs of age from Germany and the
Netherlands.
Other health outcomes
Three studies investigated the effect of exposure to visible
mould on allergic rhinitis [30, 45, 46]; one study reported
findings on allergic sensitisation [48] and one on physician-
diagnosed asthma [30]. However, no significant associations
were found.
Exposure to mould spores
Only one birth cohort study reported findings on the association
between exposure to mould spores and allergic health out-
comes. Exposure to certain dust-borne fungal species such as
Alternaria, Aspergillus, Aureobasidium as well as nonsporulating
genera and total dust-borne fungal mass were significantly
positively associated with physician-diagnosed allergic rhinitis
or hay fever at 5 yrs of age [45].
Exposure to mould components
Two European and two US birth cohort investigations studied
the effect of exposure to mould components on the risk of allergic
health outcomes. IOSSIFOVA et al. [12] reported that exposure to
low levels of (1,3)-b-D-glucan from children’s primary activity
room was associated with a higher risk of recurrent wheeze (OR
3.04 (95% CI 1.25–7.38)) in 1-yr-old children, high levels were
protective (OR 0.39 (95% CI 0.16–0.93)). However, this could not
be confirmed at 3 yrs of age in the same birth cohort [8]. The two
European studies did not observe an effect of exposure to
(1,3)-b-D-glucan on asthma, wheezing or allergic rhinitis symp-
toms in school-aged children [9, 30].
The Prevention and Incidence of Asthma and Mite Allergy
(PIAMA) birth cohort study and a follow-up of the European
AirAllerg collaboration reported significant inverse effects of
exposure to higher levels of EPS on asthma, wheeze and
allergic rhinitis in 4–6-yr-old children. Within the PIAMA
cohort, there was also an inverse effect on allergic sensitisation
status [9, 30].
Results from the systematic review: cohort studies (not
recruited at birth)
The cohort study findings are summarised in the online
supplement 2. There was no clear exposure–response relation-
ship between exposure to visible mould and asthma. However,
the findings did suggest that domestic visible mould may have a
harmful effect on wheeze. Exposure to airborne mould spores
was associated with wheezing in children aged up to 1 yr.
Visible mould exposure
Asthma
Three studies investigated the relationship between exposure
to visible mould and physician-diagnosed asthma, and overall
results were inconclusive. Studies from the USA and Finland
[21, 51] found no associations, while a second US study
ASTHMA AND ALLERGY C. TISCHER ET AL.
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reported that current exposure to mildew was significantly
inversely related to physician-diagnosed asthma at 12 yrs of
age [52]. However, this was only found for children with a
wheezing phenotype.
Wheeze
Three cohort studies, all from the USA, investigated the effect
of visible mould exposure on wheezing in children.
BRUNEKREEF et al. [21] reported a significantly positive associa-
tion between domestic mould and persistent wheeze in 12-yr-
old children. BELANGER et al. [53] observed an increased risk
among 1-yr-old children who were genetically predisposed to
allergic diseases, while a second study found no association
among children in the same age range (although this may have
been due to inadequate power as the study included only 103
children) [43].
Other health outcomes
Reported visible mould during pregnancy was a risk factor for
physician-diagnosed atopic eczema in 2–9-month-old Japanese
infants without parental allergy [54]. A US study of 12-yr-old
schoolchildren reported a significant increased risk of hay
fever when exposed to self-reported domestic mould [21].
Exposure to mould spores
Three US studies investigated the relationship between
exposure to airborne mould spores and wheezing in 1-yr-old
children. GENT et al. [55] and ROSENBAUM et al. [43] reported an
increased risk of wheeze in 1-yr-old infants, when exposed to
airborne Penicillium (o1,000 and 120–1270 cfu?m-3, respec-
tively). A subsequent US study on infants found a positive
association between exposure to airborne total fungi sampled
at 3 months and wheeze at 1 yr [53]. A German cohort study
found an increased risk for sensitisation against grass
(immunoglobulin E) in 3-yr-old children when exposed to
airborne Aspergillus genera [56].
Results from the systematic review: case–control studies
There was no clear direction observed for the effect of visible
mould or mould spores on measured allergic health outcomes
among studies with a case–control design (online supplement
2, case–control studies). However, in studies with a larger
sample size, there was a tendency for an increased risk of
Electronic search (PubMed)
(January 1, 1980_January 1, 
2010)
1398 publications
Excluded after reading abstract: 
1366 publications
Reasons for exclusion:
- Other study type
(review, comments, experimental 
study design, genetic studies) 
(727 publications)
- Other exposure-response





(up to July 1, 2010) 
25 publications
61 publications included
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asthma when exposed to domestic visible mould. In contrast,
the findings suggested that mould component exposure was
inversely associated with risk of allergic health outcomes.
Visible mould exposure
Asthma
Five case–control studies investigated the relationship between
exposure to visible mould and asthma. One study from China
with 1,209 subjects [27], and two studies from Europe [31, 33]
reported an increased risk of physician-diagnosed asthma with
exposure to visible mould, in children up to school age. This
association could not be confirmed by LI and HSU [35] in a
small population of 46 Taiwanese school children. A Nigerian
case–control study of 5-yr-old schoolchildren reported protec-
tive effects on current asthma for mould growth at home [34].
Other health outcomes
Two European studies investigated the effect of visible mould
exposure on wheezing [36, 38], but no association was ob-
served. A study of 3-yr-old children from New Zealand also
found no association between visible mould exposure and
atopic dermatitis [57]. One small study from Taiwan reported a
significant increased risk for allergic rhinitis in school-aged
children [35].
Exposure to mould spores
Asthma
Four studies investigated the effect of mould spore exposure
on physician-diagnosed asthma among children. One small
study from Taiwan reported positive associations between
exposure to airborne Cladosporium and asthma in school-aged
children [35]. However, three publications from Europe could
not find an association between higher levels of dust-borne
fungal species and asthma [58–60].
Allergic rhinitis
One European study from Germany [58] with 272 subjects,
reported a higher risk of allergic rhinitis symptoms with
exposure to total fungi, Cladosporium and Penicillium (.200,000,
.35,000 and .55,000 cfu?g-1, respectively). A similar finding
was observed in a Danish cohort: children sensitised to house
dust mites had a significantly higher risk of allergic rhinitis
when exposed to dust-borne Cladosporium .35 cfu?mg-1 [59].
In contrast, higher levels of airborne Penicillium and total fungi
measured in summer, were found to be protective against
allergic rhinitis in a small Taiwanese study of school-aged
children [35].
Other health outcomes
Two studies investigated the effect of dust-borne mould spore
exposure on physician-diagnosed eczema and eczema symp-
toms. While there was no association observed within the
German population [58], there was an increased risk for eczema
in Swedish children sensitised to house dust mites but not to
aeroallergens [59]. Two German studies looked at the associa-
tion between exposure to domestic mould spores and the risk of
allergic sensitisation to inhalant allergens (immunoglobulin E).
While JOVANOVIC et al. [61] found no association, JACOB et al. [58]
reported a higher risk of sensitisation against inhalant allergens
when exposed to Cladosporium and Aspergillus (.35,000 and
0–25,000 cfu?g-1 and above, respectively). No association was
found between exposure to dust-borne mould genera and
wheezing phenotype in a German study [58].
Mould components exposure
Three European studies investigated the effect of mould
component exposure on allergic disorders. Exposure to EPS
was found to significantly reduce the risk of physician-diagnosed
asthma [62] and atopic wheeze [10], while exposure to (1,3)-b-D-
glucan was significantly inversely related to sensitisation against
inhalant allergens among 2–4-yr-old children [13].
Results from the systematic review: cross-sectional studies
A large number of cross-sectional studies reported increased
risk of asthma and wheeze when exposed to domestic visible
mould. However, the results for other allergic health outcomes
such as allergic rhinitis, atopic eczema and atopic sensitisation
were less conclusive (online supplement 2, cross-sectional
studies). Only two investigations considered the effects of
mould component exposure, and they suggested that higher




A total of 30 cross-sectional studies were included, out of
which 15 investigated the effect of exposure to visible mould on
asthma in school-aged children. There were 10 studies [15–20,
22–24, 63] with sample sizes above 1,500 subjects. Out of these,
nine observed a significantly increased risk of asthma. A study
from Tasmania, Australia did not observe an association [18],
but this may have been due to the young age of the children
(7 yrs). No association was found in the remaining studies,
which had smaller sample sizes (403–2,720) [25, 26, 28, 29, 32].
Wheeze
The picture with wheeze was similar to that with asthma: nine
out of 15 cross-sectional studies found that exposure to mould
at home was associated with a higher risk of wheeze in
children. This was especially true among studies with a larger
sample size [15–17, 19, 22, 23, 37, 39, 64]. However, five studies
did not find any association [26, 28, 29, 65, 66]. In one Spanish
study, an increased risk of wheezing was observed only in
nonatopic schoolchildren [67].
Allergic rhinitis
Two out of eight studies investigated the relationship between
visible mould exposure and allergic rhinitis and observed
positive associations. The Pollution and the Young (PATY) study
reported a significantly increased risk for hay fever in 6–12-yr-old
children when exposed to visible mould at home [15]. Two Asian
studies from Singapore also reported higher risks for rhinitis and
rhinoconjunctivitis among 1–12-yr-old children [25, 65]. The
remaining six studies did not observe any statistically significant
exposure–response relationships [17, 22, 26, 44, 47].
Atopic eczema
Four studies investigated the relationship between exposure to
visible mould and atopic eczema. One German study by SCHA¨FER
et al. [68] observed a significantly increased risk of atopic eczema
in a sample of 6-yr-old children. However, no association was
observed for the remaining three studies [25, 47, 65].
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Atopic sensitisation
Two investigations examined the association between domes-
tic visible mould exposure and atopic sensitisation in school-
aged children. ANTOVA et al. [15] observed an increased risk of
sensitisation against inhalant allergens in a pooled analysis of
.58,000 children. In a smaller German study of 1,235 children,
exposure to visible mould was found to increase the risk of
sensitisation against mugwort, dust mites and cat (assessed by
skin-prick test) among 5–7-yr-old children [68].
Exposure to mould spores
Allergic rhinitis
There were only two cross-sectional studies that investigated
the effect of mould spores on the risk of allergic health
outcomes in childhood. A small study from Australia reported
that exposure to airborne Penicillium and airborne Cladosporium
was significantly positively associated with asthma and
wheeze, respectively [69]. Exposure to airborne Penicillium
was significantly related to sensitisation (skin-prick test) to
Penicillium mix, Aspergillus mix, house dust and dog dander.
Higher levels of airborne Cladosporium were also associated
with sensitisation to Aspergillus mix and exposure to airborne
Aspergillus was suggested to increase the risk for sensitisation
against inhalant allergens [69]. SALO et al. [70] could not find
any association between dust-borne Alternaria alternata and
physician-diagnosed asthma.
Exposure to mould components
There were only two investigations of one cross-sectional
study in Germany, Austria, Switzerland and The Netherlands
(the Prevention of Allergy–Risk Factors for Sensitization
Related to Farming and Anthroposophic Lifestyle study).
KARADAG et al. [71] and colleagues found that exposure to
EPS from children’s mattresses was negatively associated with
physician-diagnosed eczema but not with eczema symptoms.
In the second investigation by EGE et al. [72], EPS was found to
significantly decrease the risk of asthma ever and current
wheeze. However, there was no effect on atopic sensitisation
against inhalant and food allergens. The associations were less
conclusive for exposure to (1,3)-b-D-glucan. KARADAG et al. [71]
found an association with decreased risk of atopic eczema
symptoms.
Results of the meta-analysis for the association between
visible mould exposure and asthma, wheeze and allergic
rhinitis
A total of 21, 19 and 10 publications of different study designs
on exposure to domestic visible mould in relation to asthma,
wheeze and allergic rhinitis health outcomes, respectively,
were included in the meta-analysis. The summary estimates
illustrate that exposure to visible mould at home was
significantly positively associated with asthma, wheeze and
allergic rhinitis (OR 1.49 (95% CI 1.28–1.72), OR 1.68 (95% CI
1.48–1.90) and OR 1.39 (95% CI 1.28–1.51), respectively). Forest-
plots in figure 2 illustrate the odds ratios with their 95%
confidence intervals and provide a summary estimate for
the association between the investigated exposure–response
relationships.
Owing to the limited number of studies that investigated the
relationship between exposure to mould-derived components
and allergic health outcomes, it was not possible to aggregate
the results to perform a meta-analysis.
DISCUSSION
This systematic review included 61 publications. The most
commonly reported health outcomes were asthma, wheeze
and allergic rhinitis. There was a statistically significant
increased risk of asthma (OR 1.49 (95% CI 1.28–1.72)), wheeze
(OR 1.68 (95% CI 1.48–1.90)) and allergic rhinitis (OR 1.39 (95%
CI 1.28–1.51)) in children when exposed to visible mould.
There were fewer studies on exposure to airborne, dust-borne
mould spores or measured mould components. While mould
spore exposure was found to increase the risk for asthma and
wheeze in children at a younger age, our review suggests,
however, that mould components such as (1,3)-b-D-glucans
and EPS do not increase the risk for allergic health outcomes.
This systematic review on the health impact of visible mould,
mould spores and mould-derived components in children
provided a comprehensive overview on the literature over the
past 30 yrs, which, for the first time, is combined with a
quantitative assessment of the reviewed studies. The only
previous meta-analysis to examine the health effects of
dampness and mould exposure was by FISK et al. [5], which
reported a significant positive association with wheezing
symptoms in children and adults. These prior findings are
consistent with those of the present meta-analysis. However,
we aimed to go beyond the work of FISK et al. [5] and
specifically addressed issues such as specificity of exposure,
study design, study population, validation criteria and validity
of exposure assessment.
Studies after the inclusion deadline for the meta-analysis of
FISK et al. [5]
A number of studies were considered here that had not been
published in time to be included in the previous meta-analysis
of FISK et al. [5]. For the association between exposure to mould
and wheeze, there were 19 additional publications and for
asthma there were 17 additional studies. Furthermore, we
identified studies published before 2006 that were not part of
the meta-analysis of FISK et al. [5], supporting the application of
a systematic approach. FISK et al. [5] looked at the association
between dampness and mould exposure in relation to a
number of different upper respiratory tract symptoms,
whereas we focused on (physician-diagnosed) allergic rhinitis
exclusively. Although we constrained exposure and health
outcome definition and limited the analysis to children only,
we did reach a higher number of publications than the meta-
analysis in 2007 [5].
Specification of type of exposure
Previous investigations, including the work from FISK et al. [5],
have often assessed dampness, water leakage, mould, mould
spores, mould odour and mould-derived exposure as a
common exposure type. In order to specify the type of
exposure, we defined three different kinds of mould exposure
to account for conflicting study results in the past: domestic
visible mould, measured airborne fungal species and mea-
sured mould-derived components assessed by house dust
sampling. While there is a good correlation suggested between
visible mould exposure and the concentration of fungal spores
[73], recent literature indicated that exposure to mould-derived
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components might have a different impact on children’s health
and may not measure a single kind of exposure. This
hypothesis was supported by a US cohort study that did not
find a correlation between (1,3)-b-D-glucan exposure and
visible mould [8, 12]. This might be partly due to the fact that
(1,3)-b-D-glucan is also part of the structure of plant materials,
including pollen and cellulose, as well as soil bacteria;
therefore, the level of mould exposure may be overestimated
by using (1,3)-b-D-glucan as a surrogate [7]. EPS are stable
carbohydrates secreted or shed during fungal growth and have
antigenic specificity at the genus level but cannot represent
exposures to all of the fungal species in an indoor environ-
ment. Furthermore, it has been suggested that mould-derived
components such as (1,3)-b-D-glucan or EPS can protect
children from developing allergic disorders, as shown in
recent longitudinal investigations [8, 9, 12]. A protective
tendency of mould-derived components on allergic diseases









































































FIGURE 2. Odds ratios and 95% confidence intervals for the association between visible mould and a) asthma, b) wheeze and c) allergic rhinitis from original studies
and from a meta-analysis (combined effect) performed using the random effects model. For each study, the size of the box is proportional to the precision (inverse of
variance) of the study. The combined estimate from the meta-analysis is indicated by the diamond-shaped box (labelled ‘‘Summary’’) at the bottom of the figure.
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early exposure to indoor microbial elements may have strong
immune-stimulatory properties, as has been suggested for
endotoxin in several studies [74–76]. The present review
revealed that there are still not enough data on exposure to
mould-derived components to perform combined analyses,
which would be required to make a more definite statement on
the impact of exposure to these components.
Study design
Compared to FISK et al. [5], we further addressed different
types of study design. Nearly half (41%) of the publications
included in this review were cross-sectional studies, and a
considerable proportion of these had large sample sizes. In
contrast, the proportion of cohort studies and case–control
studies is lower (14 and 23%, respectively) and with
considerably fewer study subjects. Compared with cross-
sectional studies, it was not possible to determine a clear
direction of the investigated exposure–response relationships,
which might be partly due to lack of power within the original
studies. Nevertheless, birth cohort studies and cohort studies
not recruited at birth might be given more weight as they can
better assign the temporal sequence and presumably the
important perinatal exposure window. However, due to the
limited number of (birth) cohort studies and short follow-up
time, we were not able to quantify them separately in a meta-
analysis. In future, combined investigations focused on long-
itudinal studies exclusively may be able to assess causality
over a longer time period. This is currently ongoing in the
frame of the Environmental Health Risks in European Birth
Cohorts initiative (www.enrieco.org).
Study population
In contrast to previous investigations, the current review
focused on studies in children only, as it is suggested that the
exposure–response relationship alters with ageing; and the
development of allergic diseases and symptoms occurs during
early childhood. Furthermore, the incidence of allergic diseases
in adults may be provoked by different triggers, for example
due to occupational exposure and causing nonallergic rather
than allergic responses [76].
Validation criteria
The interpretation of the results from this review is based on
systematic, validated criteria in terms of the search for eligible
publications and also interpretation and analysis. We performed
a reasonable and replicable systematic search using the
electronic database PubMed in order to make the process
transparent. Until now, there has been no review on the
association between mould exposure and allergic health out-
comes in children according to systematic search criteria. In
addition to the meta-analysis on mould exposure and allergic
health outcomes, we evaluated the results of the systematic
review according to the Bradford Hill criteria for assessing
evidence of causation [77], which are discussed in detail later on.
Validity of exposure assessment
Visible mould exposure at home was assessed mainly by
questionnaire. Although this method is convenient and fav-
ourable, questionnaire-based methods are difficult to vali-
date against microbial measurements [40, 48]. Numerous
studies validated self-reported visible mould questions against
inspector-reported observations [36, 31, 78–81] and did not find
any evidence for over- or underreporting of dampness and
mould by occupants. Further, against the backdrop of fungal
diversity, it is not clear whether the obviously visible mould or
unknown, invisible species contribute to the observed effects in
children’s health [69, 82]. The most ideal exposure assessment
for exposure to mould or mould-derived components would be
repeated sample collections through a mobile personal air
sampler. However, individual biological measurements are
costly and therefore usually not feasible, especially in larger
(birth) cohort studies. Some studies collected fungal species or
mould-derived components by means of settled house dust or
air samples. While these methods are generally considered more
standardised, in that they follow a protocol and reduce the risk
of systematic biases such as reverse causation compared with
questionnaire-based methods, there are some shortcomings. To
begin with, sampling methods vary considerably between the
studies. Dust sampling from floors or mattresses using a
vacuum cleaner provides a crude mixture of different particle
sizes [10, 83, 84], but some of the dust fraction may never
become airborne and might not have an effect on children’s
health. Hence some investigations sampled specific airborne
dust fraction in domestic environments [43, 46, 53, 55, 56, 61].
However, this requires considerable time and cost resources.
Recently, new exposure assessment methods have been devel-
oped. Passive airborne sampling (‘‘pizza box’’), electrostatic
dust-fall collector or electrostatic dust clothes [85–87] can be
used for a broad range of allergen measurements. These newly
developed exposure assessment methods might be a valuable
substitute for existing methods in terms of cost and work.
In addition to the meta-analysis on mould exposure and
allergic health outcomes, we evaluated the results of the
systematic review according to the Bradford Hill criteria [77].
Epidemiological studies typically examine associations be-
tween exposure and health outcomes, while the Bradford Hill
criteria are suggested to assess the causal nature of an
observed association on the basis of nine categories [88, 89].
These nine criteria should not be used as a checklist, but
instead highlight important aspects of an investigation.
According to these criteria, the evaluation supports the find-
ings of the meta-analysis, especially with regard to aspects
such as strength of association, temporal relationship, biologi-
cal gradient, plausibility and coherence. Further research is
needed to examine exposure specification against the backdrop
of microbial diversity in indoor environments (see online
supplement 3 for an extensive description).
Limitations
The timing of health outcome assessment is crucial in
epidemiological studies. Some birth cohorts included in this
review were too young to classify wheezing symptoms into
transient, persistent and late-onset wheezing. Five out of six
studies had an age range of 6 months to 3 yrs. There might be
children having transient symptoms of asthma at an early age,
but who are not a risk of developing clinical symptoms later
during childhood. However, the follow-up time was too short to
allow monitoring of disease development over a long period.
Therefore, findings from birth cohort studies at younger ages
should be interpreted with caution and the results may be of a
short-term rather than a long-term character.
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Although we specified mould exposure in terms of three
different exposure sources, namely visible mould, airborne or
dust-borne measurement of mould spores, and measured
mould components from settled house dust, a clear assignment
to the observed health effects is difficult. While there is a good
correlation suggested between visible mould exposure and the
concentration of fungal spores [73], exposure to mould-derived
components might have different impacts on children’s health.
Indoor environments consist of a variety of indoor and outdoor
sources, not only the measured ones. Visible mould or measured
mould spore and mould-derived component exposure might
only partly represent the actual microbial pollution at home. A
recent study on predictors of bacterial and fungal biomarkers in
house dust concluded that home characteristics such as
dampness or visible mould explain variation in microbial
exposure levels only partially [90]. Moreover, a study from
Finland indicated that a considerable part of the measured
microbial pollution from mattresses is human-derived (up to
88%) rather than from environmental sources, and varies in
addition to that from other sampling locations [91]. Therefore, to
draw a causal relationship is complicated by the variability of
microbial biomarkers and their suspected effects on children’s
health. In conclusion, further research measuring specific
biomarkers in the home should be emphasised.
Conclusion
The reviewed studies on visible mould exposure indicated an
increased risk for allergic respiratory symptoms in children.
These findings were confirmed by the meta-analysis results;
exposure to visible mould was significantly associated with a
higher risk of allergic respiratory disorders including asthma,
wheezing and allergic rhinitis in children. Furthermore, the
results of this meta-analysis are consistent with the evaluation
of causation according to the Bradford Hill criteria. In order to
disentangle the different effects of overall microbial exposure
in children’s health, research on specific microbial markers in
the home, in combination with new assessment techniques
such as recently developed molecular methods, should be
followed. In this context, more weight needs to be given to
studies with longitudinal design as they can better assign the
temporal sequence; especially studies with a long follow-up
and multiple time-point measurements to account for the
variation of the complex microbial milieu over time.
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1) Funnel plots 
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Online Supplement 1: Funnel plots to check the existence of publication bias in meta-analyses. The vertical dashed line represents the mean of all study results. 
A symmetric shape suggests a balanced study publication which displays the study results with a natural statistical variance. An asymmetric shape indicates a 
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2) Results of the systematic review by epidemiological study design 
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high vs. none 
 
(Q) Rhinitis (1y): 1.1(0.8-1.6) 
 
 
(Q) Allergic rhinitis (1y): 3.2(0.7-14.8) 
(Q) Rhinitis (1y): 1.7(0.7-3.8) 


















483 Visible mould (8 m) 
(parental-reported) 
low vs. none 
high vs. none 
 
Visible mould (8 m) 
(parental-reported) 
low vs. none 
high vs. none 





(Q) Wheezing with API=1 (Asthma Predictive 
Index) (3y):  
1.68(0.96-2.94) 
7.08(2.22-12.60) 























405 Mould/mildew (1y) 
(parental-reported) 
(Q) Physician-diagnosed allergic rhinitis or hay 
fever (at 5y):  
1.28(0.74-2.22)  HR (crude) 






































(Q) Physician-diagnosed wheezing (1y):  
0.99(0.38-2.58) 
(Q) Wheezing apart from cold (1y): 
0.81(0.31-2.12) 
(Q) Nocturnal cough apart from cold (1y): 
0.74(0.30-1.85) 
 
(Q) Physician-diagnosed wheezing (1y): 
1.39(0.57-3.39) 
(Q) Wheezing apart from cold (1y): 
1.98(0.90-4.35) 
(Q) Nocturnal cough apart from cold (1y): 
1.13(0.51-2.53) 
 
(Q) Physician-diagnosed wheezing (1y): 
1.06(0.41-2.71) 
(Q) Wheezing apart from cold (1y): 
1.96(0.89-4.31) 
(Q) Nocturnal cough apart from cold (1y): 
0.94(0.40-2.21) 
 
(Q) Physician-diagnosed wheezing (1y): 
3.92(1.54-10.00) 
(Q) Wheezing apart from cold (1y): 
1.22(0.43-3.45) 
(Q) Nocturnal cough apart from cold (1y): 
1.73(0.69-4.30) 
 














































(Q) Wheezing apart from cold (1y): 
1.92(0.48-7.60) 

















Visible mould (6y) 
 
(Q) Physisician-diagnosed astma: 
 GERMANY: 1.03(0.26-4.16) 
NETHERLANDS: 1.14(0.48-2.70) 
(Q) Wheezing (6y): 
GERMANY: 1.29(0.52-3.21) 
NETHERLANDS: 1.28(0.65-2.49)  
(Q) Physician-diagnosed allergic rhinitis (6y): 
GERMANY: 1.77(0.79-3.99) 
NETHERLANDS: 1.60(0.62-4.14) 
(Q) Rhinoconjunctivitis (6y): 
GERMANY: 1.36 (0.56-3.26) 








current ETS, pets 





















275 Indoor moulds (3y) 
(parental-reported) 











MOULD SPORES EXPOSURE 




405 Air-borne (child’s bed 








Dust-borne (child’s bed 













(Q) Physician-diagnosed allergic rhinitis or hay 
fever (at 5y): 


























IgE > 0.35 U/mL, 































































IgE > 0.35 U/mL, 
sex, birth date in 
fall, any lower 
respiratory 










MOULD COMPONENTS EXPOSURE 







696 (1,3)-ß-D-glucan from 
living-room floor (3 m) 
(settled house dust) 
















EPS from living-room 
floor (3 m) 
(settled house dust) 
[EPSU / m2] 
(Q) Physician-diagnosed asthma (4y): 
Medium exposure: 0.63(0.27-1.48) 
High exposure: 0.70(0.30-1.60) 
(Q) Current wheeze (4y): 
Medium exposure: 1.50(0.77-2.94) 
High exposure: 0.76(0.34-1.72) 
(Q) Early transient wheeze (0-4y): 
Medium exposure: 0.89(0.46-1.71) 
High exposure: 0.57(0.28-1.16) 
(Q) Persistent wheeze (0-4y): 
Medium exposure: 1.16(0.52-2.62) 
High exposure: 0.43(0.15-1.21) 
 
(Q) Physician-diagnosed asthma (4y): 
Medium exposure: 0.85(0.32-2.27) 





(Q) Physician-diagnosed asthma (4y): 
Medium exposure: 0.78(0.40-1.55) 
High exposure: 0.42(0.18-0.99) 
(Q) Current wheeze (4y): 
Medium exposure: 1.28(0.70-2.32) 
High exposure: 0.63(0.30-1.32) 
(Q) Early transient wheeze (0-4y): 
Medium exposure: 0.99(0.56-1.76) 
High exposure: 0.67(0.36-1.23) 
(Q) Persistent wheeze (0-4y): 
Medium exposure: 1.07(0.53-2.16) 
High exposure: 0.37(0.15-0.96) 
 







































































































Medium exposure: 1.19(0.50-2.82) 
High exposure: 0.39(0.10-1.59) 
 




























574 (1,3)-ß-D-glucan from 
children’s primary 
activity room (8 m)  







activity room (8 m) [ 
µg/g] 








activity room (8 m)  
(settled house dust) 
[ µg/g] 
(Q) Recurrent wheeze (1y):  
 
1st quartile (3-22 µg/g): 3.04(1.25-7.38)  
2nd quartile (23-60 µg/g): 1.29(0.99-1.67) 
3rd quartile (61-133 µg/g): 0.82(0.65-1.05)  
4th quartile (134-900 µg/g): 0.39(0.16-0.93)  
 
 
(Q) Recurrent wheeze with SPT(+, any) vs. no 
wheeze with SPT(-) (1y):  
 
1st quartile (3-22 µg/g): 4.89(1.02-23.57)  
2nd quartile (23-60 µg/g): 1.23(0.79-1.92) 
3rd quartile (61-133 µg/g): 0.59(0.38-0.92)  
4th quartile (134-900 µg/g): 0.13(0.03-0.61)  
 
 
(Q) Recurrent wheeze with SPT(+, any) vs. no 
wheeze with SPT(+) (1y):  
 
1st quartile (3-22 µg/g): 160.51(4.85-5311.00)  
2nd quartile (23-60 µg/g): 2.54(0.97-6.62) 
3rd quartile (61-133 µg/g): 0.17(0.05-0.57)  
4th quartile (134-900 µg/g): 0.00(0.00-0.07)  









































483 (1,3)-ß-D-glucan from 
children’s primary 
activity room (8 m)  






activity room (8 m)  
(settled house dust) 
[ µg/ge] 
(Q) Wheezing with SPT(+, any) (3y):  
 
1st quartile (0.35-22.0 µg/ge): 1.91(0.18-20.56)  
2nd quartile (22.1-60.0 µg/ge): 0.97(0.72-1.31) 
3rd quartile (60.1-133.0 µg/ge): 0.80(0.54-1.18)  
4th quartile (133.1-960.0 µg/ge): 0.47(0.13-1.71)  
 
(Q) Wheezing with API=1 (Asthma Predictive 
Index) (3y):  
 
1st quartile (0.35-22.0 µg/ge): 3.44(0.50-23.52)  
2nd quartile (22.1-60.0 µg/ge): 1.14(0.87-1.50) 
3rd quartile (60.1-133.0 µg/ge): 0.91(0.70-1.17)  
4th quartile (133.1-960.0 µg/ge): 0.61(0.24-1.59) 

























* enriched: stands for studies which has over selected subjects who are at risk of developing allergic diseases for their study population.    
RR = Relative Risks 
HR = Hazard Ratio 
IRR = Incident Risk Ratio 
ETS = Environmental Tobacco Smoke 
IgE = Immunoglobulin E, immune reaction in the serum 
SPT = Skin Prick Test Reaction 











children’s mattress (5y) 











EPS from children’s 
mattress (5y)  
(settled house dust) 
[ mg/m2] 
(Q) Physician-diagnosed asthma (6y): 
GERMANY:  0.76 (0.40-1.45) 
NETHERLANDS: 1.28 (0.72-2.29) 
(Q) Wheezing (6y): 
GERMANY: 0.78 (0.35-11.54) 
NETHERLANDS: 0.82 (0.53-1.28) 
(Q) Physician-diagnosed allergic rhinitis: 
GERMANY: 0.69 (0.45-1.05) 
NETHERLANDS: 0.83 (0.42-1.63) 
(Q) Rhinoconjunctivitis: 
GERMANY: 0.74 (0.49-1.12) 
NETHERLANDS: 1.11 (0.62-1.97)) 
 
(Q) Physician-diagnosed asthma (6y): 
GERMANY: 0.60 (0.39-0.92) 
NETHERLANDS: 1.24 (0.78-1.96) 
(Q) Wheezing (6y): 
GERMANY: 1.02 (0.71-1.48) 
NETHERLANDS: 1.02 (0.74-1.42) 
(Q) Physician-diagnosed allergic rhinitis: 
GERMANY: 0.67 (0.49-0.92) 
NETHERLANDS: 1.00 (0.61-1.65) 
(Q) Rhinoconjunctivitis: 
GERMANY: 0.77 (0.56–1.07) 








current ETS, pets 




























 COHORT STUDIES (not recruited at birth) 
     










Other factors in 
the multivariate 
model 









al., 1989, U.S. 
Population-
based 
4625 Mould or mildew (7-11 y)
(parental-reported) 
(Q) Persistent wheeze (8-12 y):  
1.79(1.44-2.32) 
(Q) Hay fever (8-12 y): 
1.57(1.31-1.87) 
(Q) Physician-diagnosed asthma (8-12 y): 
1.27(0.93-1.74) 





















(Q) Physician-diagnosed asthma 
at ø 16 years, stratified by 
wheeze: 
YES: 0.6(0.4-0.9) RR 














(Q) Physician-diagnosed asthma (1-6 y): 




parent or guardian, 
maternal smoking 
during pregnancy, 
ETS, gas cooking, 
furry or feathery 













Visible mould in the 
kitchen (pregnancy) 
(parental-reported) 







time of delivery, 
older siblings, 
baby’s sex, baby’s 
birth weight 
(Q) Physician-diagnosed atopic 













849 Mould in the living room 
area (1 y) 
(parental-reported) 


















stove, wood stove, 
respiratory illness 
Rosenbaum et 





103 Visible mould (3 m) 
(inspector reported) 
 
(Q) Wheeze (1y): 0.90(0.35-2.29) cOR 
 
  n.s.  
MOULD SPORES EXPOSURE 





880 Air-borne (main living 











(Q) Wheeze (1 y): 
 
 
Low (1-499 cfu/m3): 1.11(0.87-1.42) 
Medium (500-999 cfu/m3): 1.29(0.65-1.48) 
High (≥ 1000 cfu/m3): 2.15(1.34-3.46)  
 
Low (1-499 cfu/m3): 0.92(0.69-1.22) 
Medium (500-999 cfu/m3): 0.95(0.61-1.49) 
High (≥ 1000 cfu/m3): 0.91(0.53-1.56) 
 
Low (1-499 cfu/m3): 0.97(0.75-1.26) 
Medium (500-999 cfu/m3): 0.91(0.49-1.68) 


























849 Air-borne (main living 
room) (ø 3 m) [cfu/m3] 
 
Total fungi 




cat and dog 
allergen, nitrogen 
dioxide 
















475 Air-borne (children’s 




Sensitization to grass (IgE) (3y): 5.28(1.02-27.1) ETS, parental 
atopy 
  + 
Rosenbaum et 





103 Air-borne (main living 












(Q) Wheeze (1y): 
 
 
2nd quartile (269-571 cfu/m3): 3.64(0.67-19.65) 
3rd quartile (572-1214 cfu/m3): 3.64(0.67-19.65) 
4th quartile (1215-4770 cfu/m3): 0.96(0.19-4.84)  
 
 
Low (16-64 cfu/m3): 1.27(0.41-3.98) 
High (65-2604 cfu/m3): 1.58(0.43-5.79)  
 
Low (16-119 cfu/m3): 1.80(0.50-6.55) 





























*enriched: stands for studies which has over selected subjects who are at risk of developing allergic diseases for their study population  
§ Non-sporulating fungi with dark hyphae 
IRR = Incident Risk Ratio 
RR = Relative Risks 
cOR = Crude Odds Ratios 
ETS = Environmental Tobacco Smoke 
IgE = Immunoglobulin E, immune reaction in the serum 





















Low (16-191 cfu/m3): 2.11(0.51-8.74) 
High (192-1715 cfu/m3): 2.28(0.41-12.67)  
 
Detected (16-478 cfu/m3): 1.72(0.49-6.03) 
 
Detected (16-191 cfu/m3): 0.96(0.27-3.45) 
 
Low (16-63 cfu/m3): 0.76(0.24-2.40) 
High (64-2191 cfu/m3): 0.77(0.24-2.49) 
 
2nd quartile (34-142 cfu/m3): 0.44(0.11-1.68) 
3rd quartile (143-381 cfu/m3): 0.64(0.18-2.32)  
4th quartile (382-2159 cfu/m3): 0.71(0.20-2.52)  
 
Low (16-64 cfu/m3): 0.61(0.19-1.96) 
High (65-413 cfu/m3): 0.76(0.23-2.57) 
 
Low (16-79 cfu/m3): 1.37(0.44-4.21) 
High (80-604 cfu/m3): 1.01(0.27-3.74) 
 
Insurance, sex, 


























 CASE-CONTROL STUDIES  
     










Other factors in 
the multivariate 
model 









































speech in the 
past year) 
961 Mould in the bedroom 
(parental-reported) 
(Q) Severe wheeze: 1.25(0.67-2.31) Sex, year of birth, 
housing tenure, 
gas for cooking, 
maternal smoking, 
paternal smoking, 
type of pillow, type 
of quilt, age 
mattress 
 n.s.  















(inspector reported)  
Living room 
Child’s bedroom 









 Sensitized to mite/mould: 
Visible mould (parental-reported)




Visible mould (inspector reported) 
















(3.5 y, case:  





550 Mould in ceilings / walls
(parental-reported) 
(Q) Atopic dermatitis: 1.25(0.65-2.38) cOR Parental atopy, 
breast feeding, 
history of wheeze, 
rash or runny nose 
at 1 year 
 n.s.  








540 Mould spots on surface 
materials in wet areas 
(2 m) 
(inspector reported) 





 n.s.  
Pekkanen et al., 
2007, Finland  
Case-Control 






362 Visible mould 
(inspector reported) 
 




















(Q) Physician-diagnosed asthma, 
stratified by atopy (IgE): 
YES: 4.74(0.94-24.01) 
NO: 1.08(0.32-3.64) 
(Q) Physician-diagnosed asthma, 















(ø 5.5 y, case: 
current asthma, 
matched by 
sex, age, SES) 
280 Mould growth elsewhere
(parental-reported) 
(Q) Current asthma: 0.48(0.30-0.79) Town of residence  -  
Li and Hsu, 
1997, Taiwan 
Case-control 
(7-15 y, case: 
asthma, atopic 
status) 
46 Visible mould 
(parental-reported) 
(Q) Asthma: 1.02(0.39-2.69) 
(Q) Allergic rhinitis: 3.50(1.00-12.34) 
Age, parental 






MOULD SPORES EXPOSURE 
Jovanovic et al., 
2004, Germany 
Case-control  
(9-11 y, case: 
allergy history) 
397 Air-borne [cfu/m3] AND 
dust-borne [cfu/m2] 




Sensitization to mould (IgE): n.s.     n.s. 









272 Dust-borne (living room 
floor) [cfu/g]: 
 
Total  moulds 
IQR 











Total  moulds 
> 200.000 (CFU/g)  




48.750-200.000 (CFU/g): 1.56(0.85-2.86) 
> 200.000 (CFU/g): 1.67(0.65-4.29) 
 
5.000-35.000 (CFU/g): 1.15(0.67-1.95) 
> 35.000 (CFU/g): 2.93(1.17-7.36) 
 
5.000-55.000 (CFU/g): 1.09(0.64-1.84) 
> 55.000 (CFU/g): 1.38(0.54-3.51) 
 
LOD*-25.000 (CFU/g): 2.11(1.22-3.65) 
> 25.000 (CFU/g): 1.76(0.73-4.28) 
 
















































































> 25.000 (CFU/g) 
(Q) Persistent wheezing: 
0.82(0.10-7.13) 
(Q) Physician-diagnosed hay-fever (ever): 
2.14(0.39-11.8) 
(Q) Red eyes/runny, congested nose: 
11.3(1.23-103.1) 
(Q) Physician-diagnosed eczema (ever): 
1.65(0.57-4.81) 
(Q) Itchy rash: 
1.46(0.54-3.96) 
 
(Q) Physician-diagnosed asthma (ever):  
0.52(0.06-4.27) 
(Q) Persistent wheezing: 
1.18(0.47-2.94) 
(Q) Physician-diagnosed hay-fever (ever): 
1.89(0.35-10.3) 
(Q) Red eyes/runny, congested nose: 
15.5(2.08-1154.0) 
(Q) Physician-diagnosed eczema (ever): 
0.54(0.12-2.44) 
(Q) Itchy rash: 
1.18(0.41-3.39) 
 
(Q) Physician-diagnosed asthma (ever):  
1.74(0.35-8.73) 
(Q) Persistent wheezing: 
2.55(0.44-14.7) 
(Q) Physician-diagnosed hay-fever (ever): 
2.57(0.54-12.3) 
(Q) Red eyes/runny, congested nose: 
17.6(1.69-183.4) 
(Q) Physician-diagnosed eczema (ever): 
1.21(0.83-3.88) 
(Q) Itchy rash: 
0.62(0.17-2.24) 
 
(Q) Physician-diagnosed asthma (ever):  
1.29(0.27-6.18) 
(Q) Persistent wheezing: 
2.15(0.41-11.4) 
(Q) Physician-diagnosed hay-fever (ever): 
Not estimable 
(Q) Red eyes/runny, congested nose: 
Not estimable 
(Q) Physician-diagnosed eczema (ever): 
2.16(0.80-2.52) 


















































Wickman et al., 
1992, Denmark 
Case-control  
(3-17 y, case: 
sensitization 
status, SPT to 
mite or inhalant 
allergens) 
175 Dust-borne  
(living room floor) 
[cfu/mg]  ≥ median 
 






















(Q) Physician-diagnosed allergic rhinitis: 
 HDM-sensitized: cOR 
























































Hyvärinen et al., 
2007, Finland 
Case-control  
(1-7 y, case: 





sex, age, place 
of residence) 
72 Dust-borne [cfu/g] 






























Li and Hsu, 
1997, Taiwan 
Case-control 
(7-15 y, case: 
asthma, atopic 
status) 
46 Air-borne [cfu/g] 
from living room floor 








1.55(0.71-3.36) Summer (S) 
0.69(0.28-1.73) Winter (W) 
Age, parental 





































































MOULD COMPONENTS EXPOSURE 







(2-4 y, matched 
by sensitization 
status) 
1052 (1,3)-ß-D-glucan from 
children’s mattresses  
(5-7 y)  
(settled house dust) 
[µg/m2] 
 
EPS from children’s 
mattresses (5-7 y)  




children’s mattresses  
(5-7 y)  
(settled house dust) 
[µg/g] 
 
EPS from children’s 
mattresses (5-7 y)  
(settled house dust) 
[EPSU/g] 

























































(5-13 y, case: 
atopic or non-
atopic wheeze) 
879 (1,3)-ß-D-glucan from 
children’s mattresses 
(settled house dust) 
[µg/g] 
 

















cOR = Crude Odds Ratios 
ETS = Environmental Tobacco Smoke 
IgE = Immunoglobulin E, immune reaction in the serum 
SPT = Skin Prick Test Reaction 
LOD = Limit of detection
Switzerland 
(PARSIFAL) 
EPS from children’s 
mattresses  
(settled house dust) 
[EPSU/g] 
(Q) Atopic wheeze: 0.79(0.63-0.98) during pregnancy - 




(6-12 y, case: 
respiratory 
symptoms) 
60 EPS-Asp/Pen from  
living room floor  
(settled house dust) 
[EPSU/mg] 
 










(Q) Physician-diagnosed asthma: 0.1(0.0-0.7) 
 
 
(Q) Physician-diagnosed asthma: 0.8(0.2-3.9) 
 










 CROSS-SECTIONAL STUDIES       










Other factors in 
the multivariate 
model 










































(Q) Hay fever ever: 1.35(1.18-1.53) 
(Q) Asthma ever: 1.35(1.20-1.51) 
(Q) Current wheeze: 1.43(1.36-1.49) 
(Q) Nocturnal dry cough: 1.30(1.22-1.39) 
Sensitization to inhalant allergens: 1.33(1.23-
1.44) 
 
(Q) Hay fever ever: 1.48(1.34-1.62) 
(Q) Asthma ever: 1.36(1.19-1.56) 
(Q) Current wheeze: 1.44(1.35-1.53) 
(Q) Nocturnal dry cough: 1.26(1.16-1.38) 
Sensitization to inhalant allergens: 1.38(1.26-
1.52) 
 
(Q) Hay fever ever: 1.47(1.35-1.61) 
(Q) Asthma ever: 1.23(1.07-1.41) 
(Q) Current wheeze: 1.46(1.31-1.61) 
(Q) Nocturnal dry cough: 1.23(1.12-1.34) 
Sensitization to inhalant allergens: 1.29(1.12-
1.49) 


































35036 Visible mould 
(parental-reported) 





(Q) Asthma, stratified by gender 








13495 Nr. of mould sites 
(parental-reported) 
0 vs. 1 
0 vs. 2 
 
 
0 vs. 1 
0 vs. 2 





(Q) Physician diagnosed asthma: 
1.40(1.16-1.68) cOR 
1.67(1.27-2.19) cOR 
Age, sex, race, 
parental 
education, gas 
cooking, nr. of 
smokers in home, 
















10784 Visible mould 
(parental-reported) 
(Q) Physician-diagnosed asthma (ever):  
1.54(1.22-1.94) 
(Q) Current asthma (past 2 y): 
Age, sex, 
breastfeeding, 






(Q) Current wheeze: 
1.65(1.25-2.17) 
(Q) Physician-diagnosed allergic rhinitis (ever): 
1.21(0.97-1.50) 
schooling, house 
type, area of 
residence, number 
of rooms, distance 
to traffic pollution 
source near by 
house, indoor coal 
use, current ETS 
exposure, ETS 
exposure in the 
first 2 years and 
during pregnancy, 




















(Q) Asthma: 1.26(0.87-1.81) 
 
 



















5951 Presence of moulds 
(parental-reported) 
(Q) Physician-diagnosed asthma: 2.82(1.63-4.88) 
(Q) Wheeze: 1.52(1.19-1.94) 
(Q) Asthma symptoms: 1.98(1.53-2.55) 
(Q) Physician-diagnosed any allergy: 1.51(1.25-
1.82) 



















Cox proportional hazard 
regression 
(Q) Wheeze: 1.34(0.91-1.96) PR 
(Q) Rhinitis: 1.55(1.16-2.07)  PR 
(Q) Rhinoconjunctivitis: 2.38(1.51-3.75)  PR 
(Q) Eczema: 1.28(0.83-1.97)  PR 
(Q) Flexural rash: 1.15(0.70-1.88)  PR 












Freeman et al., 
2003, U.S. 
Cross-sectional 












(Q) Physician-diagnosed asthma: 1.54(1.27-1.87) 
 
 














3945 Visible mould 
(parental-reported) 
(Q) Physician-diagnosed asthma: 1.56(1.13-2.16) 
(Q) Physician-diagnosed allergic rhinitis: 
1.20(0.72-1.99) 
(Q) Current asthma: 1.89(1.22-2.94) 
(Q) Current wheeze: 2.07(1.56-2.75) 
Age, sex, breast 
feeding, living in 
the city, school, 
house type, area 







rooms, distance to 
traffic, pollution 
source, indoor coal 
use, ETS, ETS < 
2y of age, smoking 
during pregnancy, 










3360 Mould on walls (1y) 
(parental-reported) 


























Study 1 (1987): 
(Q) Wheeze (6-12 y): 1.37(0.58-3.26) 
(Q) Asthma (6-12 y): 1.12(0.38-3.38) 
 
Study 2 (1989): 
(Q) Wheeze (6-12 y): 1.90(1.41-2.54) 
(Q) Asthma (6-12 y): 1.53(1.04-2.28) 
Sex, age, height, 
weight, ETS, 
(sources of) 
nitrogen dioxide in 















3003 Mould/mildew  
(parental-reported) 
(Q) Wheezing: 1.13 PReg, p=0.003 Sex, parental 
asthma, sibling 
asthma, age of 
day care 
attendance, pets 
at home during 
pregnancy, 





 +  
Garcia-Marcia 




2720 Mould stains 
(parental-reported) 
(Q) Atopic (SPT+) Wheezing: 1.86(0.81-4.24) 
(Q) Non-atopic (SPT-) Wheezing: 2.70(1.16-6.30) 
Sex, parental 
asthma, maternal 









1772 Visible mould on walls 
(parental-reported) 
 
Visible mould on walls, 
ceilings or windows 
(parental-reported) 
(Q) Physician-diagnosed asthma:  
3.26(2.38-4.45) cOR 
 
(Q)  Physician-diagnosed asthma:  
2.66(2.04-3.48)  cOR 










1452 Mould patches 
(parental-reported) 
(Q) Asthma symptoms: 1.56(0.90-2.69) 
(Q) Physician-diagnosed asthma: 1.55(0.78-3.09) 
(Q) Allergic rhinitis symptoms: 1.44(1.02-2.05) 
(Q) Physician-diagnosed allergic rhinitis:  










(Q) Eczema symptoms: 1.45(0.81-2.62) 










1340 Visible mould/ mildew 
(parental-reported) 
(Q) Physician-diagnosed asthma: 1.12(0.72-1.74) 
(Q) Allergic rhinitis (symptoms):  1.27(0.96-1.68) 
(Q) Wheeze: 1.20 (0.73-1.99) 
Age, sex, parental 
education, ETS, 









1235 Dampness and mould 
(parental-reported) 
Sensitization grass (SPT): 1.49(0.85-2.61) 
Sensitization birch (SPT): 0.75(0.28-2.00) 
Sensitization mugwort (SPT): 2.86(1.29-6.35) 
Sensitization alternaria (SPT): 1.65(0.69-3.93) 
Sensitization dust mites (SPT): 3.37(1.63-6.96) 


























(Q) Wheeze: 3.70(2.22-6.15) cOR 
 
 
(Q) Wheeze: 3.25(1.60-6.60) cOR 









925 Visible mould 
(parental-reported) 
(Q) Physician-diagnosed asthma: 
1.3(0.9-1.9) cPR 













858 Dampness and mould 
(parental-reported) 
(Q) Early wheeze (0-3y): 2.37(1.52-3.69) cOR 
(Q) Early transient wheeze: 2.28(1.34-3.87) cOR 
(Q) Persistent wheeze(0-6y): 2.53(1.30-4.87) 
cOR 
(Q) Late-onset wheeze(3-6y): 2.46(1.29-4.66) 
cOR 










775 Damp stains and mould
(parental-reported) 
(Q) Wheeze: 1.54(0.59-4.00)  cOR 
(Q) Asthma: 1.56(0.50-4.87)  cOR 
  n.s. 
n.s. 
 






606 Visible mould 
(parental-reported) 













470 Mould growth 
(parental-reported) 
 Sex, age, height, 
education level 





























(~ 10 y) 
403 Ever mould/mildew 
(parental-reported) 
(Q) Physician-diagnosed asthma: 0.91(0.42-1.95) Age, sex, parental 
allergy, parental 




 n.s.  
Koskinen et al., 
1999, Finland 
Cross-sectional 
















(Q) Rhinitis: 8.01(0.77-83.82) 
(Q) Atopic eczema: 3.02(0.59-16.27) 
(Q) Allergic eczema: 2.09(0.24-18.47) 
 
(Q) Rhinitis: 1.77(0.69-4.53) 
(Q) Atopic eczema: 2.29(0.79-6.60) 
(Q) Allergic eczema: 3.51(0.67-18.47) 
Age, gender´, 
allergy, pets at 











MOULD SPORES EXPOSURE 




762 Dust-borne Alternaria 
alternata  
[µg/g] 




 n.s.  
Garret et al., 
1998, Australia 
Cross-sectional 
(7-14 y)  
148 Air-borne Penicillium 



























(500 cfu/m3 increase) 
(Q) Current asthma: 1.43(1.03-2.00) 
Sensitization Cladosporium cl. (SPT): 1.24(0.92-
1.67) 
Sensitization Penicillium mix (SPT): 1.60(1.13-
2.18) 
Sensitization Aspergillus mix (SPT): 1.42(1.04-
1.95) 
Sensitization Alternaria alt. (SPT): 1.18(0.88-
1.57) 
Sensitization Mould mix A. (SPT): 1.19(0.88-
1.62) 
Sensitization D. pteronyssinus (SPT): 1.22(0.89-
1.67) 
Sensitization D. farinae (SPT): 1.32(0.95-1.85) 
Sensitization House dust (SPT): 1.49(1.05-3.17) 
Sensitization Dog (SPT): 1.46(1.09-1.96) 
Sensitization Cat (SPT): 1.21(0.92-1.59) 
Sensitization Bermuda grass (SPT): 1.12(0.85-
1.47) 
Sensitization Grass mix no. 7 (SPT): 1.12(0.85-
1.47) 
 
Sensitization Cladosporium cl. (SPT): 1.24(1.00-
1.54) 
Sensitization Penicillium mix (SPT): 1.29(1.02-
1.62) 
Sensitization Aspergillus mix (SPT): 1.37(1.07-
1.76) 


























































































(10 cfu/m3 increase) 
1.36) 
Sensitization Mould mix A. (SPT): 1.16(0.95-
1.43) 
Sensitization D. pteronyssinus (SPT): 1.02(0.93-
1.13) 
Sensitization D. farinae (SPT): 1.03(0.95-1.11) 
Sensitization House dust (SPT): 1.06(0.96-1.17) 
Sensitization Dog (SPT): 1.02(0.91-1.15) 
Sensitization Cat (SPT): 1.08(0.98-1.19) 
Sensitization Bermuda grass (SPT): 1.04(0.94-
1.15) 
Sensitization Grass mix no. 7 (SPT): 1.03(0.95-
1.11) 
 
(Q) Current asthma: 1.92(0.96-3.80) 
(Q) Current wheeze: 1.58(1.00-2.50) 
 













MOULD COMPONENTS EXPOSURE 








933 (1,3)-ß-D-glucan from 
children’s mattresses  
(settled house dust)  
[µg/g] 
 
EPS from children’s 
mattresses  
(settled house dust) 
[EPSU/g] 
(Q) Symptoms of atopic eczema: 0.75(0.53-1.06) 




(Q) Symptoms of atopic eczema: 0.76(0.65-0.90) 





















440 (1,3)-ß-D-glucan from 
children’s mattresses  




EPS from children’s 
mattresses  





children’s mattresses  
(settled house dust, self 
sampling)  
[µg/g] 
(Q) Ever asthma: +  





(Q) Ever asthma: -  










Sex, study centre, 
group, parental 










Sex, study centre, 
group, parental 
atopy, maternal 
































PR = prevalence ratio    
ETS = Environmental Tobacco Smoke  
SES = Socioeconomic Status   
cOR = Crude Odds Ratios  
cPR = Crude Prevalence Ratios 
pReg = Poisson Regression 
IgE = Immunoglobulin E, immune reaction in the serum 
SPT = Skin Prick Test Reaction 
 
EPS from children’s 
mattresses  




Sensitization inhalant and food allergens: + 
 











3) Evaluation of evidence of causation according to the Bradford Hill Criteria 
 
(1) Strength  
We observed a statistically significant increased risk of asthma (1.49 (1.28-1.72), wheeze 
(1.68 (1.48-1.90) and allergic rhinitis (1.39 (1.28-1.51) in children when exposed to visible 
mould in studies over the past 30 years. According to Hill’s criteria, inadequacy could 
derive from systematic errors such as reverse causation, without affecting the effect 
estimates. We were not able to look into every study included in the meta-analysis, 
however, numerous studies validated self-reported visible mould questions against 
inspector reported observations (1-6) and did not find any evidence for over- or 
underreporting of dampness and mould by occupants. 
 
(2) Consistency 
Has the association between visible mould exposure and allergic health outcomes been 
repeatedly observed by different persons, in different places, circumstances and times?  
This review was comprised of a number of publications on adverse health effects of 
mould and mould derived components exposure over the past 30 years. Visible mould 
exposure was reported to increase the risk for allergic health outcomes in every 
epidemiological study design described in our study. The same was found for mould 
spore exposure; however, the number of studies was limited. In contrast, we observed a 
protective tendency of mould derived components on allergic diseases in prospective and 
retrospective studies. Therefore, mould derived components such as (1,3)-ß-D-glucan or 
EPS might be an inadequate surrogate of visible mould exposure. 
 
(3) Specificity 
Multi-causation is generally more likely in epidemiological studies. Although we observed 
strong associations between mould exposure and allergic health outcomes, there were 
other risk factors such as second hand smoke (SHS), hidden microbial pollution or 
subject related risk factors. In order to account for specificity in the meta-analysis we 
included only studies with clearly defined exposure (“visible mould at home”), well-
defined health outcomes and similarly adjusted effect estimates. 
 
(4) Temporality 
Temporality refers to the temporal relationship of the association. In almost all birth 
cohort and cohort studies not recruited at birth there is at minimum one year between 
exposure and health outcome assessment. For case-control and cross-sectional based 
61 
 
studies, exposure was determined retrospectively. However, for the meta-analysis we 
had to combine studies regardless of their study design due to the limited number of 
prospective (birth) cohort studies. 
 
(5) Biological gradient 
There were only 8 publications included in this review that looked at the dose-response 
relationship between exposure and health outcomes assessment. One birth cohort study 
and one cross-sectional study reported that the number of mould sites at home 
significantly increased the risk for wheeze in 1 year old children, which was confirmed at 
the age of three years within the U.S. birth cohort study. Two U.S. cohort studies and one 
case-control study from Germany found that higher levels of Penicillium and 
Cladosporium increased the risk for allergic disorders. In contrast, two birth cohort 
studies from the U.S. and Europe found that higher levels of mould (1,3)-ß-D-glucan and 
EPS were associated with a decreased risk for physician-diagnosed asthma and 
(recurrent) wheeze.  
 
(6) Plausibility and (7) Coherence 
The inflammatory and allergenic potential of fungal allergens was investigated in a 
number of experimental studies (7, 8). Fungal exposure was associated with type 1 
allergies, with a focus on proteins produced by the respective species as suggested by 
IgE-inducing allergens (9-11). Several fungi and isolated mycotoxins were linked with 
inflammatory responses in vitro (12-14). Mould derived components such as (1,3)-ß-D-
glucans originate among others from fungi and have the capacity to initiate a variety of 
inflammatory reactions in vertebrates (15).  
 
(8) Experiment 
There are some intervention studies which investigated the effect of remediation of mould 
or microbial exposure in affected home or school environments in follow-up studies. After 
remediation, symptoms of allergic respiratory health outcomes and medication use 
decreased (16-20).  
 
(9) Analogy 
The indoor environment consists of a complex mixture of viable and non-viable organisms 
and a clear assignment to the observed health effect is difficult (21). Home dampness and 
visible mould, as an apparent exposure, might be only partly responsible for the observed 
health effects. However, most of the studies included in the meta-analysis were adjusted for 
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Abstract
Background: Several cross-sectional studies during the past 10 years have observed
an increased risk of allergic outcomes for children living in damp or mouldy envi-
ronments.
Objective: The objective of this study was to investigate whether reported mould or
dampness exposure in early life is associated with the development of allergic disor-
ders in children from eight European birth cohorts.
Methods: We analysed data from 31 742 children from eight ongoing European
birth cohorts. Exposure to mould and allergic health outcomes were assessed by
parental questionnaires at different time points. Meta-analyses with ﬁxed- and ran-
dom-effect models were applied. The number of the studies included in each analysis
varied based on the outcome data available for each cohort.
Results: Exposure to visible mould and/or dampness during ﬁrst 2 years of life was
associated with an increased risk of developing asthma: there was a signiﬁcant asso-
ciation with early asthma symptoms in meta-analyses of four cohorts [0–2 years:
adjusted odds ratios (aOR), 1.39 (95%CI, 1.05–1.84)] and with asthma later in
childhood in six cohorts [6–8 years: aOR, 1.09(95%CI, 0.90–1.32) and 3–10 years:
aOR, 1.10 (95%CI, 0.90–1.34)]. A statistically signiﬁcant association was observed
in six cohorts with symptoms of allergic rhinitis at school age [6–8 years: aOR, 1.12
(1.02–1.23)] and at any time point between 3 and 10 years [aOR, 1.18 (1.09–1.28)].
Conclusion: These ﬁndings suggest that a mouldy home environment in early life is
associated with an increased risk of asthma particularly in young children and aller-
gic rhinitis symptoms in school-age children.
Allergy
ª 2011 John Wiley & Sons A/S
Reviews conducted in the past 10 years have found an
increased risk of respiratory and allergic health outcomes in
children with a parent-reported damp and mouldy home
environment (1–5). Although a small number of collaborative
investigations have consistently reported increased risks of
asthma, wheeze and allergic rhinitis in children exposed to
visible mould (6–8), these previous studies have been primar-
ily cross-sectional, comprised different deﬁnitions of exposure
and health outcome and assessed the health outcome at a sin-
gle time point. The Environmental Health Risks in European
Birth Cohorts (ENRIECO) initiative included only popula-
tion-based prospective birth cohort studies and allows for
investigation into allergic health outcomes from birth to
10 years of age in a large, comprehensive, longitudinal data
set from eight European studies. The objective of this investi-
gation was to assess whether early residential exposure to
mould/dampness up to 2 years is associated with the develop-
ment of asthma, symptoms of allergic rhinitis and sensitiza-




ENRIECO is a project conducted within the European
Union’s Seventh Framework Programme [Theme 6, Environ-
ment (Including Climate Change)] focusing on the potential
health effects of environmental exposures. For this investiga-
tion, eight birth cohort studies with suitable information on

















Country UK UK Sweden Germany The
Netherlands
Germany Denmark Italy
First year of recruitment 1985 1991 1994 1995 1996 1997 1998 2004
N (birth) 330 14 057 4089 5991 3182 3097 562 434
Sex (female) 48% 48% 49% 48% 48% 49% 49% 51% 0.777
Early mould and/or
dampness (0–2 years)
19% 67% 28% 26% 55% 37% 36% 13% <0.001
Early asthma (0–2 years)* No data No data 14% 3% 4% 0.5% 24% 13% <0.001
School-age asthma
(6–8 years)
16% 10% 9% 5% 6% 5% 4% No data <0.001
Ever asthma (3–10 years) 16% 10% 18% 5% 9% 4% 4% No data <0.001
Symptoms of allergic rhinitis
at school-age (6–8 years)
36% 19% 14% 25% 33% 24% 3% No data <0.001
Ever symptoms of allergic
rhinitis (3–10 years)
36% 19% 19% 27% 42% 27% 3% No data <0.001
Sensitization to
aero-allergens at early school
age (6 –8 years)
No data No data 25% (8) 28% (6) 30% (8) 27% (6) 17% (6) No data <0.001
Sensitization to mould at early
school age (6–8 years)
No data No data 2% () 2% (6) 2% (8) 0.8% (6) 3% (6) No data <0.001
Parental allergy§ 61% 72% 61% 50% 40% 55% 59% 51% <0.001
Parental education
Low 57% – 20% 13% 13% 6% 19% – <0.001
Medium 26% 47% 27% 29% 37% 37% 65% 54%
High 17% 53% 53% 57% 50% 57% 16% 46%
Maternal smoking (pregnancy) No data 30% 13% 15% 27% 18% 33% 12% <0.001
Early SHS– exposure
(0–2 years)
29% 25% 6% 15% 13% 12% 21% 3% <0.001
Early day care (1–2 years) No data 10% 84% 53% 56% 25% 94% No data <0.001
Breastfeeding (‡4 months)** 27% 20% 80% 51% 32% 58% 20% 91% <0.001
IgE, Immunoglobulin E.
*DARC: High prevalence of early asthma because of high medication intake (medication prescribed for asthma or bronchitis).
DARC: Low prevalence of school-age symptoms of allergic rhinitis partly because of different assessment methods.
Sensitization to aero-allergens (6–8 years): IgE >0.35 ku/l for at least one of the measured aero-allergens in each birth cohort (cat dander,
dog dander, mite, mould, grass and tree pollen).
§Parental allergy: mother or father having at least one of the following allergic dispositions: asthma, hay fever, atopic eczema, pet allergy
and house dust mite allergy (ever).
–SHS: second-hand smoke (maternal smoking).
**Breastfeeding (at least 4 months).
Asthma and allergy in eight European birth cohorts Tischer et al.
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exposure and health outcomes were included. The cohorts
recruited subjects between 1985 and 2004 with a sample size
between 330 and 14 057 children (Table 1). Most studies were
single-centre studies, except two German birth cohorts
(LISAplus and GINIplus) and a Dutch birth cohort (PI-
AMA-NHS). All cohorts were population-based except the
PIAMA-NHS cohort that over-sampled nonallergic pregnant
women in the NHS component. All cohorts obtained ethical
approval from their local review boards.
Definition of exposure and health outcomes
Exposure was deﬁned as parent-reported mould and/or damp-
ness in any room of the home during the ﬁrst 2 years of life
(Data S1).
We deﬁned seven health end points, based on the compa-
rability across the birth cohort studies (Data S2): ‘Early
childhood asthma’ (0–2 years), ‘school-age asthma’ (6–
8 years), and ‘ever asthma’ at any time between 3 and
10 years of life. The asthma deﬁnition was based on the
ISAAC-related questions (17) and satisﬁed two of three con-
ditions: physician-diagnosed asthma ever, parent-reported
wheezing (last 12 months) and asthma medication (last
12 months). If there was no comprehensive information on
‘physician-diagnosed asthma ever’, we used ‘physician-diag-
nosed asthma in the past 12 months’ for the assessment.
School-age and childhood ‘symptoms of allergic rhinitis’ (6–
8 years) were deﬁned as sneezing attacks, runny, blocked and
itchy nose without having a cold.
Sensitization against aero-allergens and mould allergens
was available for ﬁve of the eight cohorts. Sensitization was
deﬁned as having speciﬁc Immunoglobulin E (IgE) of at least
0.35 kU/l to at least one of the measured aero-allergens (cat
dander, dog dander, mite, mould allergens, grass or tree pol-
len) between 6 and 8 years.
Definition of potential confounders
Individual cohort analyses were adjusted for the following
potential confounders: gender, parental atopy, parental edu-
cational level at birth (proxy for socio-economic status),
maternal smoking during pregnancy, environmental tobacco
smoke during the ﬁrst 2 years of life, breastfeeding (at least
4 months) and early day care attendance. A confounder was
considered a risk factor in the adjusted model if it was associ-
ated (v2-test, P < 0.1) with the respective health outcome in
at least two birth cohorts.
Statistical analysis
Logistic regression was used to calculate crude odds ratios
(OR) and adjusted odds ratios (aOR) to assess the effect of
early exposure to mould and/or dampness on the develop-
ment of allergic disorders including asthma, symptoms of
allergic rhinitis and sensitization to aero-allergens individu-
ally for each cohort and combined. Meta-analyses with
ﬁxed- and random-effect models were applied to account
for the heterogeneity between the cohorts. The number of
the studies included varies according to the data available
from each individual cohort. The results of the meta-analy-
sis are presented as forest plots with central point estimates
and 95% conﬁdence intervals (CI). We further stratiﬁed the
analyses by atopic sensitization status and parental allergy.
Statistical analyses were performed using the statistical




There were considerable variations among the European
birth cohorts regarding the distribution of most exposure
variables and potential confounders. During the ﬁrst 2 years
of life, exposure to residential mould and/or dampness ran-
ged from 13% in Bologna, Italy (CO.N.ER), to 67% in
Bristol, UK (ALSPAC). Further, in the Netherlands (PI-
AMA-NHS), Denmark (DARC) and one German birth
cohort (LISAplus), more than one-third of the parents
reported exposure to mould and/or dampness at home within
the ﬁrst 2 years of life (Table 1).
Early exposure to visible mould and/or dampness in relation
to allergic health outcomes
The results from the crude and adjusted logistic regression
models are presented in Table 2 and Fig. 1.
Among the Danish children, early asthma was reported in
24% when compared to a lower prevalence in the remaining
cohorts. In DARC, the question regarding medication intake
referred to any respiratory medication, not only asthma medi-
cation, which might partly explain the increased prevalence.
Further, the prevalence of symptoms of allergic rhinitis at
school age was reported for only 3% among the Danish chil-
dren who were assessed during clinical visits by physicians
and not by parent-reported symptoms. Owing to these differ-
ences in the assessment, the DARC cohort was excluded from
the adjusted analysis of asthma and symptoms of allergic rhi-
nitis to minimize classiﬁcation bias. However, we performed a
sensitivity analysis including the DARC cohort and observed
no major changes in the summary effects for asthma [(0–
2 years): aOR, 1.33 (95% CI, 1.05–1.69), (6–8 years): aOR,
1.39 (95% CI, 0.90–1.29), (3–10 years): aOR, 1.08 (95% CI,
0.89–1.32) and symptoms of allergic rhinitis (6–8 years):
aOR, 1.12 (95% CI, 1.03–1.23) and (3–10 years): aOR, 1.17
(95% CI, 1.08–1.26)]. Because of a similar prevalence of aller-
gic sensitization at school age among the cohorts, the DARC
cohort was included in the analysis of early exposure to
mould and allergic sensitization status at school age.
Asthma
There was a statistically signiﬁcant association between early
exposure to mould and asthma (<3 years) in adjusted analy-
sis of four cohorts (aOR, 1.39 (95% CI, 1.05–1.84), Fig. 1A).
The Leicester cohort showed a reduced risk of school-age
Tischer et al. Asthma and allergy in eight European birth cohorts
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asthma and asthma between age 3 and 10 in children who
were exposed to mould/dampness; however, this result should
be interpreted with caution because of the small sample size
of the included data set from the Leicester cohort. There was
statistically signiﬁcant heterogeneity between the cohorts in
the relationship between visible mould and/or dampness and
childhood asthma (3–10 years, P < 0.05).
Symptoms of allergic rhinitis
The combined OR between early exposure to mould and
symptoms of allergic rhinitis during early school age (6–
8 years) and childhood (3–10 years) were signiﬁcantly
increased in adjusted analyses [aOR, 1.12 (95% CI, 1.02–
1.23) and 1.18 (95% CI, 1.09–1.28)], respectively, Fig. 1B).
There was no signiﬁcant heterogeneity between the cohorts
observed.
Sensitization to aero-allergens and mould allergens
It was possible to model the relationship between early expo-
sure to mould and sensitization (assessed by speciﬁc IgE)
against aero-allergens in general and speciﬁcally against
mould allergens at 6–8 years of age for ﬁve cohorts. We
observed no association between early exposure to visible
mould and/or dampness and sensitization against aero-aller-
gens including mould at early school age in adjusted analyses
[aOR, 1.05 (95% CI, 0.89–1.24) and 1.01 (95% CI, 0.69–
1.49)], respectively (Fig. 1C). Further, we observed no signiﬁ-
cant heterogeneity between the cohorts.
To improve the comparison of the association between
early exposure to mould and asthma outcomes over time, we
restricted analyses to those birth cohorts with information at
each age category (BAMSE, GINIplus and PIAMA-NHS).
The subanalysis revealed similar results – the strongest effect
was found for early asthma [0–2 years: aOR, 1.31 (95%CI,
1.03–1.66), 6–8 years: aOR, 1.15 (95%CI, 0.94–1.40) and
3–10 years: aOR, 1.15 (95%CI, 0.90–1.48), respectively].
Stratified analysis
We further stratiﬁed the analysis for sensitization against
aero-allergens and parental allergy. The estimates showed a
positive but not statistically signiﬁcant association between
early exposure to mould and/or dampness and school-age
asthma in children without sensitization to aero-allergens
[OR 1.31 (95% CI, 0.92–1.86), Data S3].
Children with parental allergy and exposure to mould had
an increased risk of early asthma symptoms [aOR, 1.49
(95%CI, 1.00–2.22)], school-age asthma [aOR, 1.14 (95%CI,
0.97–1.35)] and asthma diagnoses between 3 and 10 years of
age [aOR, 1.28 (95%CI, 1.12–1.47)]. Similar effects were
observed for school-age and ever symptoms of allergic rhini-
tis [aOR, 1.14 (95%CI, 1.02–1.28) and aOR, 1.22 (95%CI,
1.11–1.33), respectively], but there was no association
between early exposure to mould in relation to sensitization
against aero-allergens in children with parental allergy. For
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gic, respiratory symptoms was observed; however, there was
a signiﬁcant decreased risk of sensitization against mould
allergens at school age [aOR, 0.41 (95%CI, 0.17–0.98), Data
S3].
Discussion
Our main ﬁndings of the meta-analysis of European birth
cohorts indicated that early-life exposure to visible mould
and/or dampness signiﬁcantly increased the risk of allergic
rhinitis symptoms up to 10 years of age. We also found a
modest and signiﬁcantly increased risk of asthma (<3 years)
and a nonsigniﬁcantly increased risk of later asthma out-
comes (6–8 and 3–10 years). No association was observed for
sensitization against aero-allergens or mould allergens at
school age (Fig. 1A–C).
Our results are in agreement with recent studies on mould
exposure and respiratory diseases in children (18–20). Collab-
orative studies observed statistically signiﬁcant increased risks
of asthma for children exposed to mould and dampness at
home ranging from adjusted ORs of 1.35–1.56 (6–8). Similar




Figure 1 (A) Asthma, (B) Symptoms of Allergic Rhinitis, (C) Allergic
Sensitization: Adjusted odds ratios and 95% confidence intervals
(95% CI) of asthma, symptoms of allergic rhinitis and allergic sensi-
tization in relation to early exposure to mould and/or dampness
(0–2 years), from random-effect meta-analyses (combined effect)
and separately by each cohort. For each study, the size of the box
represents the variance, the horizontal line the confidence interval
of each individual cohort. W (fixed) and W (random) indicate the
percentage weight of each cohort contributing to the combined
summary estimate.
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This is the largest investigation made into the association
of visible mould exposure and allergic disorders, using indi-
vidual participant data from birth cohorts. The prospective
design of these cohort studies is the best approach to assess
the temporal sequence between early childhood exposure and
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observation strengthens the independence of both measure-
ments. Crude variables from each of the eight birth cohorts
were harmonized. A cohort was eligible for the analysis if
there was information available for at least one of the seven
deﬁned health outcomes. As a result, not all cohorts contrib-
uted to all analysis.
Although visible mould has been consistently associated
with allergic outcomes, the causal agents have not been identi-
ﬁed (5). ‘The enormous diversity of the Fungal Kingdom is
well recognized’: in ‘healthy’ indoor environments, the pre-
dominant part of fungi is presented by the outdoor air genera
Cladosporium, followed by the genera mainly found indoors
including Penicillium and Aspergillus (19, 21). Once there is
moisture or mould, the composition of the fungal proﬁle is
shifting mainly to Penicillium and Aspergillus. Species such as
Penicillium chrysogenum, Penicillium expansum, Aspergillus
versicolor, Aspergillus penicillioides and also Stachybotris
chartarum were reported to be detected typically in moisture
damaged environments (22, 23). It has been shown that fungal
species induce inﬂammatory processes (5, 24) and that sensiti-
zation to mould allergens is linked to severe asthma (25). In
several studies, associations between exposure to spores of
Penicillium indoors and an increased risk of respiratory disor-
ders were described (26, 27). However, the epidemiological evi-
dence for the association between exposure to speciﬁc fungal
spores and asthma and allergy remains inconclusive (5, 28).
In this investigation, mould exposure was deﬁned as par-
ent-reported visible mould and/or dampness within the
homes. This common approach in epidemiological studies
might lead to misclassiﬁcation if moulds were not reported in
spite of being present (e.g. hidden behind furniture) or not
aerosolized and therefore not relevant to inhaled exposure.
As the appearance of visible mould might not be sensitive
enough, some studies measured mould exposure via settled
house dust or air sampling to reﬂect the potential inhaled
amount (29–31). This objective method is often not realizable
in large cohort populations. However, the correlation
between visible mould and the airborne concentration of fun-
gal spores seemed to be good (32), and slightly higher indoor
spore concentrations were reported for buildings with appar-
ent mould problems (33, 34). In summary, the presence of
visible mould serves as a good indicator that the indoor envi-
ronment is out of balance (19).
Our meta-analysis showed that early exposure to mould
was signiﬁcantly associated with asthma, especially in young
children. However, this positive effect could be masked by
uncertainties of the diagnosis in the ﬁrst 2 years of life and
therefore might be of a transient character. Nevertheless,
owing to the asthma deﬁnition used in our investigation, sat-
isfying at least two of three allergic conditions implies a more
serious health disorder rather than transient symptoms aris-
ing from a common cold, and adverse effects of mould expo-
sure on asthma were also observed at later ages.
Although the risk of allergic respiratory disorders was
increased in children exposed to mould/dampness, we found
no association with allergic sensitization at the same age –
which is considered to be a major risk factor (35, 36). More-
over, after stratifying children by their atopic status, there
was a positive, not-statistically-signiﬁcant association for
non-IgE-mediated asthma compared with the nonallergic and
nonsymptomatic children. In approximately 80% of child-
hood asthma cases, allergy seems to be mediated by IgE anti-
bodies (37), but it is unclear whether the tested aero-allergens
are causal agents. The mechanisms of nonallergic asthma
result from similar inﬂammatory changes, but are suggested
to be driven by the production of antibodies mainly of the
IgG, IgA and IgM isotype after inhalation of large amounts
of protein as in mould (37, 38). We further observed an
increased risk of visible mould exposure in relation to asthma
and symptoms of allergic rhinitis in children with parental
allergy, but not in children without this hereditary compo-
nent. In addition, early exposure to mould was observed to
decrease the risk of sensitization to mould allergens in chil-
dren without parental allergy; however, because of the small
sample size, these ﬁndings should be interpreted with caution.
Nevertheless, allergic parents are well advised to ensure
healthy indoor air quality and to both remove visible mould
or signs of moisture and actively prevent its formation in the
ﬁrst place.
Conclusion
The results of the ﬁrst collaborative effort of European birth
cohorts with regard to mould and/or dampness indicated an
increased risk of subsequent allergic respiratory symptoms in
children spending their ﬁrst years of life in homes with visi-
ble mould and/or dampness. To draw a causal relationship is
hindered by the variability of microbial components in
indoor air. Assessment techniques such as molecular meth-
ods and measurements of airborne enzyme activity are con-
sidered both highly sensitive and speciﬁc and may help to
identify patterns of causal agents in relation to asthma and
allergy.
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1) Definition of early mould and/or dampness exposure in each participating birth cohort 
 
Birth Cohort Early exposure to visible mould and/or dampness (birth to 2y) 
  
LEICESTER  In your child’s bedroom, during the winter months, are there patches of mould or fungus? (birth, 2y) 
 Please list other rooms in your house affected by mould or fungus. (birth, 2y) 
 In your child’s bedroom, during the winter months, does condensation ever form on the walls? (birth, 2y) 
 Please list other rooms in your house affected by condensation or damp. (birth, 2y) 
ALSPAC  Is there ever any damp, condensation or mould in your home? (birth to 2y)  
 Mould on walls? (birth to 1y) 
BAMSE  Has there been any visible mould/mildew in the home in the past year? (parental reported, birth) 
 Is there, or has there ever been, any type of moisture damage (spots and the like) in the home? (parental reported, birth) 
 Is there damage from dampness, mould or rot in wet areas, or is there a suspected (hidden) damage? (inspector reported, 
2y)  
GINIplus  (Were or) Are there damp stains or visible mould somewhere in the dwelling (except on food)? (birth) 
 (Were or) Are there damp stains or visible mould somewhere in the dwelling (except on food)? (2y) 
PIAMA-NHS  Did you see any damp stains or mould spots in the bathroom/living room/parents’ bedroom, child’s bedroom in the past 12 
months? (birth to 2y) 
LISAplus  (Were or) Are there damp stains or visible mould somewhere in the dwelling (except on food)? (birth to 2y) 
DARC  Is there mould in child’s sleeping room (birth to 1y)? 
 Are there visible wet spots or mould spots on walls/ceilings in the bathroom (birth to 1y)? 
CO.N.ER  Have you noticed dampness in the child’s bedrooms? (birth to 1y) 




2) Definition of health outcomes in each participating birth cohort 
 
Definition of “Early Asthma” in each participating birth cohort 
based on the ISAAC questions (Asher et al., 1995) defined as satisfying 2 out of 3 conditions 
 
Birth Cohort Early Asthma (birth to 2y) 
  
LEICESTER No early asthma 
ALSPAC No early asthma 
BAMSE  Has your child ever had problems involving: wheezy or raspy breathing? (1y) 
 Has your child, after the age of one year, ever had problems involving: Wheezy or raspy breathing? (2y) 
 Has your child ever/after the age of one year been prescribed any of the medicines listed below for treatment of 
asthma or breathing problems characterized by wheezing, heavy or difficult breathing? (1y, 2y) 
 Has a doctor diagnosed your child as having asthma after the age of one year? (1y, 2y 
GINIplus  Did your child suffer from wheezing in the chest while breathing in the last 12 months? (1y, 2y)? 
 Has a doctor diagnosed asthma on your child in the last 12 months? (2y)?
PIAMA-NHS  Has your child had wheezing or whistling in the chest during the past 12 months? (2y)  
 Has your child had asthma medication prescribed by a doctor during the last 12 months? (2y)  
 Has a doctor ever diagnosed asthma in your child? (2y)  
LISAplus  Did your child have chest wheezing in the last 12 months/last 6 months? (6 months, 1y, 2y)? 
 Doctor diagnosed asthma in the last 12 months/last 6 months (6 months, 1y, 2y)?
DARC  Has or has had the child occasionally suffered from wheezing since last follow-up? (birth to 2y) 
 Has the child received any prescriptive medication since the last follow-up?* (birth to 2y) 
 Do you think your child has asthma? (physician-diagnosed) (birth to 2y) 
CO.N.ER  Has your children ever had breath difficulty with wheezing symptoms at least once? (birth)  
 In the last 12 months has your children had breath difficulty with wheezing symptoms? (2y) 
 Asthma medication intake ever? (2y) 
 Has a doctor ever diagnosed asthma on your child? (2y) 




Definition of “School age Asthma” in each participating birth cohort (6-8y) 
based on the ISAAC questions (Asher et al., 1995) defined as satisfying 2 out of 3 conditions 
 
Birth Cohort School age Asthma (6-8y) 
  
LEICESTER  Has your child had wheezing or whistling in the chest in the last 12 months? (8y) 
 Asthma medication intake in the last 12 months? (8y) 
ALSPAC  Does he/she have wheezing with whistling on the chest when she/he breathes? (6y) 
 Child had asthma medication in past 12 months? (6y) 
BAMSE  Has your child had trouble with wheezing or raspy breathing since the age of 4? (8y) 
 Has your child received treatment for breathing difficulties in the last 12 months? (8y) 
 Has a doctor diagnosed your child as having asthma? (8y 
GINIplus  Did your child suffer from wheezing in the chest while breathing in the last 12 months? (6y) 
 Has a doctor diagnosed asthma on your child in the last 12 months? (6y) 
 Was your child treated for asthma in the last 24 months? (6y) 
PIAMA-NHS  Has your child had wheezing or whistling in the chest during the past 12 months? (6y) 
 Has your child had asthma medication prescribed by a doctor during the last 12 months? (6y) 
 Has a doctor ever diagnosed asthma in your child? (6y) 
LISAplus   Did your child have chest wheezing in the last 12 months? (6y) 
 Doctor diagnosed asthma in the last 12 months? (6y) 
 Was your child treated for asthma in the 5th or 6th year of life? 
DARC  Has or has had the child occasionally suffered from wheezing since last follow-up? (6y) 
 Has the child received any prescriptive medication since the last follow-up? (6y) 
 Do you think your child has asthma? (physician-diagnosed) (6y) 





Definition of “School age Symptoms of Allergic Rhinitis” in each participating birth cohort (6-8y) 
 
Birth Cohort School age Symptoms of Allergic Rhinitis (6-8y) 
  
LEICESTER  In the past 12 months, has your child had a problem with sneezing, or a runny, or blocked nose when he/she did not have 
a cold or the flu? (8y) 
ALSPAC  In the past 12 months, the child had sneezing or runny, blocked nose without having a cold or flu? (6y)
BAMSE  Has your child been afflicted with sneezing, runny nose, or stuffy nose without having a cold in the last 12 months? (8y) 
GINIplus  Did your child have sneezing attacks or a blocked, runny or itchy nose in the last 12 months, without having a cold? (6y) 
PIAMA-NHS  Hast the child had sneezed, runny or congested nose without having a cold during past 12 months? (6y)
LISAplus   Did your child have sneezing attacks or a blocked, runny or itchy nose in the last 12 months, without having a cold? (6y) 
DARC  Has the child had blocked nose (without cold) in the past 12 months? (6y) 





3) Mould and/or dampness exposure in relation to asthma and allergy, stratified by sensitization and parental allergy 
 
Crude odds ratios and 95% confidence intervals of school age asthma (6-8y) in relation to early exposure to mould and/or dampness (0-2 years),  












      
Children with sensitisation to inhalant allergens (IgE positive)
 1.02 (0.78 – 1.35) 
1.18 
(0.81 – 1.71) 
0.90 
(0.46 – 1.74) 
0.86 
(0.42 – 1.74) 
0.79 
(0.34 – 1.86) p = 0.7343 
       
Children without sensitisation to inhalant allergens (IgE negative)
       
 1.31 (0.92 – 1.86) 
1.37 
(0.87 – 2.17) 
1.45 
(0.67 – 3.16) 
0.86 
(0.32 – 2.31) 
1.41 






Adjusted Odds ratios (OR) and 95% confidence intervals (95% CI) of asthma, symptoms of allergic rhinitis and sensitisation to aero- 
allergens, respectively, in relation to early exposure to mould and/or dampness (0-2 years), stratified by parental allergy 
 
 
CHILDREN WITH PARENTAL ALLERGY 




Asthma           
Early (0-2y)  1.49 (1.00 – 2.22) n.a. n.a. 
1.28 
(1.43 – 2.32) 
0.97 
(0.58 – 1.61) 
1.18 
(0.71 – 1.97) DEM n.i. 
3.00 
(1.22 – 7.42) p = 0.0449 
School age (6-8y) 1.14 (0.97 – 1.35) 
0.28 
(0.06 – 1.22) 
1.13 
(0.88 – 1.44) 
1.23 
(0.90 – 1.67) 
1.18 
(0.70 – 1.98) 
1.19 
(0.66 – 2.14) 
1.09 
(0.57 – 2.09) n.i. n.a. p = 0.5796 
Ever (3-10y) 1.28 (1.12 – 1.47) DEM 
1.15 
(0.90 – 1.47) 
1.55 
(1.23 – 1.94) 
1.26 
(0.88 – 1.80) 
1.07 
(0.74 – 1.54) 
1.15 
(0.68 – 1.93) n.i. n.a. p = 0.4811 
           
Symptoms of allergic rhinitis          
School age (6-8y) 1.14 (1.02 – 1.28) DEM 
1.10 
(0:90 – 1.33) 
1.18 
(0.91 – 1.54) 
1.19 
(0:93 – 1.54) 
1.08 
(0.81 – 1.45) 
1.18 
(0.85 – 1.63) n.i. n.a. p = 0.9923 
Ever (3-10y) 1.22 (1.11 – 1.33) DEM 
1.15 
(0.99 – 1.33) 
1.38 
(1.11 – 1.73) 
1.31 
(1.07 – 1.61) 
1.08 
(0.86 – 1.37) 
1.25 
(0.96 – 1.63) n.i. n.a. p = 0.6364 
           
Sensitisation against          
Aero-allergens (6-8y) 1.11 (0.95 – 1.30) n.a. n.a. 
0.92 
(0.71 – 1.19) 
1.21 
(0.93 – 1.59) 
1.03 
(0.72 – 1.48) 
1.28 
(0.91 – 1.80) 
1.74 
(0.79 – 3.80) n.a. p = 0.3353 
Mould allergens (6-8y) 1.35 (0.86 – 2.11) n.a. n.a. 
0.78 
(0.36 – 1.67) 
1.55 
(0.66 – 3.61) 
1.73 
(0.65 – 4.62) 
2.57 
(0.61 – 10.83) 
2.21 













CHILDREN WITHOUT PARENTAL ALLERGY 




Asthma           
Early (0-2y)  1.15 (0.77 – 1.73) n.a. n.a. 
0.95 
(0.63 – 1.43) 
1.93 
(1.02 – 3.64) 
0.87 
(0.50 – 1.50) DEM n.i. 
2.11 
(0.42 – 10.68) p = 0.1815 
School age (6-8y) 1.06 (0.80 – 1.41) DEM 
1.46 
(0.87 – 1.47) 
1.08 
(0.61 – 1.93) 
1.14 
(0.53 – 2.47) 
0.83 
(0.47 – 1.47) 
0.37 
(0.10 – 1.33) n.i. n.a. p = 0.4408 
Ever (3-10y) 0.92 (0.74 – 1.14) DEM 
1.35 
(0.78 – 2.33) 
0.92 
(0.62 – 1.37) 
1.14 
(0.62 – 2.07) 
0.76 
(0.53 – 1.10) 
0.63 
(0.27 – 1.44) n.i. n.a. p = 0.5196 
           
Symptoms of allergic rhinitis          
School age (6-8y) 1.09 (0.93 – 1.28) DEM 
1.08 
(0:78 – 1.51) 
1.04 
(0.63 – 1.70) 
1.05 
(0:73 – 1.52) 
1.08 
(0.82 – 1.43) 
1.27 
(0.76 – 2.10) n.i. n.a. p = 0.9949 
Ever (3-10y) 1.09 (0.95 – 1.26) DEM 
1.12 
(0.86 – 1.46) 
1.16 
(0.80 – 1.69) 
1.23 
(0.94 – 1.61) 
1.15 
(0.94 – 1.39) 
0.72 
(0.49 – 1.04) n.i. n.a. p = 0.3018 
           
Sensitisation against            
Aero-allergens (6-8y) 0.94 (0.74 – 1.18) n.a. n.a. 
0.69 
(0.45 – 1.07) 
0.90 
(0.60 – 1.34) 
0.92 
(0.66 – 1.29) 
1.43 
(0.90 – 2.27) 
0.87 
(0.32 – 2.34) n.a. p = 0.2744 
Mould allergens (6-8y) 0.41 (0.17 – 0.98) n.a. n.a. 
0,29 
(0.04 – 2.24) 
0.25 
(0.03 – 1.93) 
0.52 
(0.15 – 1.79) DEM 
0.54 
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Respiratory health in children, and indoor
exposure to (1,3)-b-D-glucan, EPS mould
components and endotoxin
C. Tischer, U. Gehring, C-M. Chen, M. Kerkhof, G. Koppelman, S. Sausenthaler,
O. Herbarth, B. Schaaf, I. Lehmann, U. Kra¨mer, D. Berdel, A. von Berg, C.P. Bauer,
S. Koletzko, H-E. Wichmann, B. Brunekreef and J. Heinrich
ABSTRACT: For a long time, exposure to mould and dampness-derived microbial components
was considered a risk factor for the development of respiratory diseases and symptoms. Some
recent studies suggested that early childhood exposure to mould components, such as (1,3)-b-D-
glucan and extracellular polysaccharides (EPSs), may protect children from developing allergy.
We investigated the association of exposure to (1,3)-b-D-glucan, EPS and endotoxin with asthma
and allergies in 6-yr-old children.
This investigation was the follow-up to a nested case–control study among three European birth
cohorts. Children from two ongoing birth cohort studies performed in Germany (n5358) and one
in the Netherlands (n5338) were selected. Levels of (1,3)-b-D-glucan, EPS and endotoxin were
measured in settled house dust sampled from children’s mattresses and living-room floors when
the children were, on average, 5 yrs of age. At the age of 6 yrs, health outcome information was
available for 678 children.
In the two German subsets, domestic EPS and endotoxin exposure from children’s mattresses
were significantly negatively associated with physician-diagnosed asthma (OR per interquartile
range increase 0.60 (95% CI 0.39–0.92) and 0.55 (95% CI 0.31–0.97), respectively). In addition,
EPS exposure was inversely related to physician-diagnosed allergic rhinitis (OR 0.50, 95% CI
0.31–0.81). For the Dutch population, no associations were observed between exposure to
microbial agents and respiratory health outcomes.
We found inverse associations between domestic exposure to EPS and endotoxin from
children’s mattresses, and doctor-diagnosed asthma and rhinitis in German, but not in Dutch,
school children. The reasons for the differences between countries are not clear.
KEYWORDS: Allergy, asthma, childhood, endotoxin, rhinitis
T
he effect of visible mould and mould
components in indoor environments on
asthma and allergic diseases in children
has been widely discussed in recent years.
Several studies have investigated the associa-
tions, but the results were not conclusive.
Some studies have shown that visible mould in
homes increases the risk of physician-diagnosed
asthma and wheezing in children [1–6]. A birth
cohort study in the USA concluded that 1-yr-old
children of asthmatic and allergic mothers who
were exposed to high levels of Penicillium, a
common genus of mould, were at significantly
higher risk for wheeze and persistent cough [7].
Another US study showed that exposure to dust-
borne Aspergillus, Alternaria and Aureobasidium at
3 months of age was associated with the develop-
ment of physician-diagnosed allergic rhinitis
within the first 5 yrs of life [8].
Few studies measured biological components of
mould, such as (1,3)-b-D-glucan and extracellular
polysaccharides (EPSs), as surrogates for mould
exposure [3, 9]. (1,3)-b-D-glucans are nonaller-
genic, water-insoluble, structural cell wall com-
ponents of most fungi. This biologically active
polyglucose molecule may account for f60% of
the dry weight of the fungal cell wall [10].
However, (1,3)-b-D-glucans are also part of the
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structure of plant materials, including pollen and cellulose, as
well as soil bacteria; therefore, the level of mould exposure
may be overestimated by using (1,3)-b-D-glucan as a surrogate.
Fungal EPSs are stable carbohydrates secreted or shed during
fungal growth and have antigenic specificity at the genus level.
In contrast with the findings on visible mould and measured
specific mould species, longitudinal studies showed that
exposure to (1,3)-b-D-glucan and EPS was inversely associated
with wheezing symptoms and parentally reported physician-
diagnosed asthma in children [3, 5, 11]. In addition, one case–
control study reported that elevated levels of (1,3)-b-D-glucan
and EPS exposure from mattress dust were associated with a
lower prevalence of allergic sensitisation in 2–4-yr-old children
[9]. However, the mechanism of these inverse effects is not yet
understood. Different ways of assessing mould exposure could
explain the conflicting results. HAAS et al. [12] reported that
visible mould growth was significantly correlated with the
concentration of fungal spores. As opposed this, a US cohort
study did not observe a correlation between (1,3)-b-D-glucan
exposure and visible mould [3, 5].
Early exposure to mould components compared with exposure
later in life also showed a different impact on allergic health
outcomes [13]. The immune response of newborns is domi-
nated by T-helper (Th)2-cells and a shift to Th1-mediated
immune response takes place during early childhood. It has
been hypothesised that exposure to (1,3)-b-D-glucan and EPS
may have a similar impact on the development of immune
system of infants as early endotoxin exposure [3, 14, 15].
Endotoxins are cell wall components of the outer membrane of
Gram-negative bacteria. They are ubiquitous and can be found
in normal indoor environments as constituents of house dust.
Exposure to endotoxin has been suggested to have strong
immune-stimulatory properties [16, 17]. In support of the
‘‘hygiene hypothesis’’ [18, 19], previous studies showed that
there is a lower prevalence of allergic sensitisation and
physician-diagnosed asthma in children who were exposed
to higher levels of endotoxin at home [9, 11, 20]. It was
hypothesised that microbial products such as endotoxin could
affect the development of children’s immune systems early in
life and play a crucial role in the development of tolerance to
allergens ubiquitous in natural surroundings [21, 22].
We prospectively investigated the associations between expo-
sure to mould components and endotoxin in settled house dust
with respiratory and allergic health outcomes in 6-yr-old
children using the data from two German birth cohorts and
one Dutch birth cohort. This study is a continuation of the
work that has been done within the AirAllerg study [9, 23].
Earlier AirAllerg investigations were based on health out-
comes measured before exposure assessment. However, in the
present analysis, health outcomes from the 6-yr follow-up were
available after exposure assessment.
MATERIALS AND METHODS
Study design and study population
Three European birth cohort studies were included in this
investigation: the German LISA (Lifestyle Related Factors on
the Immune System and the Development of Allergies in
Childhood) and GINI (German Infant Nutritional Intervention)
studies, and the Dutch PIAMA (Prevention and Incidence of
Asthma and Mite Allergy) study. LISA is a population-based
birth cohort study. A total of 3,097 neonates were recruited
between 1997 and 1999 in Munich, Leipzig, Wesel and Bad
Honnef. The participants were not pre-selected based on
family history of allergic diseases [24]. A total of 5,991 mothers
and their newborns were recruited into the GINI study
between September 1995 and June 1998 in Munich and
Wesel. Infants with at least one allergic parent and/or sibling
were allocated to the interventional study arm of the GINI
study investigating the effect of different hydrolysed formulas
for allergy prevention in the first year of life [25]. All children
without a family history of allergic diseases and children
whose parents did not give consent for the intervention were
allocated to the noninterventional arm. Detailed descriptions of
the LISA [24] and GINI [25] studies were published elsewhere.
For the PIAMA study, a total of 4,146 pregnant females
were recruited in 1996–1997 during their second trimester of
pregnancy from a series of communities in the north, west and
centre of the Netherlands. Nonallergic pregnant females were
invited to participate in a ‘‘natural history’’ study arm.
Pregnant females identified as allergic through the screening
questionnaire were primarily allocated to an intervention arm
with a random subset allocated to the natural history arm. The
intervention involved the use of mite-impermeable mattress
and pillow covers.
The three European birth cohorts described above were part of
a collaborative nested case–control study (AirAllerg) within
European birth cohorts (LISA, GINI and PIAMA) using the
data on allergic sensitisation that have been collected at age
4 yrs in the Netherlands and at ages 2 and 3 yrs in Germany
(fig. 1 and supplementary material 1). The target population
size was ,180 sensitised children and 180 nonsensitised
children as controls in each country. The controls were not
matched by any criteria. Based on serum immunoglobulin
(Ig)E determination, cases were defined as children who were
sensitised to common aeroallergens. The number of children
sensitised to aeroallergens was not reached in Germany and
the Netherlands; the cases were supplemented with children
sensitised to food. Allergen panels differed between the
cohorts, but specific IgE to egg white, milk, house dust mites,
cat, and tree and grass pollens were measured in all cohorts.
Families should not have moved 6 months prior to the
AirAllerg house-dust samplings. However, in Germany it
was not possible to strictly follow this criterion; only 76% of the
German participants fulfilled the criterion of not moving
home. For the present investigation, 317 sensitised and 379
nonsensitised children were selected from the GINI, LISA and
PIAMA birth cohort studies. At the age of 6 yrs, health end-
point data was available from 346 and 332 of the German and
Dutch participants of the AirAllerg study, respectively.
Questionnaire data
In the German and Dutch populations, information on
respiratory and allergic disorders, history of moving home,
and visible mould in the child’s home was collected at
age 6 yrs, using self-administered questionnaires. An online
supplement is provided to display the exact health outcome
definitions within the 6-yr follow-up period of both subsets
(see supplementary material 2). Information on parental
educational level, family history of allergic diseases, smoking
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during pregnancy and breast feeding were collected using self-
administered questionnaires during the first year of life.
Dust collection
Between January 2002 and May 2003, trained fieldworkers
collected house-dust samples during home visits when the
study children were, on average, 5 yrs (LISA and PIAMA)
and 6 yrs (GINI) of age. A detailed description of the analysis
and collection of the house-dust samples is provided else-
where [23]. In brief, dust sampling was conducted using a
common standard operation procedure of the AirAllerg
study in the cool seasons. During the home visit, two settled
house-dust samples from the child’s mattress and the living-
room floor were collected by vacuuming. After dust
sampling, the filters and the dust were stored at -20uC until
extraction.
Dust extraction and analysis
Dust, including filters, was extracted sequentially as described
previously [14]. The first supernatant was used to measure
endotoxin by a chromogenic kinetic Limulus amoebocyte lysate
test [26]. The second supernatant was used to measure EPS
of Aspergillus and Penicillium spp. by a sandwich enzyme
immunoassay [27]. (1,3)-b-D-glucan was measured in the third
supernatant with a (1,3)-b-D-glucan-specific inhibition enzyme
immunoassay [28]. The detection limits of the assay were
0.05 endotoxin units?mL-1, 3.3 mg?mL-1 and 0.9 EPS units?mL-1
for endotoxin, (1,3)-b-D-glucan and EPS of Aspergillus and
Penicillium spp., respectively. Exposures were expressed as both
per gram of sampled dust (concentration) and per square metre
of sampling surface area (load). Samples of (1,3)-b-D-glucan and
EPS below the limit of detection (LOD) were assigned a value of
two-thirds of the respective LOD [11].
Statistical analysis
Distributions of the biocontaminant levels in house-dust
samples were highly skewed and, therefore, were described
using median (interquartile range (IQR)). Spearman’s rank
correlation coefficient was used to calculate the correlations.
The skewed variables were log-transformed for further analy-
sis. Generalised additive models using a local regression
smoothing operation were fitted to assess the relationship of
the associations between continuous indoor biological con-
taminants exposure and the logit of the binary health outcomes.
Since most associations were linear, all exposure variables
were used as continuous variables without transformation in
further analyses.
Logistic regression models were used to determine associa-
tions between microbial exposure from children’s mattresses
and living-room floors, and allergic health outcomes. The
confounders we adjusted for in logistic regression models were
selected based on the literature. For the German subset,
confounders included in all models were sex, parental allergy,
parental education, current pet ownership, breastfeeding,
case–control status in the AirAllerg study and season of dust
sampling. Total amount of dust and endotoxin was addition-
ally adjusted for current domestic exposure to environmental
tobacco smoke (ETS). Visible mould exposure was adjusted for
sex, parental allergy, parental education, outdoor activity in
summer, breastfeeding, maternal smoking during pregnancy,
study type and case or control status. Within the Dutch subset,
confounders included in all models were sex, parental allergy,
parental education, current domestic exposure to ETS, current
pet ownership, breastfeeding, AirAllerg case–control status
and season of dust sampling. Since the AirAllerg study is not a
population-based sample and selected based on sensitisation
status, we adjusted for case–control status in order to avoid
bias. Being a case or a control within the study population not
only affected the health outcomes in terms of allergic diseases
and symptoms, but also the exposure and is, therefore, a
confounder that we took into account for the current
investigation.
The results are presented as OR (95% CI) for an IQR increase in
microbial exposure. We focused on exposure from children’s
mattresses due to a considerable amount of nondetectable
values from living-room floor dust samples. The analyses were




A total of 346 German and 332 Dutch children with
information on domestic microbial exposure, and respiratory
and allergic health outcomes were included in the analysis.
Baseline characteristics and health outcomes assessed at the
age of 6 yrs are presented in table 1. There were some
significant differences between the German and Dutch subsets.
A higher percentage of the Dutch children were exposed to
visible mould and were reported to have a pet at home




































FIGURE 1. Study design and population. LISA: Lifestyle Related Factors on
the Immune System and the Development of Allergies in Childhood; GINI: German
Infant Nutritional Intervention; PIAMA: Prevention and Incidence of Asthma and Mite
Allergy; Ig: immunoglobulin.
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the Dutch subjects, but only a small number of the German
children, had visited day-care within the first year of life. The
prevalence of physician-diagnosed respiratory infections in the
previous 12 months at the age of 6 yrs was five times higher
among the German compared with the Dutch population. The
German children often reported more physician-diagnosed
allergic rhinitis and rhinoconjunctivitis, whereas the Dutch
children showed a higher prevalence of nocturnal dry cough.
The season of dust sampling differed considerably between
Germany and the Netherlands.
Amount of dust sampled, and (1,3)-b-D-glucan, EPS and
endotoxin levels
The number of samples below the LOD, the median (IQR) of
total amount of dust, mould components and endotoxin
measured from domestic dust samples are presented in table 2.
Wilcoxon tests showed significant differences in biocontami-
nant levels measured between the cohorts. Endotoxin and
(1,3)-b-D-glucan loads, and (1,3)-b-D-glucan concentrations
from children’s mattresses in Germany were significantly than
the Dutch sample. There were weak correlations between the
TABLE 1 Description of the German and Dutch AirAllerg study population at age 6 yrs
LISA and GINI PIAMA p-value




Males 204/358 (57) 186/332 (56) 0.859
Parental allergy# 294/358 (82) 260/332 (78) 0.246
Parental education"
High 198/358 (55) 193/332 (56) 0.502
Medium 106/358 (30) 110/332 (33) 0.360
Low 54/358 (15) 29/332 (9) 0.014
Visible mould in any room at 6 yrs of age 56/323 (17) 108/329 (33) ,0.001
Dwelling considered damp at 6 yrs of age 10/339 (3) NA NA
Any pets in child’s home at 6 yrs of age 86/345 (25) 133/326 (41) ,0.001
Day-care attendance
1st year 5/318 (1) 83/330 (25) ,0.001
2nd year 29/306 (8) 85/323 (26) ,0.001
3rd year 68/319 (19) 133/326 (41) ,0.001
4th year 257/324 (72) 244/324 (75) 0.260
Breastfeeding+ 179/333 (54) 201/328 (61) 0.060
Smoking in child’s home at 6 yrs of age 72/344 (21) 89/331 (27) 0.084
Maternal smoking during pregnancy 50/357 (14) 45/328 (14) 0.985
Moving home1 at 6 yrs of age 39/346 (11) 13/330 (4) ,0.001
Physician-diagnosed asthmae 17/343 (5) 27/328 (8) 0.119
Physician-diagnosed allergic rhinitise,## 47/342 (14) 24/327 (7) 0.010
Allergic respiratory symptomse
Rhinoconjunctivitis 48/343 (14) 28/327 (7) 0.036
Wheezing 43/341 (13) 48/331 (15) 0.546
Dry cough"" 56/343 (16) 80/330 (24) 0.014
Physician-diagnosed infections of the upper airwayse 275/342 (80) 47/329 (14) ,0.001
Dust sampling season++
Autumn 48/358 (13) 101/332 (30) ,0.001
Winter 57/358 (16) 113/332 (34) ,0.001
Spring 253/358 (71) 118/332 (36) ,0.001
Data are presented as n, n (%) or n/N (%), unless otherwise stated. Bold indicates statistically significant p-values. LISA: Lifestyle Related Factors on the Immune System
and the Development of Allergies in Childhood; GINI: German Infant Nutritional Intervention; PIAMA: Prevention and Incidence of Asthma and Mite Allergy; NA: not
available. #: defined as asthma and/or hay fever and/or eczema (at least one parent) for LISA and GINI and as asthma and/or allergy to house dust (mite) or pets, and/or
hay fever in at least one parent for PIAMA; ": categorised according to the German educational system as less than, equal to and more than grade 10 for low, medium and
high, respectively, for LISA and GINI and as the highest attained educational level of mother and father, where low is primary school, lower vocational or lower secondary
education, medium is intermediate vocational education or intermediate/ higher secondary education, and high is higher vocational education and university for PIAMA;
+: defined as exclusive breastfeeding during the first 4 months of life for LISA and GINI and as any breastfeeding at the age of 3 months for PIAMA; 1: defined as moving
home in the previous 24 months for GINI, and as moving home in the previous 12 months for LISA and PIAMA; e: in the previous 12 months; ##: defined as hayfever and/
or allergic rhinitis (all seasons) for LISA and GINI, and as hayfever ever for PIAMA; "": defined as nocturnal dry cough for PIAMA; ++: autumn defined as October–
November, winter as December–February and spring as March–April.
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biocontaminant levels from children’s mattresses and living-
room floors both for surface load and per gram of dust
(Spearman’s correlation coefficient: GINI and LISA ,0.25,
PIAMA ,0.13). The correlations between (1,3)-b-D-glucan, EPS
and endotoxin from mattress dust samples were weak when
these were expressed as units per gram of collected dust;
however, the correlations were stronger when they were
defined as surface loads (table 3).
Associations between mould components and endotoxin,
and respiratory diseases and symptoms
Adjusted logistic regression models showed inconsistent
results in the German and Dutch subsets. In the German
population, EPS and endotoxin exposure from children’s mat-
tresses was significantly negatively associated with physician-
diagnosed asthma (OR per IQR 0.60 (95% CI 0.39–0.92) and OR
0.55 (95% CI 0.31–0.97), respectively). EPS exposure was also
TABLE 2 Biocontaminant levels measured from children’s mattress and living-room floors
LISA and GINI PIAMA Wilcoxon test p-value
Subjects n 358# 332
Child’s mattress dust load
Amount of dust mg?m-2 0/257 (139–471) 0/247 (148–366) 0.322
Endotoxin EU?m-2 2/3053 (1521–6015) 0/2356 (1461–4208) 0.003
(1,3)-b-D-glucan mg?m-2 0/421 (238–865) 0/380 (199–625) 0.002
EPS EPSU?m-2 6/1008 (4458–25904) 5/8257 (3890–17310) 0.026
Child’s mattress dust concentration
Endotoxin EU?g-1 2/12222 (7379–21337) 0/10608 (6550–17366) 0.021
(1,3)-b-D-glucan mg?g-1 0/1859 (1277–2396) 0/1662 (1135–2205) 0.002
EPS EPSU?g-1 6/40792 (24235–65371) 5/34696 (20364–58156) 0.021
Living-room floor dust load
Amount of dust mg?m-2 0/200 (52–523) 22/104 (31–564) 0.040
Endotoxin EU?m-2 14/3749 (1034–10212) 23/2299 (441–14224) 0.126
(1,3)-b-D-glucan mg?m-2 0/445 (114–1267) 7/177 (59–1417) 0.024
EPS EPSU?m-2 28/8113 (1076–32188) 70/2009 (154–33251) ,0.001
Living-room floor concentration
Endotoxin EU?g-1 14/19400 (10104–32678) 23/18196 (9522–32106) 0.451
(1,3)-b-D-glucan mg?g-1 0/2229 (1703–3114) 7/2137 (1519–2994) 0.130
EPS EPSU?g-1 28/39344 (18290–76367) 70/20330 (3896–61555) ,0.001
Data are presented as n/median (interquartile range), where n is the number of values below the limit of detection, unless otherwise stated. Bold indicates statistically significant
p-values. LISA: Lifestyle Related Factors on the Immune System and the Development of Allergies in Childhood; GINI: German Infant Nutritional Intervention; PIAMA:
Prevention and Incidence of Asthma and Mite Allergy; EU: endotoxin units; EPS: extracellular polysaccharide; EPSU: EPS units. #: two subjects more than in [9] (n5356).
TABLE 3 Correlation between the measured microbial components
LISA and GINI PIAMA
Dust (1,3)-b-D-glucan EPS Endotoxin Dust (1,3)-b-D-glucan EPS Endotoxin
Children’s mattresses
Dust 1.00 1.00
(1,3)-b-D-glucan 0.86 1.00 0.04 0.24 0.78 1.00 0.13 0.15
EPS 0.76 0.67 1.00 0.22 0.70 0.63 1.00 0.07
Endotoxin 0.63 0.66 0.60 1.00 0.59 0.54 0.51 1.00
Living-room floor
Dust 1.00 1.00
(1,3)-b-D-glucan 0.94 1.00 0.21 0.26 0.95 1.00 0.36 0.42
EPS 0.87 0.89 1.00 0.24 0.90 0.89 1.00 0.49
Endotoxin 0.87 0.88 0.82 1.00 0.93 0.93 0.87 1.00
Data are presented as Spearman’s r. Amount of dust sampled is per square metre of surface area. Endotoxin, (1,3)-b-D-glucan and extracellular polysaccharide (EPS)
levels are per gram of dust (concentration; bold only) or per square metre of surface area (load; bold and italic). LISA: Lifestyle Related Factors on the Immune System
and the Development of Allergies in Childhood; GINI: German Infant Nutritional Intervention; PIAMA: Prevention and Incidence of Asthma and Mite Allergy.
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inversely related to physician-diagnosed allergic rhinitis (OR
0.67, 95% CI 0.49–0.92) (table 4). Further stratification for
parental allergy showed similar effects in children with allergic
parents; however, the confidence intervals are wide. No effect
on respiratory symptoms was observed. For the Dutch popu-
lation, we could not find any effect of exposure to bioconta-
minants on any health outcomes assessed (table 5). The
associations between exposure from living-room floor dust
and assessed health outcomes were similar to exposure from
children’s mattresses, but were not significant (data not
shown); this may be due to a higher number of nondetectable
values for living-room floor dust samples compared with
mattress dust samples.
In both samples, (1,3)-b-D-glucan, EPS, endotoxin and total
amount of dust were highly correlated. Mutual adjustment for
microbial exposure did not change the observed effects.
Associations between visible mould exposure and
endotoxin and respiratory diseases and symptoms
We further investigated the effect of visible mould exposure on
allergic respiratory disorders. A total number of 56 (17%) homes
in Germany and 108 (33%) homes in the Netherlands were
reported as having visible mould. We could not observe any
association between visible mould exposure and any health
outcome assessed within the German and Dutch sample (table 6).
DISCUSSION
Although we investigated birth cohort studies with a long-
itudinal design, exposure and health outcome assessment were
only measured at one time point between the ages of 5 and
6 yrs. However, in contrast with earlier AirAllerg investiga-
tions, we were now able to measure health outcomes after
exposure assessment. A further reason for the present study
design is that before and after the age of 6 yrs, the German and
Dutch birth cohorts had different time points of follow-up (i.e.
PIAMA was investigated every year while the intervals for the
GINI and LISA were less regular). To have at least one
common, comparative time-point with a standardised expo-
sure and health outcome measurement, we determined the
6-yr follow-up as a common reference.
Our results showed a mixed picture of the relationship
between exposure to biocontaminant levels at home and the
risk of respiratory diseases and symptoms in the three birth
cohorts. In the German population, exposures to total amount
of dust, (1,3)-b-D-glucan, EPS and endotoxin from children’s
mattresses were associated with a lower risk of respiratory
diseases. In contrast, in the Dutch sample, there was no
association between domestic microbial exposures and any
health outcomes assessed. To our knowledge, this investiga-
tion is the first study which reports the effects of exposure to
domestic mould components on allergic and respiratory health
in school-age children.
Within the German sample, exposure to higher levels of
(1,3)-b-D-glucan and EPS at home from children’s mattresses
was inversely related to the risk of respiratory diseases. It was
considered that exposure to mould components, such as
(1,3)-b-D-glucan and EPS, may have immune stimulatory
properties [9, 11, 14]. A US birth cohort study observed that
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dust in the first year of life was associated with a persistent
decreased risk for recurrent wheezing among genetically
predisposed children up to the age of 3 yrs [3, 5]. DOUWES
et al. [11] observed a statistically significant protective effect of
Penicillium and Aspergillus EPS exposure from living-room
floor dust at the age of 3 months on persistent wheeze in the
first 4 yrs of life in the whole Dutch PIAMA study population.
In the previous AirAllerg case–control investigation, higher
amounts of mattress dust were reported to decrease the risk
of allergic sensitisation to inhalant allergens in 2–4-yr-old
children [9]. Compared with the German sample, we could not
observe any effect of exposure to mould components on the
risk of respiratory diseases and symptoms within the Dutch
sample. We also investigated the exposure of visible mould at
home and the risk of respiratory disorders. There are a
number of studies considering visible mould as a risk factor
for respiratory diseases and symptoms among children [1, 2,
4–6]. We found no association between visible mould and
respiratory disorders within the German and Dutch popula-
tions. However, there was no evidence that the mould
components are associated with visible mould. This is in
agreement with a recent cohort study in the USA, which did
not observe a correlation between (1,3)-b-D-glucan and EPS
mould components and visible mould [3, 5]. Furthermore, it is
known that (1,3)-b-D-glucan also derives from many other
sources than mould, such as pollen or plants, which may
explain the differences. Since the indoor environment consists
of a variety of indoor and outdoor sources, not only the
measured ones, a clear assignment to the observed health
effects is difficult.
In addition, our investigation showed that exposure to higher
levels of endotoxin at home from children’s mattresses was










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TABLE 6 Adjusted logistic regression results describing
the association between allergic health
outcomes and symptoms and visible mould in
any room at home at 6 yrs of age
Visible mould
Germany# The Netherlands"
Subjects n 56 108
Allergic diseases
Asthma 1.03 (0.26–4.16) 1.14 (0.48–2.70)
Allergic rhinitis+ 1.77 (0.79–3.99) 1.60 (0.62–4.14)
Respiratory symptoms
Rhinoconjunctivitis 1.36 (0.56–3.26) 0.58 (0.22–1.53)
Wheezing 1.29 (0.52–3.21) 1.28 (0.65–2.49)
Dry Cough 1.27 (0.59–2.76) 1.24 (0.71–2.15)
Data are presented as OR (95% CI). #: adjusted for sex, parental allergy,
parental education level, outdoor activity (in hours), breastfeeding, maternal
smoking during pregnancy and AirAllerg case-status; ": adjusted for sex,
parental allergy, parental education, current environmental tobacco smoke
exposure at home, current pet ownership, breastfeeding, study arm and
AirAllerg case-status; +: defined as physician-diagnosed allergic rhinitis in
Germany and as hayfever in the Netherlands.
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population. In support of the ‘‘hygiene hypothesis’’, which
postulates an inverse effect of household size and siblings on
the risk of hayfever [18, 19], there was a considerable number
of epidemiological studies in the past investigating the effect of
living on a farm and the risk of allergic disorders (for a review,
see [29]). The farm environment contains large amounts of
microbial products, including endotoxin [30]. Endotoxin has
been suggested to have strong immune-stimulatory properties.
It may therefore be capable of enhancing the Th1-dominated
immune response and suppress the Th2-dominated allergic
response in newborns and infants [16, 17]. Being born and
growing up on a farm was protective against the risk of
developing hayfever and allergic sensitisation early in life and
some recent studies suggested that these protective effects are
persistent until adulthood [29, 31]. A protective effect on
respiratory and atopic disorders in children was also observed
for domestic endotoxin exposure in nonfarming environments.
Children who were exposed to a high level of endotoxin at
home showed a lower prevalence of physician-diagnosed
asthma and allergic sensitisation in the first years of life [9, 11,
20, 32]. A recent investigation of a US birth cohort showed that
exposure to the Gram-negative bacterial biomarker endotoxin
was inversely associated with asthma and allergic sensitisation
at school age [32]. The inverse association of exposure to high
levels of endotoxin at home and the risk of asthma could be
also observed in our German sample.
The major strengths of our study are the comparison of three
European birth cohort studies with a similar study design and
a standardised exposure measurement from two different
countries. We observed that endotoxin and (1,3)-b-D-glucan
loads, and (1,3)-b-D-glucan concentrations from children’s
mattresses in Germany were significantly higher compared
with the Dutch sample. Furthermore, the percentage of
children exposed to visible mould was higher among the
Dutch sample, which could indicate the presence of an
increased exposure to microbial components other than those
measured here. Moreover, the population density outside the
domestic area may also have different impact on the children’s
exposure to microbial contaminants. In our study, the German
children were all recruited from within and around Munich,
whereas the Dutch children were recruited from several
communities all over the Netherlands. In a recent PIAMA
investigation, CAUDRI et al. [33] presented the number of
addresses per square kilometre as a proxy for the degree of
urbanisation. As for our study population, 87% of the Dutch
children and 94 % of the German children lived in an area with
more than 1,500 addresses in a circular buffer with a 1,000-m
radius. We investigated whether the degree of population
density was associated with an increase in microbial expo-
sures. However, there was no clear association between
biocontaminants measured from children’s mattresses and
living-room floor exposure, and the number of addresses in a
circular buffer with a 1,000-m radius.
A limitation of the present study is that it had only a single
dust sampling over a period of 6 yrs. Dust samples of a single
time-point cannot represent the overall exposure, as the
microbial components in house dust samples may change
over time. A previous AirAllerg investigation showed that the
within-home variance of endotoxin, (1,3)-b-D-glucan and EPS
measurements was small compared with the between-home
variance [34]. However, some investigations looked at varia-
tions over time and performed repeatability analyses within
and between homes. HEINRICH et al. [35] concluded that a single
dust sampling and analysis of endotoxin is representative of
the exposure to these components for at least a period f1 yr.
To take into account the importance of early-life exposure to
biocontaminants on the developing immune system, we
restricted the analysis to those children who never changed
residential location since birth. We observed that although
associations between exposure to microbial components and
physician-diagnosed asthma, as well as allergic symptoms,
were getting smaller within the German subset, exposure to
domestic (1,3)-b-D-glucan, EPS and total amount of dust from
children’s mattresses was getting more pronounced for the risk
of physician-diagnosed allergic rhinitis. Within the Dutch
subset, we observed a significant inverse effect of exposure to
domestic endotoxin from children’s mattresses with the risk of
physician-diagnosed hayfever. The results indicate that a
single biocontaminant measurement provides a reasonable
proxy of the levels that were present since early life, at
least among those children who never changed residential
location.
Furthermore, the prevalence of early day-care attendance as
another source of exposure to microbial contaminants differed
considerably between the German and the Dutch samples: 2%
of the German children but 25% of the Dutch children had
visited a large scale day-care institution within the first year of
life. This difference is persistent up to the age of 4 yrs. A
number of studies observed a higher infection rate among
children with early day-care [36, 37], which was confirmed for
the Dutch PIAMA children in a recent investigation. Early day-
care and the presence of older siblings was associated with
more airway symptoms until the age of 4 yrs [33]. At the age of
6 yrs, infection rates among the Dutch PIAMA children were
considerably lower than for the German children. Therefore,
the impact of indoor exposure at home at the age of 6 yrs on
the developing immune system may be attenuated within the
Dutch subset due to a higher amount of multiple exposures
early in life. However, when restricting analysis to those
children who did not attend a large-scale day-care facility
during the first year of life, we could not observe any effect on
respiratory health at school age.
Based on our study design, we cannot exclude the possibility
of reverse causation. A considerable proportion of the German
and Dutch parents (82% and 78%, respectively) had allergic
diseases, and they may therefore more frequently remove
mould or dust, especially when having children diagnosed
with allergic disorders. However, there is little literature on
cleaning habits in relation to the levels of mould components
or endotoxin in settled house dust and no indication of a
greater variability in dust amount [38–40]. In our study, levels
of (1,3)-b-D-glucan, EPS and the total amount of dust from
children’s mattresses were not different between allergic and
nonallergic parents, except that there was a significantly lower
endotoxin load from homes of genetically predisposed
children in Germany. Further, seasonal variation as a possible
factor of influence on the actual microbial exposure could also
be excluded. House-dust sampling was performed during the
cold season (October–April) only and the differences in the
endotoxin loads between the sampling months were not
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statistically significant for the German subset. In PIAMA, the
amount of dust per square metre and the (1,3)-b-D-glucan
levels per gram of dust, both from the children’s matresses,
were significantly associated with the month of dust collection.
However, given the large overall variability in exposure levels
between the homes, the seasonal variation can be neglected as
a reason for the biased results.
Considering all of the potential reasons for the inconsistent
findings in the German and Dutch population discussed here,
we cannot provide a sufficient explanation for the observed
differences.
Conclusion
Domestic microbial exposure showed different effects on
allergic disorders among the German and the Dutch samples.
We found inverse associations between domestic exposure to
EPS and endotoxin from children’s mattresses, and doctor-
diagnosed asthma and rhinitis in German but not in Dutch
school children. The reason for the differences between
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1) Definition of allergic sensitization within three cohorts 
 
*House dust mix: Hollister-Stier Labs, D. pteronyssinus, D. farinae, German cockroach 
$Tree, grass and weed pollen mix: timothy grass, mugwort, ribwort, wall pellitory, birch 
§Mould mix: Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus, Alternaria alternate 
**Food mix: egg white, milk, fish, wheat, peanut, soy bean 
 
 Germany The Netherlands 
 GINI LISA PIAMA 
Inhalant allergens  
  Animals    
    Cat x x x 
    Dog x 
  House dust  
    D. farinae x x  
    D. pteronyssinus x x x 
    House dust mix* x  
  Tree, grass and weed    
  pollens 
 
    Birch x x 
    Cocksfoot x 
    Timothy grass x  
    Tree, grass and weed  
    pollen mix$ 
x  
Moulds  
    Alternaria alternate x 
    Mould mix§ x  
Food allergens  
  Cow’s milk x x x 
  Egg white x x x 
  Food mix** x  





2) Definition of respiratory diseases and symptoms 
 
 
 GINI & LISA PIAMA
 
Physician-diagnosed respiratory diseases 
Asthma Physician-diagnosed asthma in the last 6 months 
between the 5th and the 6th year?: Yes/No 
Did a doctor ever diagnose asthma in your child? If yes, has 
your child had asthma in the past 12 months? 
Allergic Rhinitis Physician-diagnosed hay-fever AND/OR physician-
diagnosed all-season allergic rhinitis, e.g. mite allergy 
between the 5th and the 6th year: Yes/No 
Has your child ever had hay fever? 
Respiratory symptoms 
Rhinoconjunctivitis Did your child have sneezing attacks or runny, blocked 
nose without having a cold in the past 6 months? Yes/No 
AND Did your child have itchy, watery eyes at the same 
time with nose complaints in the last 12 months? Yes/No 
Has your child been sneezing or did he/she have a 
runny/blocked nose accompanied by itchy, watering eyes 
when he/she did not have a cold during the past 12 months? 
Wheezing Did your child have wheezing or whistling sounds in the 
chest in the last 12 months? Yes/No 
Has your child had wheezing or whistling in the chest in the 
last 12 months? 
Dry cough Did your child ever have nocturnal chesty cough without 
having a cold or bronchitis? Yes/No 
Has your child ever had cough during the night, when 
she/he did not have a cold or an infection in the chest in the 







3) Adjusted logistic regression analysis (results displayed for all covariates) 
 
3.1) Adjusted logistic regression results describing the association between Physician-diagnosed asthma and ln-transformed (1,3)-ß-D-glucan 









 ORadj+ ORadj+ 
Asthma (n=17) 0.76 (0.40 – 1.45) 0.59 (0.30 – 1.19) 
Sex 1.13 (0.40 – 3.18) 1.02 (0.34 – 3.06) 
Parental allergy 1.71 (0.36 – 8.11) - 
Parental education 
Medium vs. low 
High vs. low 
0.53 (0.12 – 2.42) 
0.73 (0.19 – 2.84) 
0.51 (0.09 – 3.07)  
1.18 (0.26 – 5.28) 
Current pets at home 1.28 (0.41 – 4.00) 1.82 (0.54 – 6.16) 
Breastfeeding 1.41 (0.48 – 4.14) 1.11 (0.35 – 3.50) 
Case status 3.68 (1.15 – 11.84) 4.47 (1.19 – 16.75) 
Season of dust sampling: 
  Autumn 
  Winter 
Could not be converged 
0.23 (0.03 – 1.81) 
Could not be converged 
0.28 (0.03 – 2.30) 





 ORadj+ ORadj+ 
Asthma (n=27) 1.28 (0.72-2.29) 1.28 (0.67-2.43) 
Sex  1.64 (0.67-4.03) 1.70 (0.61-4.68) 
Parental allergy 0.79 (0.23-2.75) - 
Parental education 





Current ETS at home  0.89 (0.37-2.18) 1.45 (0.55-3.83) 
Current pets at home  0.47 (0.20-1.08) 0.51 (0.20-1.28) 
Breastfeeding  1.84 (0.68-4.95) 1.92 (0.72-5.17) 
Case status 6.77 (2.41-19.02) 4.74 (1.62-13.82) 
Season of dust sampling: 
  Autumn 












GINI/LISA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Asthma (n=17) 0.60 (0.39 – 0.92) 0.50 (0.31 – 0.81) 
Sex 1.17 (0.41 – 3.36) 1.07 (0.35 – 3.31) 
Parental allergy 1.78 (0.34 – 9.18) - 
Parental education 
Medium vs. low 
High vs. low 
0.53 (0.11 – 2.54) 
0.79 (0.20 – 3.15) 
0.42 (0.06 – 2.71) 
1.04 (0.22 – 4.79) 
Current pets at home 1.24 (0.39 – 3.96) 1.92 (0.55 – 6.70) 
Breastfeeding 1.36 (0.45 – 4.06) 1.12 (0.34 – 3.70) 
Case status 3.74 (1.15 – 12.17) 4.90 (1.25 – 19.26) 
Season of dust sampling: 
  Autumn 
  Winter 
Could not be converged 
0.24 (0.03 – 1.94) 
Could not be converged 
0.27 (0.03 – 2.31) 
PIAMA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Asthma (n=27) 1.24 (0.78-1.96) 1.29 (0.77-2.15 
Sex  1.63 (0.67-3.97) 1.71 (0.62-4.70) 
Parental allergy 0.82 (0.23-2.85) - 
Parental education 
Low/medium vs. high 
0.73 (0.30-1.76) 0.91 (0.34-2.48) 
Current ETS at home  0.91 (0.38-2.22) 1.49 (0.56-3.93) 
Current pets at home  0.45 (0.20-1.06) 0.49 (0.19-1.24) 
Breastfeeding  1.77 (0.66-4.77) 1.85 (0.69-4.98) 
Case status 6.60 (2.36-18.47) 4.57 (1.57-13.24) 
Season of dust sampling: 
  Autumn 











GINI/LISA  Parental allergy 




 ORadj.++ ORadj.++ 
Asthma (n=17) 0.55 (0.31 – 0.97) 0.46 (0.25 – 0.85) 
Sex 1.22 (0.42 – 3.56) 1.66 (0.36 – 3.71) 
Parental allergy 1.44 (0.30 – 6.99) - 
Parental education 
Medium vs. low 
High vs. low 
0.43 (0.09 – 2.07) 
0.59 (0.14 – 2.52) 
0.42 (0.07 – 2.68) 
0.97 (0.16 – 4.96) 
Current ETS at home 0.62 (0.15 – 2.59) 0.8 (0.18 – 3.64) 
Current pets at home 1.56 (0.48 – 5.04) 2.16 (0.61 – 7.57) 
Breastfeeding 1.33 (0.44 – 3.99) 0.94 (0.29 – 3.05) 
Case status 3.56 (1.09 – 11.56) 4.61 (1.2 – 17.71) 
Season of dust sampling: 
  Autumn 
  Winter 
Could not be converged 
0.18 (0.02 – 1.51) 
Could not be converged 
0.22 (0.03 – 1.92) 
PIAMA  Parental allergy 




 ORadj.++ ORadj.++ 
Asthma (n=27) 1.51 (0.94-2.42) 1.49 (0.89-2.50) 
Sex  1.59 (0.65-3.91) 1.68 (0.61-4.65) 
Parental allergy 0.73 (0.21-2.58) - 
Parental education 





Current ETS at home  0.88 (0.36-2.13) 1.46 (0.56-3.85) 
Current pets at home  0.49 (0.21-1.13) 0.54 (0.21-1.39) 
Breastfeeding  1.96 (0.72-5.32) 2.04 (0.75-5.52) 
Case status 6.95 (2.46-19.66) 4.75 (1.62-13.93) 
Season of dust sampling: 
  Autumn 








TOTAL AMOUNT OF MATTRESS DUST 
 
GINI/LISA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Asthma (n=17) 0.65 (0.35 – 1.21) 0.54 (0.27 – 1.08) 
Sex 1.04 (0.36 – 2.95) 0.94 (0.31 – 2.90) 
Parental allergy 1.73 (0.36 – 8.37) - 
Parental education 
Medium vs. low 
High vs. low 
 
0.48 (0.10 – 2.30) 
0.63 (0.15 – 2.66) 
 
0.48 (0.08 – 2.95) 
1.03 (0.21 – 5.12) 
Current ETS at home 0.58 (0.14 – 2.44) 0.8 (0.18 – 3.59) 
Current pets at home 1.38 (0.44 – 4.38) 1.89 (0.56 – 6.34) 
Breastfeeding 1.36 (0.46 – 4.01) 1.05 (0.33 – 3.33) 
Case status 3.7 (1.15 – 11.92) 4.53 (1.2 – 17.08) 
Season of dust sampling: 
  Autumn 
  Winter 
Could not be converged 
0.22 (0.03 – 1.76) 
Could not be converged 
0.26 (0.03 – 2.11) 
PIAMA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Asthma (n=27) 1.28 (0.76-2.17) 1.25 (0.70-2.23) 
Sex  1.61 (0.66-3.93) 1.67 (0.61-4.58) 
Parental allergy 0.79 (0.23-2.75) - 
Parental education 





Current ETS at home  0.89 (0.36-2.16) 1.44 (0.55-3.82) 
Current pets at home  0.47 (0.20-1.08) 0.51 (0.20-1.28) 
Breastfeeding  1.83 (0.68-4.93) 1.92 (0.72-5.14) 
Case status 6.80 (2.42-19.10) 4.71 (1.62-13.70) 
Season of dust sampling: 
  Autumn 









3.2) Adjusted logistic regression results describing the association between Physician-diagnosed allergic rhinitis and ln-transformed (1,3)-ß-D-









 ORadj+ ORadj+ 
Allergic Rhinitis (n=47) 0.69 (0.45 – 1.05) 0.58 (0.37 – 0.91) 
Sex 1.40 (0.71 – 2.77) 1.23 (0.60 – 2.52) 
Parental allergy 2.06 (0.74 – 5.73) - 
Parental education 
Medium vs. low 
High vs. low 
0.63 (0.23 – 1.69) 
0.61 (0.24 – 1.54) 
0.69 (0.23 – 2.12) 
0.79 (0.29 – 2.19) 
Current pets at home 1.22 (0.58 – 2.59) 1.07 (0.46 – 2.48) 
Breastfeeding 1.76 (0.87 – 3.55) 1.54 (0.73 – 3.26) 
Case status 3.28 (1.62 – 6.64) 3.61 (1.68 – 7.76) 
Season of dust sampling: 
  Autumn 
  Winter 
1.10 (0.41 – 2.97) 
0.53 (0.19 – 1.49) 
1.27 (0.46 – 3.55) 
0.70 (0.24 – 2.04) 





 ORadj+ ORadj+ 
Hay fever (n=23) 0.83 (0.42-1.63) 0.79 (0.39-1.60) 
Sex  3.62 (1.19-10.99) 3.32 (1.07-10.31) 
Parental allergy 6.94 (0.77-62.32) - 
Parental education 





Current ETS at home  0.25 (0.08-0.83) 0.18 (0.05-0.69) 
Current pets at home  2.45 (0.83-7.25) 2.24 (0.74-6.74) 
Breastfeeding  1.32 (0.49-3.54) 1.30 (0.48-3.51) 
Case status 3.33 (1.22-9.08) 3.95 (1.36-11.45) 
Season of dust sampling: 
  Autumn 











GINI/LISA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Allergic Rhinitis (n=47) 0.67 (0.49 – 0.92) 0.66 (0.47 – 0.93) 
Sex 1.41 (0.71 – 2.80) 1.23 (0.60 – 2.51) 
Parental allergy 2.02 (0.71 – 5.74) - 
Parental education 
Medium vs. low 
High vs. low 
0.63 (0.23 – 1.72) 
0.60 (0.24 – 1.52) 
0.69 (0.23 – 2.09) 
0.71 (0.26 – 1.95) 
Current pets at home 1.17 (0.55 – 2.46) 0.98 (0.43 – 2.23) 
Breastfeeding 1.65 (0.81 – 3.35) 1.43 (0.68 – 3.02) 
Case status 3.45 (1.70 – 7.01) 3.81 (1.77 – 8.19) 
Season of dust sampling: 
  Autumn 
  Winter 
1.16 (0.42 – 3.16) 
0.54 (0.19 – 1.52) 
1.31 (0.47 – 3.67) 
0.70 (0.24 – 2.03) 
PIAMA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Hay fever (n=23) 1.00 (0.61-1.65) 1.00 (0.59-1.70) 
Sex  3.74 (1.23-11.34) 3.42 (1.10-10.62) 
Parental allergy 6.60 (0.74-58.55) - 
Parental education 





Current ETS at home  0.24 (0.07-0.80) 0.17 (0.05-0.67) 
Current pets at home  2.42 (0.81-7.22) 2.21 (0.73-6.73) 
Breastfeeding  1.35 (0.50-3.62) 1.34 (0.50-3.60) 
Case status 3.42 (1.26-9.27) 4.06 (1.41-11.69) 
Season of dust sampling: 
  Autumn 











GINI/LISA  Parental allergy 




 ORadj.++ ORadj.++ 
Allergic Rhinitis (n=47) 0.71 (0.48 – 1.04) 0.60 (0.40 – 0.92) 
Sex 1.44 (0.72 – 2.86) 1.28 (0.62 – 2.63) 
Parental allergy 1.86 (0.67 – 5.21) - 
Parental education 
Medium vs. low 
High vs. low 
0.58 (0.21 – 1.59) 
0.55 (0.21 – 1.41) 
0.63 (0.21 – 1.94) 
0.65 (0.23 – 1.85) 
Current ETS at home 0.92 (0.38 – 2.19) 0.80 (0.30 – 2.13) 
Current pets at home 1.24 (0.59 – 2.63) 1.06 (0.46 – 2.44) 
Breastfeeding 1.63 (0.81 – 3.28) 1.37 (0.65 – 2.89) 
Case status 3.27 (1.62 – 6.63) 3.66 (1.71 – 7.84) 
Season of dust sampling: 
  Autumn 
  Winter 
1.14 (0.42 – 3.07) 
0.47 (0.17 – 1.34) 
1.32 (0.47 – 3.70) 
0.62 (0.21 – 1.80) 
PIAMA  Parental allergy 




 ORadj.++ ORadj.++ 
Hay fever (n=23) 0.61 (0.35-1.07) 0.59 (0.33-1.05) 
Sex  3.66 (1.21-11.13) 3.37 (1.08-10.52) 
Parental allergy 7.11 (0.80-63.10) - 
Parental education 





Current ETS at home  0.24 (0.07-0.81) 0.17 (0.04-0.66) 
Current pets at home  2.31 (0.78-6.82) 2.07 (0.68-6.27) 
Breastfeeding  1.27 (0.47-3.45) 1.26 (0.46-3.43) 
Case status 3.38 (1.23-9.28) 4.01 (1.37-11.72) 
Season of dust sampling: 
  Autumn 









TOTAL AMOUNT OF MATTRESS DUST 
 
GINI/LISA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Allergic Rhinitis (n=47) 0.71 (0.47 – 1.08) 0.63 (0.40 – 0.99) 
Sex 1.35 (0.68 – 2.67) 1.16 (0.57 – 2.37) 
Parental allergy 2.06 (0.74 – 5.76) - 
Parental education 
Medium vs. low 
High vs. low 
0.62 (0.23 – 1.67) 
0.58 (0.22 – 1.49) 
0.66 (0.22 – 2.03) 
0.68 (0.24 – 1.95) 
Current ETS at home 0.87 (0.36 – 2.09) 0.78 (0.29 – 2.08) 
Current pets at home 1.19 (0.57 – 2.51) 1.01 (0.45 – 2.30) 
Breastfeeding 1.66 (0.82 – 3.34) 1.44 (0.69 – 3.05) 
Case status 3.33 (1.65 – 6.74) 3.66 (1.71 – 7.83) 
Season of dust sampling: 
  Autumn 
  Winter 
1.10 (0.41 – 2.98) 
0.52 (0.18 – 1.45) 
1.25 (0.45 – 3.48) 
0.65 (0.23 – 1.89) 
PIAMA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Hay fever (n=23) 0.88 (0.49-1.60) 0.86 (0.47-1.59) 
Sex  3.70 (1.22-11.20) 3.39 (1.09-10.51) 
Parental allergy 6.72 (0.76-59.62) - 
Parental education 





Current ETS at home  0.25 (0.08-0.82) 0.18 (0.05-0.69) 
Current pets at home  2.46 (0.83-7.26) 2.25 (0.75-6.78) 
Breastfeeding  1.34 (0.50-3.59) 1.32 (0.49-3.56) 
Case status 3.37 (1.24-9.16) 3.99 (1.38-11.52) 
Season of dust sampling: 
  Autumn 














3.3) Adjusted logistic regression results describing the association between Rhinoconjunctivitis and ln-transformed (1,3)-ß-D-glucan (µg/m2), 









 ORadj+ ORadj+ 
Rhinoconjuntivitis  (n=48) 0.74 (0.49 – 1.12) 0.71 (0.46 – 1.09) 
Sex 1.66 (0.83 – 3.30) 1.53 (0.75 – 3.10) 
Parental allergy 4.01 (1.15 – 13.96) - 
Parental education 
Medium vs. low 
High vs. low 
1.64 (0.57 – 4.74) 
1.50 (0.55 – 4.08) 
2.00 (0.64 – 6.29) 
1.78 (0.61 – 5.18) 
Current pets at home 1.27 (0.60 – 2.67) 1.15 (0.52 – 2.54) 
Breastfeeding 0.81 (0.41 – 1.60) 0.74 (0.36 – 1.50) 
Case status 4.55 (2.18 – 9.50) 4.86 (2.25 – 10.51) 
Season of dust sampling: 
  Autumn 
  Winter 
1.12 (0.41 – 3.05) 
0.89 (0.34 – 2.27) 
1.2 (0.43 – 3.36) 
1.1 (0.41 – 2.92) 





 ORadj+ ORadj+ 
Rhinoconjunctivitis 
(n=28) 1.11 (0.62-1.97) 1.07 (0.59-1.95) 
Sex  1.48 (0.63-3.50) 1.68 (0.69-4.09) 
Parental allergy 9.90 (1.21-80.67) - 
Parental education 





Current ETS at home  0.19 (0.06-0.60) 0.20 (0.06-0.64) 
Current pets at home  0.76 (0.33-1.75) 0.82 (0.35-1.94) 
Breastfeeding  0.88 (0.38-2.04) 0.90 (0.39-2.09) 
Case status 2.46 (1.04-5.80) 2.26 (0.94-5.39) 
Season of dust sampling: 
  Autumn 









GINI/LISA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Rhinoconjuntivitis  
(n=48) 0.77 (0.56 – 1.07) 0.81 (0.58 – 1.15) 
Sex 1.66 (0.83 – 3.32) 1.52 (0.75 – 3.07) 
Parental allergy 3.99 (1.14 – 13.96) - 
Parental education 
Medium vs. low 
High vs. low 
1.64 (0.57 – 4.73) 
1.43 (0.53 – 3.89) 
1.97 (0.63 – 6.16) 
1.62 (0.56 – 4.67) 
Current pets at home 1.21 (0.58 – 2.52) 1.07 (0.49 – 2.33) 
Breastfeeding 0.77 (0.39 – 1.52) 0.70 (0.35 – 1.43) 
Case status 4.71 (2.25 – 9.84) 5.00 (2.31 – 10.80) 
Season of dust sampling: 
  Autumn 
  Winter 
1.13 (0.41 – 3.11) 
0.89 (0.35 – 2.28) 
1.21 (0.43 – 3.36) 
1.09 (0.41 – 2.88) 
PIAMA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Rhinoconjunctivitis 
(n=28) 1.19 (0.75-1.90) 1.17 (0.73-1.87) 
Sex  1.48 (0.63-3.50) 1.68 (0.69-4.09) 
Parental allergy 10.07 (1.24-82.12) - 
Parental education 





Current ETS at home  0.19 (0.06-0.60) 0.20 (0.06-0.64) 
Current pets at home  0.73 (0.31-1.69) 0.79 (0.33-1.88) 
Breastfeeding  0.87 (0.37-2.02) 0.89 (0.38-2.07) 
Case status 2.46 (1.05-5.79) 2.26 (0.95-5.38) 
Season of dust sampling: 
  Autumn 












GINI/LISA  Parental allergy 




 ORadj.++ ORadj.++ 
Rhinoconjuntivitis  (n=48) 0.78 (0.53 – 1.15) 0.70 (0.47 – 1.06) 
Sex 1.74 (0.86 – 3.50) 1.60 (0.78 – 3.29) 
Parental allergy 3.80 (1.09 – 13.27) - 
Parental education 
Medium vs. low 
High vs. low 
1.63 (0.56 – 4.73) 
1.46 (0.53 – 4.06) 
1.90 (0.60 – 6.01) 
1.60 (0.54 – 4.79) 
Current ETS at home 1.22 (0.52 – 2.85) 1.16 (0.52 – 2.56) 
Current pets at home 1.24 (0.59 – 2.60) 1.16 (0.52 – 2.56) 
Breastfeeding 0.76 (0.39 – 1.51) 0.68 (0.33 – 1.39) 
Case status 4.62 (2.21 – 9.64) 4.97 (2.30 – 10.77) 
Season of dust sampling: 
  Autumn 
  Winter 
1.17 (0.43 – 3.21) 
0.83 (0.32 – 2.13) 
1.25 (0.45 – 3.52) 
1.01 (0.38 – 2.69) 
PIAMA  Parental allergy 




 ORadj.++ ORadj.++ 
Rhinoconjunctivitis 
(n=28) 0.96 (0.61-1.51) 0.93 (0.59-1.48) 
Sex  1.47 (0.62-3.46) 1.67 (0.69-4.05) 
Parental allergy 10.14 (1.24-82.87) - 
Parental education 





Current ETS at home  0.19 (0.06-0.61) 0.20 (0.06-0.65) 
Current pets at home  0.76 (0.33-1.74) 0.82 (0.35-1.92) 
Breastfeeding  0.87 (0.37-2.03) 0.89 (0.38-2.07) 
Case status 2.40 (1.02-5.63) 2.20 (0.93-5.23) 
Season of dust sampling: 
  Autumn 













TOTAL AMOUNT OF MATTRESS DUST 
 
GINI/LISA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Rhinoconjuntivitis  (n=48) 0.81 (0.52 – 1.24) 0.83 (0.52 – 1.31) 
Sex 1.65 (0.83 – 3.30) 1.48 (0.73 – 3.00) 
Parental allergy 3.99 (1.15 – 13.86) - 
Parental education 
Medium vs. low 
High vs. low 
1.68 (0.58 – 4.90) 
1.49 (0.53 – 4.18) 
1.96 (0.62 – 6.16) 
1.61 (0.54 – 4.78) 
Current ETS at home 1.20 (0.52 – 2.79) 0.95 (0.38 – 2.38) 
Current pets at home 1.20 (0.58 – 2.51) 1.08 (0.49 – 2.35) 
Breastfeeding 0.78 (0.40 – 1.54) 0.71 (0.35 – 1.44) 
Case status 4.61 (2.21 – 9.62) 4.89 (2.26 – 10.54) 
Season of dust sampling: 
  Autumn 
  Winter 
1.14 (0.42 – 3.11) 
0.87 (0.34 – 2.22) 
1.19 (0.43 – 3.31) 
1.05 (0.40 – 2.76) 
PIAMA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Rhinoconjunctivitis 
(n=28) 1.01 (0.62-1.65) 0.99 (0.60-1.65) 
Sex  1.47 (0.62-3.47) 1.67 (0.69-4.06) 
Parental allergy 10.01 (1.23-81.60) - 
Parental education 





Current ETS at home  0.19 (0.06-0.61) 0.20 (0.06-0.65) 
Current pets at home  0.76 (0.33-1.75) 0.82 (0.35-1.94) 
Breastfeeding  0.88 (0.38-2.04) 0.90 (0.39-2.09) 
Case status 2.42 (1.03-5.69) 2.22 (0.93-5.30) 
Season of dust sampling: 
  Autumn 










3.4) Adjusted logistic regression results describing the association between Wheezing and ln-transformed (1,3)-ß-D-glucan (µg/m2), EPS 









 ORadj+ ORadj+ 
Wheezing  (n=43) 0.78 (2.35 – 11.54) 0.68 (0.42 – 1.09) 
Sex 1.10 (0.54 – 2.22) 1.02 (0.48 – 2.16) 
Parental allergy 1.11 (0.44 – 2.80) - 
Parental education 
Medium vs. low 
High vs. low 
0.88 (0.33 – 2.31) 
0.47 (0.18 – 1.21) 
0.82 (0.27 – 2.52) 
0.63 (0.22 – 1.78) 
Current pets at home 0.74 (0.33 – 1.66) 0.99 (0.41 – 2.38) 
Breastfeeding 1.59 (0.77 – 3.28) 1.38 (0.63 – 3.03) 
Case status 5.21 (2.35 – 11-54) 5.43 (2.24 – 13.15) 
Season of dust sampling: 
  Autumn 
  Winter 
1.3 (0.47 – 3.59) 
0.61 (0.21 – 1.74) 
1.24 (0.41 – 3.75) 
0.86 (0.29 – 2.59) 





 ORadj+ ORadj+ 
Wheezing (n=47) 0.82 (0.53-1.28) 0.92 (0.56-1.50) 
Sex  1.40 (0.71-2.75) 1.36 (0.64-2.87) 
Parental allergy 1.19 (0.44-3.22) - 
Parental education 





Current ETS at home  0.90 (0.45-1.79) 1.04 (0.49-2.20) 
Current pets at home  0.81 (0.42-1.57) 0.93 (0.45-1.91) 
Breastfeeding  1.69 (0.81-3.52) 1.77 (0.84-3.69) 
Case status 3.54 (1.77-7.08) 3.29 (1.55-6.98) 
Season of dust sampling: 
  Autumn 









GINI/LISA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Wheezing  (n=43) 1.02 (0.71 – 1.48) 0.92 (0.62 – 1.38) 
Sex 1.08 (0.54 – 2.18) 0.99 (0.47 – 2.09) 
Parental allergy 1.14 (0.45 – 2.86) - 
Parental education 
Medium vs. low 
High vs. low 
0.85 (0.32 – 2.22) 
0.43 (0.16 – 1.10) 
0.83 (0.27 – 2.50) 
0.56(0.20 – 1.57) 
Current pets at home 0.70 (0.31 – 1.56) 0.88 (0.37 – 2.08) 
Breastfeeding 1.56 (0.76 – 3.21) 1.30 (0.60 – 2.84) 
Case status 5.44 (2.46 – 12.01) 5.68 (2.35 – 13.71) 
Season of dust sampling: 
  Autumn 
  Winter 
1.31 (0.48 – 3.59) 
0.58 (0.20 – 1.66) 
1.24 (0.41 – 3.69) 
0.82 (0.27 – 2.43) 
PIAMA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Wheezing (n=47) 1.02 (0.74-1.42) 1.12 (0.77-1.64) 
Sex  1.43 (0.73-2.82) 1.39 (0.66-2.94) 
Parental allergy 1.18 (0.44-3.20) - 
Parental education 





Current ETS at home  0.87 (0.44-1.73) 1.03 (0.49-2.18) 
Current pets at home  0.80 (0.41-1.54) 0.91 (0.44-1.88) 
Breastfeeding  1.68 (0.80-3.51) 1.74 (0.83-3.65) 
Case status 3.62 (1.81-7.22) 3.34 (1.58-7.07) 
Season of dust sampling: 
  Autumn 

















GINI/LISA  Parental allergy 




 ORadj.++ ORadj.++ 
Wheezing  (n=43) 0.82 (0.54 – 1.24) 0.69 (0.43 – 1.1) 
Sex 1.11 (0.55 – 2.26) 1.09 (0.51 – 2.35) 
Parental allergy 1.06 (0.41 – 2.69) - 
Parental education 
Medium vs. low 
High vs. low 
0.83 (0.31 – 2.21) 
0.43 (0.17 – 1.14) 
0.82 (0.26 – 2.55) 
0.62 (0.21 – 1.81) 
Current ETS at home 0.94 (0.39 – 2.27) 1.34 (0.52 – 3.43) 
Current pets at home 0.75 (0.33 – 1.68) 0.96 (0.40 – 2.30) 
Breastfeeding 1.52 (0.74 – 3.13) 1.28 (0.58 – 2.80) 
Case status 5.24 (2.37 – 11.61) 5.52 (2.28 – 13.36) 
Season of dust sampling: 
  Autumn 
  Winter 
1.33 (0.48 – 3.69) 
0.57 (0.20 – 1.64) 
1.39 (0.46 – 4.25) 
0.83 (0.28 – 2.47) 
PIAMA  Parental allergy 




 ORadj.++ ORadj.++ 
Wheezing (n=47) 1.11 (0.77-1.59) 1.21 (0.82-1.80) 
Sex  1.43 (0.73-2.82) 1.38 (0.65-2.93) 
Parental allergy 1.17 (0.43-3.15) - 
Parental education 





Current ETS at home  0.86 (0.44-1.71) 1.02 (0.48-2.15) 
Current pets at home  0.81 (0.42-1.55) 0.95 (0.46-1.97) 
Breastfeeding  1.71 (0.82-3.57) 1.82 (0.87-3.82) 
Case status 3.66 (1.83-7.31) 3.41 (1.61-7.24) 
Season of dust sampling: 
  Autumn 













TOTAL AMOUNT OF MATTRESS DUST 
 
GINI/LISA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Wheezing  (n=43) 0.81 (0.52 – 1.27) 0.76 (0.46 – 1.25) 
Sex 1.07 (0.53 – 2.17) 1.02 (0.48 – 2.17) 
Parental allergy 1.11 (0.44 – 2.81) - 
Parental education 
Medium vs. low 
High vs. low 
0.86 (0.32 – 2.29) 
0.45 (0.17 – 1.19) 
0.85 (0.28 – 2.64) 
0.64 (0.22 – 1.86) 
Current ETS at home 0.91 (0.38 – 2.21) 1.33 (0.52 – 3.39) 
Current pets at home 0.73 (0.33 – 1.64) 0.91 (0.38 – 2.18) 
Breastfeeding 1.54 (0.75 – 3.16) 1.33 (0.61 – 2.91) 
Case status 5.32 (2.40 – 11.76) 5.58 (2.31 – 13.5) 
Season of dust sampling: 
  Autumn 
  Winter 
1.3 (0.47 – 3.62) 
0.60 (0.21 – 1.72) 
1.32 (0.44 – 4.00) 
0.85 (0.28 – 2.53) 
PIAMA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Wheezing (n=47) 1.00 (0.68-1.49) 1.14 (0.73-1.77) 
Sex  1.43 (0.73-2.81) 1.39 (0.66-2.93) 
Parental allergy 1.18 (0.44-3.19) - 
Parental education 





Current ETS at home  0.88 (0.44-1.74) 1.02 (0.48-2.15) 
Current pets at home  0.80 (0.42-1.54) 0.92 (0.45-1.89) 
Breastfeeding  1.69 (0.81-3.52) 1.77 (0.85-3.70) 
Case status 3.62 (1.81-7.24) 3.40 (1.60-7.22) 
Season of dust sampling: 
  Autumn 










3.5) Adjusted logistic regression results describing the association between Dry cough and ln-transformed (1,3)-ß-D-glucan (µg/m2), EPS 









 ORadj+ ORadj+ 
Dry cough  (n=56) 0.78 (0.53 – 1.13) 0.65 (0.43 – 0.98) 
Sex 1.18 (0.64 – 2.17) 0.89 (0.46 – 1.71) 
Parental allergy 1.07 (0.50 – 2.33) - 
Parental education 
Medium vs. low 
High vs. low 
0.74 (0.31 – 1.76) 
0.57 (0.25 – 1.31) 
0.81 (0.30 – 2.21) 
0.61 (0.24 – 1.56) 
Current pets at home 1.45 (0.75 – 2.78) 1.33 (0.63 – 2.82) 
Breastfeeding 1.14 (0.62 – 2.11) 1.11 (0.56 – 2.20) 
Case status 1.23 (0.68 – 2.25) 0.99 (0.51 – 1.93) 
Season of dust sampling: 
  Autumn 
  Winter 
0.85 (0.33 – 2.18) 
0.66 (0.27 – 1.61) 
0.77 (0.27 – 2.17) 
0.78 (0.29 – 2.07) 





 ORadj+ ORadj+ 
Dry cough (n=79) 0.88 (0.61-1.25) 0.93 (0.63-1.38) 
Sex  1.36 (0.79-2.35) 1.12 (0.62-2.04) 
Parental allergy 2.23 (0.99-5.02) - 
Parental education 





Current ETS at home  1.21 (0.70-2.10) 1.64 (0.90-2.99) 
Current pets at home  0.63 (0.37-1.07) 0.55 (0.30-0.99) 
Breastfeeding  1.04 (0.58-1.85) 1.10 (0.61-1.98) 
Case status 1.71 (1.00-2.91) 0.90 (0.42-1.95) 
Season of dust sampling: 
  Autumn 









GINI/LISA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Dry cough  (n=56) 0.93 (0.68 – 1.27) 0.84 (0.58 – 2.55) 
Sex 1.17 (0.64 – 2.15) 0.88 (0.46 – 1.69) 
Parental allergy 1.08 (0.50 – 2.34) - 
Parental education 
Medium vs. low 
High vs. low 
0.73 (0.31 – 1.73) 
0.55 (0.24 – 1.25) 
0.80 (0.30 – 2.17) 
0.57 (0.22 – 1.43) 
Current pets at home 1.38 (0.73 – 2.64) 1.22 (0.58 – 2.55) 
Breastfeeding 1.10 (0.60 – 2.03) 1.04 (0.53 – 2.05) 
Case status 1.28 (0.70 – 2.33) 1.05 (0.54 – 2.03) 
Season of dust sampling: 
  Autumn 
  Winter 
0.84 (0.33 – 2.15) 
0.64 (0.26 – 1.57) 
0.75 (0.27-2.11) 
0.74 (0.28 – 1.97) 
PIAMA  Parental allergy 
 EPS*             
(EPSU/m2) 
EPS*             
(EPSU/m2) 
 ORadj+ ORadj+ 
Dry cough (n=79) 1.03 (0.79-1.34) 0.94 (0.68-1.29) 
Sex  1.38 (0.80-2.39) 1.15 (0.63-2.11) 
Parental allergy 2.22 (0.99-5.00) - 
Parental education 





Current ETS at home  1.19 (0.69-2.06) 1.64 (0.90-3.01) 
Current pets at home  0.62 (0.36-1.06) 0.53 (0.29-0.96) 
Breastfeeding  1.03 (0.58-1.84) 1.07 (0.59-1.94) 
Case status 1.73 (1.01-2.95) 2.02 (1.12-3.63) 
Season of dust sampling: 
  Autumn 











GINI/LISA  Parental allergy 




 ORadj.++ ORadj.++ 
Dry cough  (n=56) 0.89 (0.63 – 1.26)        0.82 (0.55 – 1.22) 
Sex 1.18 (0.64 – 2.17) 0.90 (0.47 – 1.75) 
Parental allergy 1.04 (0.47 – 2.27) - 
Parental education 
Medium vs. low 
High vs. low 
0.70 (0.29 – 1.68) 
0.53 (0.23 – 1.23) 
0.82 (0.30 – 2.26) 
0.59 (0.22 – 1.55) 
Current ETS at home 0.93 (0.44 – 1.97) 1.17 (0.52 – 2.64) 
Current pets at home 1.43 (0.74 – 2.76) 1.23 (0.58 – 2.60) 
Breastfeeding 1.10 (0.59 – 2.02) 1.04 (0.53 – 1.05) 
Case status 1.26 (0.69 – 2.29) 1.04 (0.54 – 2.01) 
Season of dust sampling: 
  Autumn 
  Winter 
0.84 (0.33 – 2.16) 
0.61 (0.25 – 1.50) 
0.78 (0.28 – 2.2) 
0.72 (0.27 – 1.91) 
PIAMA  Parental allergy 




 ORadj.++ ORadj.++ 
Dry cough (n=79) 1.05 (0.78-1.41) 1.10 (0.79-1.52) 
Sex  1.38 (0.80-2.38) 1.13 (0.62-2.06) 
Parental allergy 2.21 (0.98-4.96) - 
Parental education 





Current ETS at home  1.19 (0.69-2.05) 1.63 (0.89-2.97) 
Current pets at home  0.62 (0.36-1.06) 0.55 (0.31-0.99) 
Breastfeeding  1.04 (0.58-1.86) 1.11 (0.62-2.00) 
Case status 1.74 (1.02-2.96) 2.04 (1.13-3.66) 
Season of dust sampling: 
  Autumn 








TOTAL AMOUNT OF MATTRESS DUST 
 
GINI/LISA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Dry cough  (n=56) 0.92 (0.63 – 1.34) 0.76 (0.50 – 1.16) 
Sex 1.16 (0.63 – 2.13) 0.88 (0.46 – 1.70) 
Parental allergy 1.08 (0.50 – 2.34) - 
Parental education 
Medium vs. low 
High vs. low 
0.72 (0.30 – 1.72) 
0.54 (0.23 – 1.25) 
0.84 (0.30 – 2.31) 
0.61 (0.23 – 1.60) 
Current ETS at home 0.91 (0.43 – 1.92) 1.17 (0.52 – 2.63) 
Current pets at home 1.40 (0.73 – 2.69) 1.22 (0.58 – 2.56) 
Breastfeeding 1.10 (0.60 – 2.03) 1.05 (0.54 – 2.06) 
Case status 1.27 (0.7 – 2.31) 1.03 (0.53 – 1.99) 
Season of dust sampling: 
  Autumn 
  Winter 
0.83 (0.32 – 2.14) 
0.63 (0.26 – 1.55) 
0.77 (0.27 – 2.17) 
0.74 (0.28 – 1.97) 
PIAMA  Parental allergy 
 Amount  of dust*  
(mg/m2) 
Amount of dust*  
(mg/m2) 
 ORadj.++ ORadj.++ 
Dry cough (n=79) 0.88 (0.61-1.25) 0.93 (0.63-1.38) 
Sex  1.37 (0.80-2.36) 1.12 (0.62-2.05) 
Parental allergy 2.22 (0.99-5.00) - 
Parental education 





Current ETS at home  1.20 (0.69-2.07) 1.64 (0.90-2.99) 
Current pets at home  0.62 (0.36-1.06) 0.55 (0.30-0.99) 
Breastfeeding  1.04 (0.58-1.85) 1.10 (0.61-1.98) 
Case status 1.72 (1.01-2.93) 2.02 (1.12-3.64) 
Season of dust sampling: 
  Autumn 
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